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GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS
I. General introduction
! e pituitary gland is the master regulator of the endocrine system. 
Di% erent pathophysiological conditions can a% ect the function of the 
pituitary gland and, consequently, endocrine homeostasis. ! e evaluation 
of pituitary function is therefore complex and the di% erent tools that 
have become available to evaluate pituitary function only provide limited 
information of di% erent aspects of hormone secretion. In this thesis, 
several di'  culties encountered in establishing a diagnosis of pituitary 
insu'  ciency are studied in di% erent pathophysiological conditions. 
Figure 1. The pituitary gland  
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II. The pituitary gland
Anatomy and Physiology
! e pituitary gland is a small gland located at the base of the skull in a 
socket of sphenoid bone, called the sella turcica. ! e gland consists of 
two lobes, the anterior lobe (or adenohypophysis; 80%), and a posterior 
lobe (neurohypophysis; 20%) (Figure 1). 
Together with the hypothalamus, the pituitary controls the function 
of di% erent endocrine glands (i.e. thyroid, adrenal and reproductive 
glands) (1). ! e hypothalamus receives signals from upper corticol inputs 
and the environment (such as light and temperature) and, in turn, delivers 
signals to the pituitary gland (i.e. regulating the endocrine system). 
Hormones released by the pituitary gland in+ uence the endocrine 
systems in the body and also have a feedback on the hypothalamus. 
! e communication between the hypothalamus and anterior 
pituitary is via the portal system that runs through the pituitary stalk. 
Hormones released by the hypothalamus are delivered to the anterior 
pituitary through these vessels and reach the anterior lobe through a 
dense capillary network. ! e communication with the posterior gland 
is via axons and nerve terminals of larger neurons that originate from 
within the hypothalamus. ! e hormones produced in these neurons, 
arginine-vasopressin and oxytocin, are released directly from the 
posterior pituitary into the systemic circulation. 
! e anterior pituitary is controlled by speci" c hypothalamic hormones: 
thyrotropin releasing hormone (TRH), gonadotropin releasing hormone 
(GnRH), corticotropin releasing hormone (CRH), growth hormone 
releasing hormone (GHRH), and somatostatin, that bind speci" c 
transmembrane receptors expressed in di% erent anterior pituitary cells. 
! ese anterior pituitary cells are classi" ed by their speci" c secretory 
products: somatotrophs (GH-secreting cells, expressing the GHRH and 
somatostatin receptor; 50%), lactotrophs (PRL-secreting cells, expressing 
the prolactin receptor; 10–25%), corticotrophs (cells secreting ACTH, 
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expressing the CRH receptor; 15–20%), thyrotrophs (cells secreting TSH, 
expressing the TRH receptor; 10%), and gonadotrophs (LH and FSH 
secreting cells, expressing the GnRH receptor; 10–15%) (2).
1. Regulation and secretion of growth hormone and IGF-I 
! e regulation of growth hormone (GH) secretion is complex and involves 
many stimulatory and inhibitory hypothalamic peptides. However, 
the two most important components are growth hormone-releasing 
hormone (GHRH), which stimulates the somatotrophic cells, and 
somatostatin (SST) which inhibits GH release (2). ! e secretion of GH is 
also a% ected by factors such as nutrition (increased in fasting, stimulated 
by high protein meals and inhibit by hyperglycemia and leptin), other 
hormones (stimulated by estrogens and inhibited by glucocorticoid 
excess), neuropeptides, neurotransmitters and opiates (2–4).
! e secretion of GH is pulsatile with undetectable serum GH levels 
between the pulses. In normal subjects the 24-hour pro" le of plasma 
GH levels consists of stable low levels interrupted by bursts of secretion 
(Figure 2 and 3). ! e major determinant of GH secretion in humans is 
sleep. GH secretion is lower in elderly and obese subjects and there are 
sex-speci" c di% erences in GH pulse amplitude and mass (5;6). ! e age-
associated changes in the GH pro" le include a reduction in GH secretory 
burst frequency, the half life of endogenous GH and the daily secretory 
rate (7). In obese subjects decreased GH concentrations result from both 
diminished pulsatile GH secretion and accelerated metabolic clearance 
(4;8). 
In the liver, GH stimulates the production of insulin-like growth 
factor (IGF-I). ! e primary function of GH is promotion of linear 
growth in children by acting directly and indirectly (via the synthesis 
of IGF-I which mediates most of the peripheral actions of GH) on the 
epiphyseal plates of long bones. Whereas GH and IGF-I have synergistic 
e% ects on linear and organ growth by their control of mitogenesis and 
apoptosis and on glomerular " ltration rate, their metabolic actions are 
opposing: GH stimulates lipolysis and reduces insulin sensitivity, IGF-I 
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Figure 2. Plasma hormone concentration pro! les of a 33 year-old healthy female 
volunteer. Blood samples were taken at 10 min intervals during 24 hours. The black bar 
in the top of the panels indicate the period with lights o" . Note the diurnal and the 
pulsatile characteristics of each hormone. (The ! gure was provided by Dr. F. Roelfsema, 
Leiden University.)
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Figure 3. Plasma hormone concentration pro! les of a 37 year-old healthy male 
volunteer. Blood samples were taken at 10 min intervals during 24 hours. The black bar 
in the top of the panels indicate the period with lights o" . Note the diurnal and the 




2. Regulation of ACTH and cortisol secretion 
! e secretion of corticotropin (ACTH) and cortisol is regulated by 
hormonal interactions between the hypothalamus, pituitary, and adrenal 
glands. ! e secretion of hypothalamic corticotropin-releasing hormone 
(CRH) is regulated mainly by hippocampal neurons that express both 
receptors for cortisol, the mineralocorticoid- and glucocorticoid receptor. 
In addition the secretion is in+ uenced by the circadian pacemaker and 
stress (2;11). CRH regulates the secretion of ACTH by the pituitary gland, 
which is potentiated by arginine-vasopressin. Subsequently ACTH 
binds to its receptor on the adrenal cortex to stimulate the secretion 
of cortisol and other steroids. ! e negative feedback loop is completed 
by the inhibitory e% ect of cortisol on CRH and ACTH synthesis and 
secretion (11).
Pulsatile secretion and circadian rhythm
ACTH is secreted in brief episodic bursts resulting in a diurnal rhythm of 
ACTH secretion with a concordant diurnal secretion of cortisol from the 
adrenal cortex (12;13). Plasma ACTH and serum cortisol concentrations 
are highest early in the morning at time of awakening. During the day 
plasma cortisol levels fall resulting in low levels in the late a& ernoon 
and evening with a nadir one or two hours a& er sleep onset (Figure 2 
and 3) (11;14;15). 
Stress-induced secretion
! e HPA axis is activated both by physical and psychological stressors, 
resulting in increased plasma ACTH and cortisol concentrations. 
Physical stressors include severe trauma, like burns (16;17), or illnesses, 
major surgery (18;19), but also hypoglycemia (20;21), hypotension, 
exercise (22), and cold exposure (23).
Negative feedback inhibition by glucocorticoids
Both endogenous and exogenous glucocorticoids have a negative 
feedback on ACTH secretion which occurs at both the hypothalamic 
(CRH suppression) and pituitary (ACTH suppression) levels. ! is 
leads to atrophy of the adrenal glands resulting in loss of cortisol 
secretory capacity (24). ! e degree of probably depends upon the dose, 
potency and duration of action of the glucocorticoid, and the time 
of its administration (25–29). ! e shorter the interval between the 
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administration of glucocorticoid and the normal early morning peak of 
ACTH secretion, the greater the suppressive e% ect of the glucocorticoid. 
! e duration of suppression is increased by higher doses and longer-
acting glucocorticoids. A& er withdrawal of chronic administration of 
high doses of glucocorticoid, suppression of the hypothalamic-pituitary-
adrenal axis may persist for weeks but may even persist for many years. 
3. Regulation and secretion of thyroid hormone, gonadotropins 
and prolactin
! e hypothalamus-pituitary thyroidal axis regulates the production 
of thyroid hormone by the thyroid gland. ! e hypothalamus produces 
thyroptropin releasing hormone (TRH) which stimulates the pituitary 
gland to secrete thyrotropin (TSH). TSH stimulates the synthesis of the 
thyroid hormones (thyroxine (T
4
) and triiodothyronine (T
3
)) by binding 
to the TSH receptors on the thyroid cells. ! e response of TSH to TRH 









 inhibit and low levels stimulate TSH 
synthesis (2).
! e reproductive axis is controlled by periodic pulsatile release of 
the hypothalamic gonadotropin-releasing hormone (GnRH). GnRH 
stimulates the pituitary to secrete the gonadotropins, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH). ! e production of steroid 
hormones (including estradiol, progesterone and testosterone), as well 
as other factors such as inhibin, activin and insulin-like growth factor-I 
(IGF-I) are induced by the gonadotropins. ! e circulating sex steroids 
have a positive as well as negative feedback on GnRH and thereby also 
in+ uence LH and FSH concentrations. 
! e function of LH in men is to stimulate testosterone production 
from interstitial cells of the testes (Leydig cells) and FSH is required for 
spermatogenesis. In women, LH is critical for ovulation and maintenance 
of the corpus luteum, whereas FSH promotes follicular development (2). 
! e main physiological role of prolactin (PRL) is for nursing. ! e 
hypothalamic control of PRL secretion is predominantly inhibitory, 




III. Pituitary insu!  ciency
Hypopituitarism refers to decreased secretion of pituitary hormones, 
which can result from diseases of the pituitary gland and/or the 
hypothalamus, which cause diminished secretion of hypothalamic 
releasing hormones, thereby reducing secretion of the corresponding 
pituitary hormones. Pituitary insu'  ciency can be congenital (which will 
not be further addressed in this thesis) or acquired. 
Pituitary adenomas and its treatment
A common cause of pituitary dysfunction is the presence of a pituitary 
adenoma. Macro-adenomas (> 10 mm) can be associated with pituitary 
insu'  ciency, with one or more anterior pituitary hormone de" ciencies 
(30–32). In the presence of macroadenomas, hypopituitarism may result 
from compression of the rest of the pituitary and/or compression of the 
portal vessels in the pituitary stalk, secondary to either the expanding 
tumor mass or directly by increased intra-sellar pressure (30). Conversely, 
reduction of tumor mass by surgery and/or medication relieves the 
pressure and may restore pituitary function. 
In pituitary surgery the surgeon attempts to preserve the adjacent 
normal pituitary tissue. However, if the surgeon is not able to visually 
distinguish the normal pituitary tissue from the adenoma, the normal 
tissue may be damaged, resulting in pituitary de" ciency (33;34). 
Radiation of pituitary adenomas, usually to prevent regrowth of 
residual tissue a& er surgery or to control excessive GH or ACTH secretion, 
also exposes the nonadenomatous pituitary and the hypothalamus to 
irradiation resulting in pituitary insu'  ciency (35;36). Not only patients 
with pituitary tumors but also patients treated with radiotherapy for 
suprasellar lesions, primary brain tumors, nasopharyngeal tumors, head 
and neck tumors, or hematological malignancies (i.e. acute lymphoblastic 
leukemia (ALL)) are at risk for developing pituitary hormone de" ciencies 
if the hypothalamus and/or the pituitary have been exposed to radiation 
(37–39).
19
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Traumatic brain injury
In recent years, several studies have reported a high prevalence of 
pituitary insu'  ciency ranging from 15–90% in patients who experienced 
traumatic brain injury (TBI) (40–51). Large neuropathological series 
demonstrate pituitary as well as hypothalamic lesions a& er TBI (52). 
Infarction is believed to be the cause of posttraumatic hypopituitarism, 
found at post mortem in 26% to 86% of patients who died a& er TBI. 
Possible mechanisms for post-traumatic infarction include compression 
of the pituitary gland caused by changes in intracranial pressure resulting 
from cerebral edema, hemorrhage or skull fracture, hypoxia, or direct 
damage to the gland itself (53;54).
! e diagnosis of hypopituitarism, de" ned as de" cient secretion of one 
or more pituitary hormones secondary to pituitary or hypothalamic 
disease, is made by documenting subnormal secretion of these pituitary 
hormones under de" ned (i.e. controlled) circumstances. Since there 
is a variable pattern of hormone de" ciencies among patients with 
hypopituitarism, each pituitary hormone must be tested separately. 
For the evaluation of each axis basal serum hormones levels, but also 
dynamic testing is available. 
Growth hormone de! ciency 
Clinical consequences
Growth hormone de" ciency (GHD) in adults is characterized by 
increased body fat and decreased lean body mass, decreased bone mass 
and increased fracture rate, impaired cardiac function and reduced 
muscle strength (55–57). Adult patients with GHD also share a number 
of characteristics of the metabolic syndrome, including hypertension, 
abdominal obesity, insulin resistance and dyslipidemia (58). In addition, 
quality of life is impaired, with reduction in physical and mental 
energy, increased anxiety, and dissatisfaction with body image and 
poor memory (2;57;59;60). Replacement therapy with growth hormone 
(rhGH) was associated with apparent bene" ts, particularly in terms of 
body composition, bone mass, muscle strength, cardiac function and 




Because of the pulsatile nature of GH secretion, basal serum GH levels 
are not useful to assess the GH-IGF-I axis, although basal serum IGF-I 
levels below the reference ranges are indicative for GHD in the presence of 
two or more other insu'  ciencies (62;63). Normal IGF-I concentrations, 
however, do not exclude the diagnosis of GHD, as IGF-I levels are within 
the normal reference range in about one third of patients with GHD, 
especially in elderly subjects (64–66). ! erefore, the use of dynamic 
testing is mandatory for the evaluation of GH secretory reserve.
Di% erent stimulation tests are available (i.e. insulin tolerance test 
(ITT), and stimulation tests with glucagon, GHRH, GHRH-arginine, 
or GHRH-GHRP6). However the preferred test for evaluation of 
this axis still remains the insulin tolerance test (63;67). With the 
administration of insulin a hypoglycemia is induced which is a very 
strong physiological stimulator of the stress response. Hypoglycemia 
activates the hypothalamus to secrete GHRH resulting in stimulation 
of GH by the somatotropic cells of the pituitary gland. A peak GH 
response below 3 μg/L indicates a severe GHD (63;67). During ITT 
simultaneous assessment of the hypothalamus-pituitary-adrenal (HPA) 
axis is possible. Important contra-indications to perform the ITT are 
coronary insu'  ciency and/or epilepsy. To assess the GH axis in these 
patients, alternative provocative tests for GH secretion must be used with 
adapted appropriate cut-o% s. ! e combined administration of arginine 
and GHRH is the most frequently used alternative GH stimulation test 
(66;68;69). GHRH and arginine both have a stimulatory e% ect on the 
pituitary gland (70;71). When given simultaneously they enhance their 
e% ect resulting in a secretion of GH. A bolus dose of GHRH (1 μg/kg body 
weight) is given intravenously at baseline, immediately followed by an 
intravenous infusion of arginine (0.5 gr/kg body weight (to a maximum 
of 30 gr)) for 30 minutes. Measurements of GH are done 30, 45, 60 and 
90 minutes a& er infusion. Recently, cut-o%  values adjusted for both body 
mass index (BMI) and age have been published (72).
Pitfalls
Several factors play a role when testing the GH secretion reserve, such as 
age, gender, BMI, other hormones and insulin sensitivity. Obese subjects 
have a blunted GH response to any provocative stimulus (8;73;74). ! ere is 
an estrogen-related di% erence in GH axis activity: GH secreted per burst 
21
GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS
greater and 24-hour GH release pattern is less orderly in women than 
men (75). Finally, GH secretion decreases with increasing age. ! erefore, 
these factors should be considered when de" ning the diagnostic cut-o%  
points in the assessment of GHD (72;76).
Corticotropin de! ciency
Clinical consequences
ACTH de" ciency leads to adrenocortical insu'  ciency, characterized 
by decreased secretion of cortisol. Normal corticotroph function is 
mandatory for adequate increase of cortisol concentrations in case of 
stress. However, to maintain su'  cient cortisol concentrations, normal 
basal secretion of ACTH is necessary. 
Hypocortisolism can be secondary to either adrenal gland destruction 
(primary adrenal insu'  ciency, mostly auto-immune adrenalitis or 
tuberculous adrenalitis) or to ACTH de" ciency (secondary or central 
adrenal insu'  ciency) (77).
Diagnosis
Similar to the secretion of GH, the secretion of ACTH is pulsatile with 
circadian variation resulting in a circadian rhythm of cortisol secretion. 
! erefore, it is necessary to evaluate basal serum cortisol secretion in the 
early morning, during fasting. When cortisol concentrations are lower 
than, or exceed, a certain threshold (< 100 nmol/L or > 500 nmol/L) the 
likelihood of the presence or absence of adrenal insu'  ciency is very 
high, or negligible, respectively. In these cases stimulatory tests are not 
necessary (78). In all other condition, a dynamic test is mandatory. 
! e initial and most convenient test to evaluate the function of the 
HPA axis is the plasma cortisol response to synthetic ACTH (Synacthen 
test) (79;80). ! e test is performed by administering a bolus of 1 or 250 μg 
of cosyntropin intramuscularly or intravenously with measurements 
of serum cortisol 30 and 60 minutes therea& er. A serum cortisol 
concentration of ≥ 500–550 nmol/L is considered a normal response. 
However, this test does not discriminate between the di% erent causes of 
adrenal insu'  ciency, and a normal test response does not exclude mild 
secondary forms of adrenal insu'  ciency (81–84). 
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Other tests, that directly evaluate pituitary reserve are also available 
(insulin induced hypoglycemia, metyrapone administration, or CRH 
stimulation). Also in the assessment of the HPA axis (similar to the GH-
IGF-I axis) the ITT still remains the golden standard (85;86). Insulin 
induced hypoglycemia results in stress which actives the entire HPA 
axis providing proof for adequate hypothalamic (CRH) and pituitary 
(ACTH) function. In healthy subjects serum cortisol levels will increase 
above 550 nmol/L if adequate hypoglycemia is achieved (glucose 
2.2  mmol/L or lower). Stimulation with metyrapone is an alternative 
test to assess the HPA axis. ! e adrenal enzyme 11-ß-hydroxylase 
(CYP11B1) that catalyzes the conversion of 11-deoxycortisol to cortisol, 
is inhibited by metyrapone, resulting in a reduction of cortisol secretion. 
Administration of metyrapone will thus result in activation of the HPA 
axis, an increase in ACTH secretion and consequently an increase in 
adrenal steroidogenesis up to 11-deoxycortisol. An 11-deoxycortisol 
concentration above 200 nmol/L in the presence of suppressed cortisol 
levels (below 100 nmol/L) is then indicative for central adrenal 
insu'  ciency (87–89). ! is test can be performed as a prolonged and short 
overnight version, depending on the number of dosages of metyrapone 
given. It appears, however, that the ACTH stimulus of a single dose of 
metyrapone is comparable to that of an insulin tolerance test (89). 
Since the 1980’s ovine CRH is used for the evaluation of the HPA axis, 
mainly to discriminate between pituitary or adrenal causes of Cushing’s 
syndrome (90-94). However, in recent years the CRH test is more o& en 
used to assess secondary adrenal insu'  ciency (95;96). Administration of 
an intravenous bolus of ovine CRH results in pituitary ACTH secretion 
resulting in cortisol secretion by the adrenal glands. In healthy subjects 
a 1 μg/kg i.v. CRH bolus results in a peak ACTH response within 15 min 
and a peak cortisol response within 30–60 min. A peak cortisol of 
550 nmol/L or higher is considered to be a su'  cient reaction. ! e CRH 
test however, is inferior to the ITT and metyrapone test (97).
Pitfalls 
! e use of exogenous corticosteroids can suppress the HPA axis. 
! erefore, in case of exogenous glucocorticoid use, a reliable evaluation 
of the HPA axis can not be performed within 6 weeks a& er withdrawal 
of the steroid but might even be disturbed many months therea& er. 
Contraceptives in females should also be stopped for at least 6 weeks 
23
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! e symptoms and signs associated with thyrotropin (TSH) de" ciency 
are similar to those of primary hypothyroidism but usually are less 
severe, as there o& en is some residual thyrotropin secretion. In addition, 
TSH de" ciency is almost always part of complete anterior pituitary 
hormone de" ciency because thyreotroph secretion is the most resistant 
to insu'  ciency. Tiredness, cold intolerance, weight gain, constipation, 
dry skin, and hair loss are common features. 
Diagnosis
TSH de" ciency is diagnosed by low or normal serum TSH concentrations 
in the presence of low serum free thyroxine (fT
4
) level. Measurement of 
serum fT
3
 is not of additional value but may be low or normal. ! yrotropin-
releasing hormone (TRH) can be used to assess TSH secretion. However, 
the response to TRH varies widely among individuals. ! erefore it is not 
possible to discriminate between a normal and abnormal response in 
the majority of cases and TRH has not been incorporated into routine 
clinical practice of the evaluation of TSH de" ciency (100). 
Gonadotropin de! ciency
Clinical manifestations
! e clinical features of gonadotropin de" ciency are determined by gender 
and the age of development. ! e physical examination in men with recent 
onset hypogonadism will usually be normal. However, in longstanding 
hypogonadism diminished facial and body hair, gynaecomastia, and 
small, weak testes can be present. Libido may be reduced and the ability 
to achieve and maintain an erection may be compromised. Patients 
can also complain of nonspeci" c symptoms, such as tiredness, reduced 
muscle strength, reduced exercise capacity, but also emotional lability 
and depression. ! e symptoms in men are nonspeci" c and therefore 
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may not become evident for many years, particularly if fertility is not an 
issue (77).
In women gonadotropin de" ciency leads to menstrual disturbances 
(i.e. oligomenorrhea or amenorrhea) and therefore o& en earlier diagnosed 
compared to men (2). 
Diagnosis
! e diagnosis in women is straightforward. In premenopausal women 
secondary amenorrhea with low levels of estradiol and low or nomal 
levels of gonadotropins will con" rm the diagnosis. Whereas, in post-
menopausal women FSH and LH will be (undetectably) low. 
Low or normal gonadotropin levels combined with serum testosterone 
levels below the reference range, corrected for age are su'  cient to con" rm 
the diagnosis. Because of the great circadian variation randomly found 




Mild hyperprolactinaemia (up to 5 times the upper limit of normal) 
is common in patients with hypopituitarism. A pituitary mass with 
supra-sellar extension may compress the stalk resulting in decreased 
dopaminergic inhibition of prolactin secretion. 
Raised prolactine levels e% ects pulsatile secretion of gonadtropins 
resulting in hypogonadism. Galacthorrhea can also be present. Prolactin 
de" ciency almost invariably results from lactotroph de" ciency secondary 
to hypothalamic damage as a result of irradiation and or surgery.
Diagnosis
! e diagnosis of prolactin de" ciency is straightforward using com-
mercially available assays with gender adjusted reference ranges for the 
determination of prolactin concentrations. However, unless it is in the 
postpartum period, there are no clinical implications.
25
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IV. Outline of this thesis
Pituitary insu'  ciency in the presence of a pituitary macroadenoma or 
a& er pituitary irradiation is frequently reported. In addition, pituitary 
insu'  ciency is increasingly reported a& er traumatic head injuries. ! e 
correct evaluation and interpretation, however, of the pituitary axes, and 
consequently, the potential therapeutical consequences are a matter of 
controversies. ! e studies reported in this thesis aim to provide better 
insight into the complexity of di% erent endocrine tests used for the 
evaluation of possible pituitary insu'  ciency and in the treatment of 
patients with pituitary insu'  ciency. 
The evaluation of pituitary function in patients after 
traumatic brain injury
Traumatic brain injury (TBI) has emerged as an important cause of 
hypopituitarism. However, considerable variations in the prevalence of 
hypopituitarism are reported. ! ese variations can partly be explained 
by the severity of trauma and timing of hormonal evaluation, but may 
also be dependent on endocrine tests and criteria used for diagnosis of 
hypopituitarism. ! erefore, in chapter 2, we performed a systematic 
review of the literature to critically compare pituitary function tests, 
and de" nitions of hypopituitarism in studies that assessed the long-term 
outcome of TBI on pituitary function.
Because of the great variation in prevalence rates reported and the 
great variation in endocrine assessments used, we decided to perform 
a cross-sectional study in the Netherlands of a large cohort of 112 TBI 
patients evaluated a& er long-term follow-up. We assessed the prevalence 
of pituitary insu'  ciency in our own large cohort of TBI patients using 
a standardized endocrine evaluation, described in chapter 3. In these 




Dynamic tests of pituitary function in other pituitary 
diseases 
Pituitary adenomas and their treatment (i.e. surgery and/or radiotherapy) 
are also causes for pituitary insu'  ciency. Pituitary insu'  ciency is a 
complication that can be attributed to the tumor itself (compression) 
but also to the surgical approach and/or subsequent radiotherapeutical 
intervention. ! erefore, accurate assessment of pituitary function is 
critical for appropriate management of patients with pituitary adenoma 
a& er surgery with or without irradiation. For many years, all patients 
in our hospital underwent a CRH stimulation test for the evaluation of 
the HPA axis shortly a& er pituitary surgery. In chapter 4, we describe a 
retrospective study that evaluated the clinical applicability of the CRH 
test directly a& er TS in our center. 
! e ITT, however, is considered the golden standard test for the 
evaluation of the HPA axis. In chapter 5, we describe a study on the long-
term prevalence of adrenal insu'  ciency a& er transsphenoidal surgery for 
growth-hormone secreting pituitary adenomas using the ITT and CRH 
test in the majority of the patients. ! e reason for this evaluation was 
a recently published study that reported a remarkably high prevalence 
of adrenal insu'  ciency a& er surgical and/or medical treatment without 
postoperative radiotherapy in patients treated for acromegaly. ! erefore, 
in our study, we evaluated the prevalence and incidence rate of adrenal 
insu'  ciency in 91 consecutive patients during long-term follow-up a& er 
successful transsphenoidal surgery for acromegaly. 
In addition to patients with pituitary tumors, patients with 
nonpituitary intracranial and or nasopharyngeal tumors are treated by 
radiotherapy, in which the pituitary gland is involved in the radiation 
" eld. ! ese patients are also at risk for pituitary insu'  ciency. To assess 
the prevalence of possible pituitary insu'  ciencies we performed a 
systemic literature search and meta-analysis focusing on the prevalence 
of pituitary dysfunction in adult patients treated with radiotherapy for 
nonpituitary tumors, which is described in chapter 6. 
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Treatment of GH de! ciency
When growth hormone de" ciency is diagnosed, the therapeutical 
consequences should be carefully evaluated, especially in certain 
conditions like obesity and during senescence where GH secretion overlaps 
with a GH de" cient state. With increasing age, but also increasing BMI, 
GH secretion decreases. ! erefore, the e% ects of treatment with rhGH in 
obesity and in the elderly diagnosed with GHD might be di% erent.
! erefore, in chapter 7, we performed a structured review, to critically 
assess the available literature in order to evaluate the available evidence 
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Objective: Traumatic brain injury (TBI) has emerged as an important 
cause of hypopituitarism. However, considerable variations in the 
prevalence of hypopituitarism are reported. ! ese can partly be 
explained by severity of trauma and timing of hormonal evaluation, but 
may also be dependent on endocrine tests and criteria used for diagnosis 
of hypopituitarism. 
Methods: Systematic review of studies reporting prevalence of 
hypopituitarism in adults ≥ 1 year a& er TBI focusing on used (dynamic) 
tests and biochemical criteria.
Results: We included data from 14 studies with a total of 931 patients. 
! ere was considerable variation in de" nition of hypopituitarism. 
Overall, reported prevalences of severe GH de" ciency varied between 
2 and 39%. Prevalences were 8–20% using the GHRH-arginine test (cut-
o%  < 9 μg/L), 11–39% using the glucagon test (cut-o%  1–5 μg/L), 2% using 
the GHRH test (no cut-o% ) and 15–18% using the insulin tolerance test 
(ITT) (cut-o%  < 3 μg/L). 
Overall, the reported prevalence of secondary adrenal insu'  ciency 
had a broad range from 0 to 60%. ! is prevalence was 0–60% with 
basal cortisol (cut-o%  < 220 or < 440 nmol/L), 7–19% using the ACTH 
test and 5% with the ITT as " rst test (cut-o%  < 500 or < 550 nmol/L). 
Secondary hypothyroidism was present in 0–19% (free T
4
) or 5–15% 
(TRH stimulation). Secondary hypogonadism was present in 0–29%. 
Conclusion: ! e reported variations in the prevalence rates of 
hypopituitarism a& er TBI are in part caused by di% erences in de" nitions, 
endocrine assessments of hypopituitarism and confounding factors. 
! ese methodological issues prohibit simple generalizations of results of 
original studies on TBI-associated hypopituitarism in the perspective of 
meta-analyses or reviews.
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Introduction
In recent years, an increasing number of studies have reported the 
presence of pituitary insu'  ciency in patients who experienced traumatic 
brain injury (TBI) (1–14). ! e prevalence of pituitary insu'  ciency a& er 
TBI appeared to be unexpectedly high (15;16). Remarkably, the prevalence 
rates varied considerably among the di% erent studies, ranging from 15 to 
even 90% of the patients. 
Several factors in+ uence the prevalence of hypopituitarism a& er 
TBI. First, the time interval between TBI and the assessment of pituitary 
function, since hormone alterations mimicking pituitary insu'  ciency 
are prevalent in the early post-traumatic period. Second, the type and 
severity of the brain injury a% ects the prevalence of hypopituitarism, 
because persistent pituitary insu'  ciency is only frequent a& er severe 
TBI (7;15). ! ird, endocrine tests, assays, and criteria for the diagnosis 
of hypopituitarism di% er between the studies. Although many reviews 
have addressed TBI-related hypopituitarism, a detailed comparison of 
these methodological issues between the di% erent studies has not been 
performed for each pituitary axis.  
We hypothesized that these methodological di% erences may have 
contributed, at least in part, to the discrepancies in prevalence rates of 
hypopituitarism a& er TBI, reported by the di% erent studies. ! erefore, 
the aim of this study was to critically compare the pituitary function 
tests, and de" nitions of hypopituitarism between studies that assessed 





We performed a search in PubMed, EMBASE, Web of Science, and the 
Cochrane database, for all published studies on the association between 
TBI and hypopituitarism. ! e following search strategy was used: 
(Traumatic Brain Injury OR Traumatic brain injuries) AND (traumatic 
OR trauma) AND (Hypopituitarism OR Hypopituitar* OR Hypothalamus 
Hypophysis System OR “Hypothalamopituitary dysfunction” OR “pituitary 
dysfunction” OR Hypothalamo-Hypophyseal System OR Pituitary Gland 
OR Hypophysis).
In addition, the references of relevant articles were checked for 
additional articles. ! e search was performed on 23 March 2009. Only 
original articles were included. We used the following exclusion criteria: 
pediatric or adolescent population, publications concerning pituitary 
testing < 12 months a& er injury (a median of 12 months was accepted), 
and articles that evaluated pituitary insu'  ciency a& er subarachnoidal 
bleeding (SAB). 
Data review
! e following data were extracted from each study: 1) age and gender, 
2) the endocrine tests used for assessment of each pituitary axis, 
3)  de" nitions used for pituitary insu'  ciency for each pituitary axis, 
4) hormone assays, 5) reference values provided in the manuscript, and 
6) use of control populations. Tables were constructed per pituitary axis. 
! ese tables are added as supplemental data " les. ! e growth hormone 
(GH)-IGF-I axis (Table 2), the pituitary-adrenal axis (Table 3), the 
pituitary-thyroidal axis (Table 4), the pituitary-gonadal axis (Table 5), 
and prolactin (Table 6). 
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Results
We identi" ed 278 articles, of which 218 were excluded on the basis of 
title and abstract. Of the remaining 60 articles, 46 were reviews. Finally, 
14  original studies were included with a total of 931 patients. Details 
of these studies are summarized in Table 1. ! e number of patients 
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The GH-IGF-I axis
! e prevalence of GH de" ciency (GHD) ranged between 2 and 66% 
(severe GHD 39%; Figures 1 and 2 and Suppl Table 2). ! e presence of 
GHD was associated with higher body mass index (BMI) values in some 
of the studies (Figure 1). In addition to basal serum GH and IGF-I values, 
all studies used a dynamic test to assess GH secretory reserve. However, 
di% erent dynamic tests were used.
! ree studies (196/931=21% of all patients) used the combined GHRH-
arginine test as the " rst screening. ! e criterion for severe GHD was a 
peak GH level < 9.0 μg/L in all three, which was not adjusted for BMI. 
Prevalence rates of severe GHD varied between 8 and 20% (weighted 
mean 12%) (2;3;5). Schneider et  al. (11) also used the GHRH-arginine 
test, but only in a subset of the patients (those with abnormal serum 
cortisol levels, n=32); the prevalence of GHD in this study was 10%.
Two studies (112/931=12% of all patients) used an insulin tolerance 
test (ITT) as the primary screening test (6;7). ! e criterion for severe 
GHD was a peak GH response < 3 μg/L in both, and the prevalence of 
GHD was comparable (18 and 15% respectively; weighted mean 16%). 
Of the eight remaining studies, three used a stimulation test with 
glucagon (n=209) (1;4;9) with prevalence rates for severe GHD between 
11 and 39% (weighted mean 20%). ! e cut-o%  values di% ered considerably 
and varied between 1 and 5 µg/L between these studies. Just one study 
used a stimulation test with GHRH only (number of patients not 
recorded) reporting a GHD prevalence of 2% (13). Two studies (n=119) 
used the combined GHRH-GHRP6 test with a prevalence of 15 and 33% 
respectively (weighted mean 21%) (10;12). ! e cut-o%  values were similar 
(GH < 10 μg/L) within these studies, and were derived from another 
report (17).
Finally, two studies used a combination of these tests (8;14). For 
instance, Agha et al. (1) used a glucagon stimulation test for the initial 
screening in 102 subjects, and in case of incomplete GH response, they 
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Figure 2. Absolute and weighted mean prevalence 
rates of severe GH de! ciency (GHD) according to 
the stimulation tests used per study. The number of 
patients tested is depicted in each bar. Panel A: the 
combined GHRH-arginine test; de! nition severe GHD: 
peak GH < 9 μg/L for all four studies. Panel B: the insulin 
tolerance test (ITT); *de! nition severe GHD: GH < 95% 
CL according to AUC; **de! nition severe GHD: peak 
GH < 3 μg/L. Panel C: the combined GHRH-GHRP6 
test; de! nition severe GHD: peak GH < 10 μg/L for 
both studies. Panel D: the glucagon stimulation test; 
de! nition severe GHD: *peak GH < 3 μg/L; **peak GH 
< 5 μg/L. Panel E: combined stimulation tests as initial 
screening followed by con! rmation test; ΔGHRH-
GHRP6 test as initial test; ITT and glucagon stimulation 
test as con! rmation tests; ΔΔGHRH-GHRP6 test as initial 




! e prevalence of secondary adrenal insu'  ciency de" ciency ranged 
from 0 to 60% between the studies (Figure 3, Suppl Table 3). 
Four studies (251/931=27% of all patients) only measured basal 
morning fasting serum cortisol and/or ACTH levels (2–4;10), resulting 
in prevalence rates between 0 and 60% (weighted mean 15%). ! e 
criteria for pituitary-adrenal insu'  ciency di% ered between three studies 
(cortisol < 220–440 nmol/L), and were not reported in the fourth study 
(10). ! e study reporting the highest prevalence of 60% used a cut-o%  
value of 440 nmol/L (4).
Four studies (145/931=12% of all patients) used an ACTH stimulation 
test (Synacthen; either with 1 or 250 μg). However, only one study 
performed this test in all patients and the prevalence of ACTH de" ciency 
was 7% (9). In the other three studies, only a subset of the patients (those 
with subnormal basal cortisol levels) underwent stimulation with ACTH. 
! e prevalence in these studies varied between 7 and 19% (weighted 
mean 10%) (11;12;14). 
One study (55/931=6% of all patients) used nonstimulated cortisol 
values between 1600 and 2000 h (reference values 63–339 nmol/L), which 
was followed by a corticotrope releasing hormone (CRH) test only in 
those with values below this reference range, or in those who responded 
con" rmatory to a speci" c questionnaire (13). 
In the remaining " ve studies (403/931=43% of all patients), the ITT 
was used in 169 patients as a primary test (n=112) resulting in a prevalence 
of 5% in both studies (6;7), or as a con" rmation test in a subset of the 
patients. Two studies measured basal serum cortisol levels and used ITT 
as a con" rmation test (prevalence of 3 and 11% respectively) (5;8). One 
study assessed primarily with a glucagon stimulation test (n=102), and 
used the ITT and ACTH tests to con" rm ACTH de" ciency (prevalence 
13%) (1). ! e criteria for a normal cortisol response to hypoglycemia 
were a peak cortisol level > 550 nmol/L in one (8), and > 500 nmol/L 
in three other studies (1;5;7). ! e " & h study used a control group of 
18 healthy subjects to de" ne normal cortisol responses to ITT (cortisol 
response < 95% con" dence limit according to the obtained area under 
the curve)  (6). ! e CRH test was used in only one study and did not 
report the number of patients (13).
47






























































































































































































Figure 3. Absolute and weighted mean prevalence rates of corticotropin (HPA axis) de! ciency 
according to the stimulation test used per study. The number of patients tested is depicted in each 
bar. Panel A: basal cortisol concentrations only using di" erent cut-o"  levels; *cut-o"  level: NR; **cut-
o"  level: cortisol < 220 nmol/L; ***cut-o"  level: cortisol < 440 nmol/L. Panel B: the ACTH stimulation 
test *using 250 µg ACTH and peak cortisol < 500 nmol/L; **using 1 µg ACTH and peak cortisol 
< 550  mol/L. Panel C: the insulin tolerance test (ITT); *peak cortisol < 95% CL according to AUC; 
**peak cortisol < 500 nmol/L; ***peak cortisol < 550 nmol/L. Panel D: other stimulation tests: Δthe 




! e prevalence of hypothalamus-pituitary-thyroid axis de" ciency ranged 
from 0 to 19% between the studies (Suppl Table 4). 
! e criteria for TSH de" ciency were di% erent. Nine studies used 
basal free thyroxine (fT
4
) and TSH levels only. Within these studies, 
the cut-o%  value for decreased fT
4
 varied between 8 and 12 pmol/L 
(2;5;7;11;14;18;19). In two studies, reference values were not reported 
(4;10), one of which (Bushnik et al.) reported the highest prevalence of 
secondary hypothyroidism.
! e thyroid-releasing hormone (TRH) stimulation test was used in 
" ve studies, using i.v. doses of 200 (13) and 500 µg (5;6;8;9). ! e criterion 
for a normal response di% ered considerably: a TSH peak response 
> 7 mIU/L, a TSH peak between 5 and 30 mIU/L, or were not reported 
(12;13).
! e prevalence rates between the studies that only measured basal 
fT
4
 levels varied between 0 and 19% (weighted mean 5%) (1–5;7;10;11;14), 
and between 5 and 15% (weighted mean 8%) in those that also used TRH 
(6;8;9;12;13).
The Hypothalamus-Pituitary-Gonadal axis
! e hypothalamus-pituitary-gonadal axis de" ciency ranged from 0 
to 29% (weighted mean 13%) between the studies (Table 5). Basal LH 
and FSH were measured in all but one study (4). Basal estradiol (E
2
 
in women) was measured in 9 studies, and the menstrual history was 
recorded in 10 out of 14 studies. Testosterone (in men) was measured in 
all studies. In four studies, a GnRH stimulation test was performed in a 
subset of the patients (6;8;9;13). ! e criterion for a normal test response 
di% ered between the studies (Suppl Table 5). ! e de" nition of secondary 
hypogonadism was mainly based on basal testosterone (in men) and E
2
 
concentrations (in women) below the reference ranges, in the presence 
of decreased or normal LH and FSH levels. A subset of the studies also 
incorporated the GnRH test result (see above) and menstrual cycle 
abnormalities in premenopausal females.
Prolactin
! e prevalence of abnormal serum PRL concentrations ranged from 
0 to 16% (Suppl Table 6). Abnormal PRL secretion was de" ned as 
hyperprolactinemia (8/14 studies) (1;2;5;7;9;11;12;14), hypoprolactinemia 
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(one study) (6), or both (3). In accordance, prevalence rates were between 
3 and 12% using the de" nition of hyperprolactinemia, 0% using the 
de" nition of hypoprolactinemia, and 16% using the combination of 
both. Out of the 14 studies, 10 measured basal serum PRL concentrations 
only (1–3;5;7;9–12;14). ! ree studies also used a TRH test (doses 100 and 
500 μg respectively) (6;8;13). Prevalence rates were not reported in two of 




! is review demonstrates that the endocrine evaluations and de" nitions 
of hypopituitarism di% er considerably among the studies that have 
assessed TBI-related hypopituitarism. From the existing literature, the 
notion emerges that most of the tests that are currently used to establish 
the diagnosis of hypopituitarism in general, and GHD in speci" c, are 
not validated su'  ciently regarding cut-o%  values, reproducibility, and 
dependence on confounding factors in TBI patients. 
In general, there are hardly any data on reproducibility of tests or 
dependence on confounding factors in TBI patients. One factor that 
comes forward in the current review is the potential e% ect of increased 
BMI, which in general is associated with decreased GH responses 
to GH stimulation tests. ! erefore, increased BMI may result in an 
inadvertently higher incidence rate of GHD, if the cut-o%  values for 
normal GH responses to GH stimulation tests are not adapted according 
to BMI. All these methodological issues limit the applicability of the 
individual studies, i.e. the decision whether the study results are valid 
for patients to whom the results are generalizable but who are subjected 
to a di% erent endocrine diagnostic assessment than the original study 
population. Moreover, these methodological limitations prohibit simple 
generalizations of the results from the perspective of a meta-analysis or 
a review. 
! e question arises whether post-traumatic hypopituitarism, 
especially GHD, has been overdiagnosed on the basis of the older 
cross-sectional studies. Consensus guidelines for the evaluation of 
adult GHD state that di% erent dynamic tests can be used to diagnose 
GHD, including the ITT, the glucagon stimulation test, the combined 
GHRH-arginine test, and the combined GHRH-GHRP6 test (20). ! e 
present assessment, however, documents a higher prevalence of GHD 
for the glucagon stimulation test and the combined GHRH-GHRP6 
test, compared to the results of the combined GHRH-arginine test and 
the ITT. With the exception of the ITT (which was used in only 12% 
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of the patients (6;7)), the outcome of each test varied greatly (Figure 2) 
using di% erent (glucagon stimulation test) or similar cut-o%  levels (other 
test). In addition, the studies that used two dynamic tests to assess GH 
reserve revealed a lower prevalence of GHD than the studies with only 
one test. Moreover, the results of GH stimulation tests are confounded 
by BMI, with higher BMI being associated with decreased GH responses. 
Although BMI-adjusted reference values have been reported (21), none 
of the studies on TBI-associated GHD reports adjusted their cut-o% 
values for BMI. Moreover, the data indicate that BMI tends to be higher 
in the TBI patients with GHD (Figure 1). Finally, an important aspect is 
that most patients had only GHD or one additional pituitary hormone 
de" ciency. ! erefore, one test may not be su'  ciently reliable and the use 
of two tests would increase the con" dence in the diagnosis, although 
only if the two tests yield concordant results. However, the application of 
two tests may introduce an even greater uncertainty in case of discordant 
results. ! is discrepancy has been documented for instance in GHD in 
irradiated patients, in whom the attenuation in GH responses to the 
ITT was greater compared with the combined GHRH-arginine test (22). 
! ese factors impose major problems for an accurate assessment of GHD 
in these patients. ! erefore, these methodological issues have contributed 
to the suspicion that GHD is probably over diagnosed in the older cross-
sectional studies.
We observed similar variations in test results of the pituitary-adrenal 
axis (Figure 3). ! e use of di% erent tests with di% erent cut-o%  values 
resulted in prevalence rates that varied between 5 and 19%. ACTH 
de" ciency can be diagnosed by measuring basal early morning cortisol 
levels: values below 100 nmol/L are indicative of ACTH de" ciency, 
whereas cortisol values above 500 nmol/L essentially exclude ACTH 
de" ciency. ! e ACTH stimulation test is reliable in diagnosing clinically 
signi" cant adrenal insu'  ciency in patients who are at risk (23–25). 
ACTH stimulation tests, however, are not fully reliable in excluding 
the presence of mild secondary adrenal insu'  ciency (26). ! e ITT still 
remains the golden standard, and has the advantage that ACTH/cortisol 
and GH secretory reserve can be assessed simultaneously. If an ITT is 
contraindicated, a CRH test can be alternatively used (27). ! e e% ect 
of the initial choice for a speci" c stimulation test on the variation in 
outcome of adrenal insu'  ciency and GHD based on the available data 
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! e diagnosis of secondary hypothyroidism is usually made based 
on fT
4
 values. However, basal fT
4
 levels show a relatively small intra-
individual variability, although inter-individual variability is large (28). 
As a consequence, a diagnosis of possible secondary hypothyroidism 
may not be straightforward, since fT
4
 levels within the normal reference 
range can re+ ect hypothyroidism in one patient but euthyroidism 
in another patient. Basal TSH levels are also of limited help for the 
diagnosis of secondary hypothyrodism, since normal or even increased 
levels of TSH can be found (29). In addition, a TRH test is of limited 
value because patients with central hypothyroidism may show di% erent 
patterns of TSH responses to TRH, with absent or exaggerated responses, 
which considerably overlap with those found in healthy volunteers. 
Moreover, the magnitude of the TSH peak is proportional to the injected 
TRH dose, is higher in women, and tends to decline with age (30). In 
accordance, the prevalence rates were not a% ected by the use of TRH 
stimulation. In analogy, the interpretation of the GnRH test is complex, 
and individual responses vary greatly in both adults and children (31). 
In men, it is su'  cient to measure non-stimulated LH, FSH, and 
testosterone concentrations. In premenopausal women, the evaluation of 
the menstrual cycle is a prerequisite, whereas in postmenopausal women, 
the absence of increased LH and FSH levels almost invariably indicates 
hypogonadotropic hypogonadism. 
Analytical factors will most likely also have a% ected the di% erent 
outcomes of the studies. For instance, the GH and cortisol assays 
varied between studies, and it is known that the between-laboratory 
performance of the GH assay is not very good. Moreover, most were not 
validated su'  ciently regarding normal cut-o%  values, reproducibility, 
and dependence on confounding factors even in a ‘normal’ population. 
None of these tests have been validated in TBI patients at all. 
! e time point of evaluation may also in+ uence outcome; therefore, 
we focused only on studies in the chronic phase a& er TBI, i.e. one year 
a& er the trauma. Studies that analyzed patients with a median duration 
of 12 months a& er TBI, however, were also included. ! us, part of these 
patients was assessed within 12 months a& er TBI. In general, the transient 
e% ects of TBI mimicking pituitary insu'  ciency are almost exclusively 
reported only within the " rst six months a& er TBI (15). ! erefore, it is 
unlikely that the pituitary results of the studies with a median duration 
of follow-up of 12 months of TBI are caused by the transient e% ects of 
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TBI. ! is is supported by similar results of additional analyses of the 
remaining studies, which included only patients with a follow-up of 
more than 12 months a& er TBI. Lastly, the underlying mechanisms of 
TBI-related hypopituitarism have not been resolved. It is unclear to that 
extent hypothalamic versus pituitary damage is present in TBI patients 
with hypopituitarism and what impact these processes may have on 
endocrine tests. 
Recently, many clinical reviews have summarized the studies on 
pituitary insu'  ciency a& er TBI (15;16). ! ese studies concluded that 
hypopituitarism is a common complication of TBI and might contribute 
to morbidity and poor recovery a& er brain injury (16). However, these 
reviews did not take into account the variability in diagnostic strategies 
and de" nitions of pituitary insu'  ciency. ! ese discrepancies, in addition 
to di% erences in inclusion and exclusion criteria, limit the possibility to 
compare the results of studies on TBI. We agree with Klose and Feldt-
Rasmussen that future studies should be designed to ensure a high 
diagnostic robustness for proper identi" cation of reliable predictors, as 
the results may be highly dependent on diagnostic pitfalls (15). 
In conclusion, the reported prevalence rates of pituitary insu'  ciency 
a& er TBI vary considerably, which is associated with major di% erences 
in endocrine and analytical methods of assessment and de" nitions 
used for hypopituitarism. ! is does not only apply to the case of TBI-
related hypopituitarism, but most likely also to hypopituitarism caused 
by pituitary diseases. ! e same caution with respect to the evaluation of 
pituitary function should be considered in pituitary diseases, because the 
diagnosis of de" nitive hypopituitarism remains a challenge in clinical 
endocrinology. In pituitary pathology, de" nitive data on robust accuracy 
of basal or dynamic hormonal tests are incomplete.
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Objective: Hypopituitarism a& er traumatic brain injury (TBI) is 
considered to be a prevalent condition. However, prevalence rates di% er 
considerably among reported studies, due to di% erences in de" nitions, 
endocrine assessments of hypopituitarism, and confounding factors, like 
timing of evaluation and the severity of the trauma. 
Aim: To evaluate the prevalence of hypopituitarism in a large cohort of 
TBI patients a& er long-term follow-up using a standardized endocrine 
evaluation. 
Study design: Cross-sectional study
Patients and Methods: We included 112 patients with TBI, hospitalized 
for at least 3 days and a duration of follow-up > 1 yr a& er TBI from 5 
(neurosurgical) referral centers. Evaluation of pituitary function included 
fasting morning hormone measurements and insulin tolerance test 
(ITT n=90) or, when contraindicated, ACTH-stimulation and/or CRH-
stimulation test and a GHRH-arginine test (n=22). Clinical evaluation 
included quality of life questionnaires.
Results: We studied 112 patients (75 males), with median age 48 yr, and 
mean BMI 26.7±4.8 kg/m2. Mean duration of hospitalization was 11 days 
(3–105) and 33% had a severe trauma (Glasgow Coma Scale < 9) a& er 
TBI. ! e mean duration of follow-up was 4 (1–12) years. Hypopituitarism 
was diagnosed in 5.4% (6/112) of patients: severe GH de" ciency (n=4), 
hypogonadism (n=1), adrenal insu'  ciency (n=2). Patients diagnosed 
with pituitary insu'  ciency had signi" cantly higher BMI (P =0.002).
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Conclusion: In this study, the prevalence of hypopituitarism during 
long-term follow-up a& er TBI was low. Prospective studies are urgently 
needed to " nd reliable predictive tools for the identi" cation of patients 




Traumatic brain injury (TBI) is common and an important cause of 
death, especially among adolescents in developed countries. ! e last 
decade, pituitary insu'  ciency has emerged as an important sequel 
following TBI, potentially in+ uencing short- and long-term morbidity. 
A& er TBI, many patients experience persistent, invalidating complaints 
that resemble those observed in patients with hypopituitarism, such 
as impaired cognition, depression, fatigue and impaired quality of life 
(QoL) (1–4). Consequently, pituitary insu'  ciency following TBI may 
contribute to the problems reported by these patients (4). ! is condition 
is important to identify since it can be treated by hormone replacement 
therapy resulting in improved QoL (3;5). 
However, the actual prevalence of hypopituitarism a& er TBI in an 
unselected population is subject for debate. ! e available cohort studies 
studying the prevalence of pituitary insu'  ciency report percentages 
ranging from 15 to 90% (6–18). ! ere are several explanations for this 
remarkably wide range in reported prevalences, including di% erences in 
inclusion criteria, di% erences in duration of follow-up since TBI (short vs 
long term follow-up) and the use of di% erent tests, di% erent assays and 
di% erent cut-o%  values (19). 
! erefore, the aim of our study was to evaluate the prevalence of 
hypopituitarism in a large cohort of TBI-patients a& er long-term follow-
up, using standardized endocrine evaluation including golden standard 
tests. ! e secondary aim was to assess QoL and the contribution of 
hypopituitarism on QoL. 
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Patients and methods
Study protocol
We performed a multicenter study in 5 hospitals across the Netherlands 
(Leiden University Medical Center; Academic Medical Center, 
Amsterdam, St. Elisabeth Hospital, Tilburg; Isala Clinics, Zwolle; 
Medical Spectrum Twente, Enschede). Eligible patients were selected from 
electronic registries of the departments of neurology using the following 
inclusion criteria: con" rmed diagnosis of TBI and hospitalization for 
at least three days for head injury at least one year prior to endocrine 
evaluation (to exclude possible hormone alterations mimicking pituitary 
insu'  ciency in the early post trauma period), age 18–70 yrs. Exclusion 
criteria were: medical or psychological problems (not related to TBI) 
that could disturb interpretation of results, including drug- or alcohol 
abuse, previously known hypothalamic- or pituitary dysfunction or 
history of cranial irradiation or pregnancy. Details on trauma severity 
were derived from the medical records. ! e Glasgow Coma Scale (GCS) 
at hospitalisation de" ned trauma severity. A GCS 13–15 indicates mild 
trauma, between 9–12 moderate trauma, and < 9 severe trauma (20;21). 
Ethical approval was obtained by the Medical Ethics Committees of all 
centers and all patients gave written informed consent.
Patients
A total of 2350 potential patients were retrieved from the electronic 
databases that had been diagnosed with TBI. ! e electronic patient 
records of these patients were retrieved in the departments of neurology 
of all participating hospitals. However, 1960 patients did not meet the 
abovementioned inclusion criteria and were excluded. ! e remaining 
390 patients were invited to participate, of whom 278 patients could 
not be included for various reasons: not willing to participate without 
giving any reason, not meeting the inclusion criteria (either 2 days of 
hospitalization, drug or alcohol abuse, or medication that could not be 
stopped) or were loss to follow-up. Ultimately, we included a total of 




‘brain injury’ retrieved from 




did not meet inclusion criteria
n=1960
Patients invited to
participate in study 
n=390 
Excluded because of:
unwilling to participate, 
loss to follow-up, 
not ful!lling inclusion criteria. 
n=278 
Patients included in study
n=112
Figure 1. Flow chart of inclusion of patients
Endocrine evaluation
Blood was sampled for assessment of basal and stimulated hormone 
concentrations between 08.00 and 09.00h A.M. a& er an overnight fast. 
All patients rested 30 min prior to testing a& er insertion of an indwelling 
catheter in a large forearm vein. Baseline samples were drawn for analyses 
of cortisol, free thyroxine (fT
4
), TSH, testosterone (men) estradiol (E
2
; 
women), LH, FSH, prolactin (PRL), GH and IGF-I. Oral contraceptives 
were discontinued for at least 6 weeks before testing.
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! e hypothalamic-pitutiary adrenal (HPA) and GH-IGF-I axes were 
evaluated with an insulin tolerance test (ITT), unless contraindicated, 
or alternatively by ACTH/CRH and GHRH-stimulation tests. An 
ACTH-test (1 or 250μg Synacthen iv, Novartis Pharma BV, Arnhem, the 
Netherlands), with measurement of cortisol at T= -5, 30 and 60 min, was 
performed routinely in all patients prior to the ITT to ensure su'  cient 
adrenal function. ITT was performed by administering soluble insulin 
intravenously (0.10 U/kg, Actrapid, Novo, Alphen aan den Rijn, ! e 
Netherlands) to induce hypoglycaemia (glucose < 2.2 mmol/L). Cortisol, 
ACTH, GH and glucose levels were measured at T = -15, 0, 15, 30, 45, 60 
and 90 min. Peak values of GH of 3 μg/L and cortisol of >500 nmol/L were 
considered to re+ ect su'  cient pituitary GH and ACTH function. If ITT 
was contraindicated, a GHRH-arginine test was conducted to evaluate 
GH secretory reserve. Patients received 1 μg/kg GHRH (Ferring BV, 
Hoofddorp, the Netherlands) and 500 mg/kg arginine with a maximum 
of 30 gr. GH levels were measured at T = –15, 0, 30, 45, 60, 75 and 90 
min. BMI adjusted cut-o%  values of 11.5 μg/L (< 25 kg/m2), 8.0 μg/L 
( 25-30 kg/m2), and 4.2 μg/L (> 30 kg/m2) were used (22). For the evaluation 
of the HPA axis when ITT was contraindicated, the response to ACTH-
stimulation was considered and an additional CRH-stimulation test was 
performed in selected cases (Table 2). 
Assays
GH was measured in participating centers using in-house assays. ! e 
measurement of GH has been harmonized in the Netherlands (23) and 
in all centers, GH was calibrated against the WHO-IRP 98/574 (1 μg/L 
= 3.0 mU/L). IGF-I measurement was centralized at the Department of 
Clinical Chemistry, Sahlgrenska University Hospital, Göteborg, Sweden 
using a chemiluminescence immunoassay (DPC, Immulite 2500 system, 
Siemens Healthcare Diagnostics, Deer" eld, IL, USA). ! e intra- and 
inter-assay coe'  cients of variation (CVs) were 4 and 11%. Reference 
values based on Brabant et al. (24) were used. With these IGF-I values 
IGF-I SD scores were calculated. 
! e participating centers used the following in house assays and cut-o%  
values: 
Leiden University Medical Center, Leiden:  Cortisol, fT
4
, TSH, LH, FSH 
and prolactine blood levels were measured by electrochemoluminescent 
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immunoassay (ECLIA), using a Modular E170, (Roche Diagnostics, 
Mannheim, Germany). ! e maximal inter-assay coe'  cient of 
variation was 5.0%. ACTH, GH and IGF-I were determined by 
immunolimunimetric assay using an Immulite 2500 (Siemens Healthcare 
Diagnostics, Deer" eld, IL, USA). ! e maximal inter-assay coe'  cient 
of variation was between 5.0 and 10.0%. Glucose levels were measured 
using a Modular P800 (Roche Diagnostics Mannheim, Germany) 
(CV is 3%). For measurement of estradiol levels a radioimmunoassay 
(RIA, Orion Diagnostica, Espoo, Finland) was used (CV is 6% at 
70 pmol/L). ! e estradiol detection limit was 20 pmol/L. Testosterone 
was measured using a RIA (Siemens Healthcare Diagnostics, Deer" eld 
IL, USA). (CV is 20% at 1.0 nmol/L and 12% at 14 nmol/L) ! e detection 
limit was 0.2 nmol/L.
Academic Medical Center, Amsterdam: Plasma LH, TSH and FSH were 
analysed by an automated assay on the E170 of Roche (Roche, Mannheim, 
Germany). ! e maximal intra- and inter-assay variations were < 5%. 
Plasma fT
4
, PRL and GH were analyzed by + uoroimmunoassay (Del" a, 
Perkin Elmer, Waltham, MA, USA) using the Del" a 1232 Fluorometer 
(Perkin Elmer). ! e maximal intra- and inter-assay CVs were 5.1 and 
6.8% for fT4, 3.4  and 5.3% for PRL, and 3.8 and 6.2% for GH, respectively. 
Testosteron was analysed by an in-house RIA. ! e maximal intra- and 
inter-assay CVs were 11.8 and 12.8% respectively. Cortisol was analysed 
by chemoluminiscence assay using the Immulite 2000 (Siemens, 
Healthcare Diagnostics). ! e maximal intra- and inter-assay CVs were 
5.5 and 8.3% respectively. E
2
 was measured by RIA (Siemens Healthcare 
Diagnostics). ! e intra- and inter-assay CVs were < 20% (low level) and 
maximal at 8.6% (medium level).
St. Elisabeth Hospital, Tilburg and Isala Clinics, Zwolle: Plasma TSH, 
fT
4
, PRL, LH, FSH, testosterone and E
2
 were analyzed by ECLIA (Modular 
Analytics E170, Roche, GmbH). ! e maximal intra- and inter-assay CVs 
as speci" ed by the manufacturer were as follows: TSH, 3.0 and 7.2%; fT
4
, 
2.0 and 4.8%; PRL, 1.7 and 2.0%; LH, 1.2 and 2.2%; FSH, 2.8 and 4.5%; 
testosterone, 2.8 and 3.2%; and E
2
, 3.6 and 3.9%. GH was analyzed by a 
solid-phase, two-site chemiluminescent immunometric assay (Immulite 
2000, Siemens Healthcare Diagnostics). Intra- and inter-assay CVs given 
by the manufacturer were 4.2 and 6.6% respectively.
Medical Spectrum Twente, Enschede: Plasma GH, LH, FSH, PRL, 
testosterone, and E
2
 levels were analyzed by solid-phase, two-site 
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chemiluminescent immunoassays (Immulite 2000, Siemens Healthcare 
Diagnostics). ! e maximal intra- and inter-assay CVs were as follows: 
GH, 4.2 and 6.6%; LH, 3.6 and 6.7%; FSH, 2.9 and 4.1%; PRL, 3.6 and 
7.4%; testosterone, 10.0 and 10.3%, and E
2
, 7.8 and 11.0%. Cortisol was 
analyzed by a solid-phase, competitive chemiluminescent immunoassay 
(Immulite 2000, Siemens). Intra- and inter-assay CVs were 7.4 and 9.4% 
respectively. Plasma TSH and fT
4
 were analysed by ECLIA (Modular 
Analytics E170, Roche, GmbH). Intra- and inter-assay CVs were: 3.0 and 
7.2% for TSH and 2.0 and 3.6% for fT
4
.
Quality of life assessment 
To assess QoL the following questionnaires were used: 
Hospital Anxiety and Depression Scale (HADS) – ! e HADS 
questionnaire consists of 14 items pertaining to anxiety and depression, 
measured on a four-point scale. ! e scores for the two subscales anxiety 
and depression range from 0–21 and the total score from 0–42. A high 
score indicates more severe anxiety or depression (25).
Nottingham Health Pro" le (NHP) – ! e NHP questionnaire features 
38 yes/no questions subdivided in six subscales, i.e. energy, pain, 
emotional reaction, sleep, physical ability and social isolation. Scores of 
the subscales are valued in a range from 0–100. ! e total score is the 
mean of all subscales. A high score indicates a worse QoL (26;27).
Multidimensional fatigue index (MFI-20) – ! e MFI-20 questionnaire 
contains 20 statements to assess fatigue, measured on a " ve-point scale. 
! e scores of the " ve subscales general fatigue, physical fatigue, reduced 
activity, reduced motivation and mental fatigue vary from 0 to 20. A high 
score indicates more fatigue experienced (28).
Short Form-36 (SF-36) – ! e SF-36 consists of 36 statements or 
questions evaluating general well-being during the previous 30 days. 
Scores of the nine subscales physical functioning, social functioning, role 
limitations due to physical problems, role limitations due to emotional 
problems, mental health, vitality, pain, general health perception and 
health change are expressed in a 0–100 scale. Higher scores indicate a 
better QoL (29;30).
Statistics
Data were analyzed using PASW Statistics version 17.0.2 
(SPSS  Inc.,Chicago, IL, USA). All data were presented as mean±SD, 
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unless mentioned otherwise. ! e analysis comprised the comparison of 
the results between patients with and without pituitary insu'  ciency. 
Groups were compared using an independent-samples t-test. A 
χ2-test was used in case of categorical data. To analyse QoL the groups 
were compared using univariate analysis of variance (ANOVA) with 
gender and GCS as " xed factors and age as covariate when appropriate. 
Factors in+ uencing QoL were explored using a Pearson correlation. A 
P-value of <0.05 was considered to be statistically signi" cant.
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Results
Patient demographics 
We included 112 patients (75 males) with a median age of 48 (range 
19–69) years (Table 1). Patients were evaluated 1–12 years a& er trauma 
(median 3 years). ! e median duration of hospitalization a& er TBI had 
been 11  (3–105) days. BMI was 25 (18–43) kg/m2. ! e causes of TBI had 
been tra'  c accidents (51%), fall (38%), violence (5%), and sport- or work 
related accidents (6%), respectively. A total of 36 patients (32%) had been 
diagnosed with a severe trauma and 56% of the patients (n=60) had a mild 
trauma, in 4 patients the GCS was not clear from the medical records. 




Age (years) 48 (19–69)
BMI (kg/m2) 26.7 ± 4.8
GCS: 
Mild (%) 57%
Moderate – Severe (%) 43%
Time since TBI (years) 4.2 ± 3.3
Duration of hospitalization (days) 11 (3–105)
BMI, body mass index; F, female; M, male; TBI, traumatic brain injury
Data are presented as mean±SD or median (range).
Endocrine evaluation
Any pituitary insu'  ciency was diagnosed in only 6/112 patients, 
resulting in a prevalence rate of 5.4%. Patients with and without pituitary 
insu'  ciency were comparable in age and gender, but in patients 
diagnosed with pituitary insu'  ciency BMI was signi" cantly higher 
(P = 0.02). Trauma severity, the duration of follow-up, and duration of 
hospitalization were not di% erent between the two groups.
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GH-IGF-I axis: ! e ITT was used in 80% of the patients (90/112) for 
the evaluation of GH secretory reserve (Figure 2). Because of contra-
indications (epilepsy (n=6), ischemic heart disease or rhythm disorders 
(n=3), other (n=13)), the remaining patients were tested using combined 
GHRH-arginine stimulation. Severe growth hormone de" ciency (GHD) 
was diagnosed in 3.6% of the patients (2M/2F, Table 2). 
HPA axis: At baseline, all patients initially were screened with basal 
morning cortisol levels and a 1 or 250μg ACTH-test to evaluate adrenal 
function. Subsequently, 90 patients were tested by ITT (Figure 2). In the 
remaining 22 patients the HPA axis was assessed by the results of basal 
cortisol and the ACTH-test. In addition, 2 patients (diagnosed with other 
pituitary insu'  ciencies) were tested also by a 100 μg CRH test.
ACTH de" ciency was diagnosed in 1.8% of patients (2/112) by 
insu'  cient cortisol responses during ITT (Table 2). 
Gonadal axis: Hypogonadism was diagnosed only in one male patient 
(0.9%). 
" yroid axis: We did not diagnose any patient with thyroid 
insu'  ciency.
Quality of life 
! ere were di% erences in QoL between patients diagnosed with and 
without pituitary insu'  ciency. Patients with pituitary insu'  ciency 
scored worse on almost all subscales of the QoL questionnaires. More 
speci" cally, they scored signi" cantly worse on the subscale ‘Depression’ 
of the HADS (P = 0.05), on the subscale ‘Social isolation’ of the NHP 
(P = 0.02), on the subscale ‘Reduced activity’ of the MFI-20 (P = 0.027) 
and on the subscale ‘General health perception’ of the SF-36 (P = 0.016) 
(data not shown). 
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Figure 2.  Test results of the stimulation of GH and cortisol secretory reserves during 
ITT  or combined GHRH-arginine test. The dotted horizontal line represents the cut-o"  
value used to de! ne an insu%  cient response. 
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Discussion
! is study demonstrates that the prevalence of hypopituitarism a& er 
TBI in a large patient cohort a& er long-term follow-up is low. Using 
a standardized evaluation that included the gold standard test for the 
evaluation of GH and cortisol secretory reserves in the majority of the 
patients, we found a prevalence of only 5.4% of any pituitary insu'  ciency.
! is prevalence of hypopituitarism is much lower compared with 
the prevalence rates reported in the majority of the previous studies
(15–90%) (6–18). ! is might be explained by the use of di% erent endocrine 
tests and cut-o%  values (19). For example, comparable low prevalences of 
hypopituitarism was found in another study that also used the ITT for 
screening (15). In addition, when using the combined GHRH-arginine 
test without BMI-adjusted cut-o%  values the prevalence of severe GHD 
varied between 8 and 20%(19). A higher BMI is associated with a decreased 
GH response to GH stimulation tests (22). If BMI-adjusted cut-o%  values 
are not used, a higher proportion of patients will be classi" ed as GHD. In 
addition, age adjusted cut-o%  values have recently been reported for the 
GHRH-arginine test (31). 
Di% erences in the duration of follow-up between TBI and endocrine 
assessment may also play an important role. Hormone alterations 
mimicking pituitary insu'  ciency can be present in the acute phase a& er 
trauma. In general, these transient e% ects are almost exclusively reported 
only within the " rst six months a& er TBI (15;32). ! erefore, assessment 
of the function of pituitary axes within this timeframe may result in 
higher prevalence rates of hypopituitarism. To avoid this bias we decided 
to assess patients at least one year a& er the trauma, as suggested in the 
consensus guidelines for the evaluation and diagnosis of patients with 
possible GHD (33). In addition to the time interval between TBI and 
endocrine assessment, the severity of trauma may a% ect the prevalence 
rate of pituitary insu'  ciency (15;34). As shown by Klose et  al. (34), 
increased trauma severity increases the risk of pituitary insu'  ciency. 
! is may result in higher prevalence rates when patients with a more 
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severe degree of trauma are included. Conversely, prevalence rates of 
hypopituitarism may decrease when patients with only minor traumas 
are included (35).
It is important to note that in our study, only a minority of the screened 
patients  ful" lled our inclusion criteria, of which 28.7% participated. 
! erefore, by de" nition, we investigated a pre-selected cohort, which 
may have a% ected the results, and, therefore, our conclusions cannot 
simply be extrapolated to all TBI patients. However, we were able to 
evaluate the most important clinical characteristics in the majority of 
the patients (79%) who did not participate and found no di% erences in 
age during TBI, gender, trauma severity and duration of hospitalization 
when compared to those that " nally did participate (data not shown). 
! is makes a possible bias as a result of pre-selection less likely.
! us, according to our results, pituitary insu'  ciency may be a rare 
complication of TBI in patients evaluated at least one year a& er TBI. 
Intriguingly, comparable low prevalence rates were found in another 
study that also used the ITT to evaluate cortisol and GH secretory 
reserve (32). However, it should be taken into account that there is a 
high incidence of TBI in the population probably translating in still a 
high prevalence of posttraumatic hypopituitarism on a population-
based level. Besides pre-selections of patients, the use of di% erent tests 
with di% erent cut-o%  values has contributed to the di% erences and large 
variations in the prevalence rates found in previous studies (19). Our 
results accentuate that we urgently need consensus for a more uniform 
and protocol endocrine evaluation a& er TBI. More importantly, we 
urgently need prospective studies to " nd reliable predictors that enable 
the identi" cation of patients with a signi" cant pre-test likelihood for 
hypopituitarism. ! is is of paramount importance, because the presence 
of pituitary failure, even in a small proportion of patients, is potentially 
treatable, may be lifesaving, and is likely to signi" cantly ameliorate 
quality of life (3;5).
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The use of an early postoperative 
CRH test to assess adrenal function 
after transsphenoidal surgery for 
pituitary adenomas
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Purpose: Transsphenoidal surgery (TS) is the treatment of choice for 
many pituitary tumors. Because TS may cause pituitary insu'  ciency 
in some of these patients, early postoperative assessment of pituitary 
function is essential for appropriate endocrine management. ! e aim of 
our study was to evaluate the clinical relevance of the CRH stimulation 
test in assessing postoperative pituitary-adrenal function.  
Methods: We performed a retrospective analysis of 144 patients treated 
by TS between January 1990 and November 2009, in whom a CRH test 
and a second stimulation test was performed to assess adrenal function 
during follow-up. Patients with Cushing’s disease were excluded. 
Hydrocortisone substitution was started if peak cortisol levels were 
< 550nmol/L. 
Results: ! e cortisol response was insu'  cient in 42 (29%) and su'  cient 
in 102 patients at the postoperative CRH test. ! irteen of 42 (30%) 
demonstrated a normal cortisol response during a second cortisol 
stimulation test. In 75 of the 102 patients with a su'  cient response to 
CRH repeat testing revealed an insu'  cient cortisol response in 14 patients 
(14%). All but one had concomitant pituitary hormone de" cits. ! ere 
were no cases of adrenal crises during follow-up. Additional pituitary 
insu'  ciency was signi" cantly more present (P < 0.001) in the group of 
patients with an abnormal response to CRH directly a& er surgery. 
Conclusion: In this study a substitution strategy of hydrocortisone guided 
by the postoperative cortisol response to CRH appeared safe and did not 
result in any case of adrenal crises. However, the early postoperative 
CRH test does not reliably predict adrenal function a& er TS for pituitary 
adenomas in all patients, and retesting should be strongly considered. 
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Introduction
Transsphenoidal surgery (TS) is the treatment of choice for many 
pituitary tumors. TS may result in (additional) pituitary insu'  ciency in 
some of these patients (1–3). ! erefore, accurate assessment of pituitary 
function is essential for appropriate management of postoperative 
patients a& er TS. In this respect, evaluation of the pituitary-adrenal axis 
is clinically relevant to assess the need for hydrocortisone replacement 
therapy at discharge.
! e insulin tolerance test (ITT) is considered to be the gold standard 
for the evaluation of secondary adrenal insu'  ciency (4;5). Because 
there are contraindications for ITT in some patients, the CRH test, the 
metyrapone test or the ACTH stimulation test can be used as alternative 
dynamic tests to assess adrenal function (6–8). However, there is no 
international consensus for postoperative testing a& er pituitary surgery. 
We performed a structured literature search for articles that 1) evaluated 
the postoperative strategy for evaluation of adrenal function and 2) use 
of the CRH test to evaluate the pituitary-adrenal axis in postoperative 
patients a& er TS for pituitary adenomas, excluding manuscripts on 
patients with Cushing’s disease. However, speci" c data on this topic 
are hardly available. Moreover, studies that compared CRH test and 
other dynamic test in other situations (i.e. in patients with (suspected) 
hypothalamic-pituitary insu'  ciency not speci" cally related to surgery) 
reported contradictory results (8;9). ! erefore, at our center we developed 
a strategy for evaluation of patients a& er pituitary surgery in 1990 using 
the CRH test as the " rst postoperative test. 
! e aim of the present study was to assess the clinical relevance of the 
CRH stimulation test, as a part of this evaluation strategy, in assessing 
pituitary-adrenal function a& er TS. We performed a retrospective 
analysis of all patients treated by TS between January 1990 and November 
2009, in whom a CRH test and a second stimulation test was performed 





We performed a retrospective chart review of all patients, who had been 
treated by TS in the Leiden University Medical Center between January 
1990 (when human CRH (hCRH) became available for routine clinical 
use) and November 2009. Patients with available data on a postsurgical 
CRH test, who also had a second (con" rmation) test of adrenal function 
during follow-up were included. We excluded patients on high dose 
glucocorticoids, reoperation, postoperative cranial radiotherapy, and 
patients treated by TS for Cushing’s disease. 
! e Medical Ethics Committee of our hospital declared that no 
formal ethical approval and written informed consent was needed for 
this anonymous retrospective chart review. 
Endocrine assessment
According to the postoperative protocol, which has been implemented 
in our hospital, the pituitary-adrenal axis is assessed by CRH test, 7–10 
days a& er surgery. ! e CRH test is performed a& er an overnight fast, 
a& er withdrawal of hydrocortisone for 24 hours, using 100 μg CRH 
(Corticoliberine, Ferring Farmaceuticals Hoofddorp, the Netherlands). 
Venous blood samples for measurement of ACTH and cortisol 
concentrations are collected at -15, 0, 15, 30, 45 and 60 minutes a& er 
infusion. A peak plasma cortisol of ≥ 550 nmol/L is considered to re+ ect 
a normal response (10;11).
In case of insu'  cient cortisol responses to CRH, hydrocortisone 
is prescribed (20 mg/day, divided in 3 doses). During follow-up, the 
treating endocrinologist decided on re-testing of the adrenal function. 
For the assessment of the HPA axis during follow-up either basal serum 
cortisol levels or a stimulation test was used. ! e ITT was performed 
a& er an overnight fast by intravenous administration of insulin
(0.10  U/kg, Actrapid, Novo Nordisk Farma, Bagsvaerd, Denmark) 
to induce adequate hypoglycemia, de" ned as nadir glucose levels 
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< 2.2 mmol/L. Blood was collected for measurement of cortisol, ACTH 
and GH at -15, 0, 15, 30, 45, 60, 90 and 120 minutes a& er i.v. administration 
of insulin. Peak values of GH > 9 mU/L (corresponding with 3 μg/L) and 
cortisol of ≥ 550 nmol/L were considered to re+ ect normal pituitary 
function of GH and ACTH secretion (4;12–15).
For the ACTH test 1 μg Synacthen (Novartis Pharma, Arnhem, ! e 
Netherlands) was administered i.v. and cortisol levels were measured at 
-15, 0 and 30 minutes a& er infusion. A peak cortisol value of ≥ 550 nmol/L 
was considered to re+ ect normal adrenal reserve (16–18). In addition, a 
basal serum cortisol concentration of > 550 nmol/L was considered to 
re+ ect normal adrenal function (9). 
In some patients a metyrapone test was used as a second test to assess 
pituitary adrenal function. Metyrapone (30 mg/kg, Metopiron, Novartis 
Pharma B.V., Arnhem, the Netherlands) was administered orally at 
midnight. ! e next morning postabsorptive blood samples were obtained 
for measurement of 11-deoxycortisol, cortisol and ACTH levels. A cut-
o%  value for 11-deoxycortisol of 200 nmol/L was used to de" ne normal 
adrenal function (6;19;20).
Assays
Between 1986 and 1994, a + uorescence energy-transfer immunoassay 
Syva-Advance (Syva Company, Palo Alto, CA) was used, with an interassay 
variation coe'  cient of 3.6 – 6.1% and a detection limit of 50 nmol/L. From 
1994, cortisol was measured by + uorescencepolarization assay on a TDx 
(Abbott Laboratories, Abbott Park, IL). ! e interassay variation coe'  cient 
is 5–6% above 500 nmol/L and amounts to 12% under 200 nmol/L. ! e 
detection limit is 20 nmol/L. ! e methods correlated well with each 
other, and therfore no correction factors were introduced for follow-up 
of patients. ACTH was determined by immunolimunimetric assay using 
an Immulite 2500 (Siemens Healthcare Diagnostics, Deer" eld, IL, USA). 
! e maximal inter-assay coe'  cient of variation (CV) was between 5.0 
and 10.0%. During the insulin tolerance test glucose levels were measured 
using a Modular P800 (Roche Diagnostics, Mannheim, Germany).
For the measurement of 11-deoxycortisol a radioimmunoassay (RIA) 
of Diasource (previously Biosource Europe, Nivelles, Belgium) was used. 





, TSH, LH, FSH and prolactine blood levels were measured by 
electrochemoluminescent immunoassay (ECLIA), using a Modular E170, 
(Roche Diagnostics, Mannheim, Germany). ! e maximal inter-assay CV 
for these hormones was 5.0%. ACTH, GH and IGF-I were determined 
by immunolimunimetric assay using an Immulite 2500 (Siemens 
Healthcare Diagnostics, Deer" eld, IL, USA). ! e maximal inter-assay 
CV was between 5.0 and 10.0%. Glucose levels were measured using a 
Modular P800 (Roche Diagnostics Mannheim, Germany) (CV is 3%). 
For measurement of estradiol levels a RIA (Orion Diagnostica, Espoo, 
Finland) was used (CV is 6% at 70 pmol/L). ! e estradiol detection 
limit was 20 pmol/L. Testosterone was measured using a RIA (Siemens 
Healthcare Diagnostics, Deer" eld IL, USA). (CV is 20% at 1.0 nmol/L 
and 12% at 14 nmol/L). ! e detection limit was 0.2 nmol/L.
Statistical analysis
PAWS for Windows version 17.0 (SPSS Inc. Chicago, IL) was used 
to perform data analysis. Data were presented as mean ± SD unless 
otherwise mentioned. To evaluate the di% erence between peak cortisol of 
the direct postsurgical CRH test and the con" rmation test during follow-
up we used a paired t-test. A χ2-test was used to evaluate the di% erence 
in prevalence of additional pituitary insu'  ciency in patients diagnosed 
with or without adrenal insu'  ciency based on the CRH stimulation test. 
! e level of signi" cance was set at P ≤ 0.05.
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Results
Patients
Between January 1990 and November 2009, 291 patients were treated 
by TS for non-functioning pituitary adenomas; NFA (n=160), GH-
producing adenomas (n=96), prolactinomas (n=16) or other pituitary 
tumors (n=19) (Figure 1). A CRH test directly following surgery was 
not performed in 82 patients for several reasons (pituitary insu'  ciency 
prior to surgery n=29, follow-up in outpatient clinic n=11, use of 
corticosteroids surrounding surgery n=5, other stimulation test directly 
a& er surgery n=7, other n=30). Consequently, a CRH test was performed 
in 209 postoperative patients a& er TS. In 65 of these 209 patients, there 
was no additional adrenal test performed in follow-up between TS and 
referral for postoperative radiotherapy (n=24), repeat surgery (n=5), or 
death of the patient (n=10), or due to follow-up in another hospital (n=17) 
and lost to follow-up (n=9). ! erefore, 144 patients were " nally included 
in this study. Baseline characteristics of these 144 patients are presented 




             (n=291)               
Excluded:                                            
No CRH test after surgery (n=82)     
Loss to follow-up (n=65)
Total number of patients
            (n=144)              
CRH test:
Peak cortisol < 550 nmol/L  
                                    (n=42)                                    
CRH test:





                    (n=22)                    
No dynamic test
               (n=27)**              
Dynamic test
                    (n=75)                
AI 
  (n=9)   
No AI
 (n=13)  
AI
   (n=20)    
AI
    (n=13)    
No AI
  (n=62)  
AI 
   (n=1)   
No AI
  (n=26)  
   
  
Figure 1. Flow-chart of patient selection and follow-up. AI = adrenal insu%  ciency. 
*pre-existent panhypopituitarism before or immediately after surgery (n=12), pre-existent isolated 
severe adrenal insu%  ciency before surgery (n=4) or very low basal serum cortisol concentrations 
(mean 10 nmol/L) during follow-up after surgery (n=4). 
**basal serum cortisol levels > 550 nmol/L (n=12), normal urine cortisol levels (n=3), short follow-
up between repeated surgery or additional radiotherapy (n=2), and follow-up < 1 year (n=2) or 
unspeci! ed reasons (n=7), basal serum cortisol < 110 nmol/L (n=1) 
Table 1. Baseline characteristics total population
Baseline characteristics Number of patients (n=144)
Gender (M/F) 71/73
Age (years) 50 (15–83)
Diagnosis (n):
    NFA 70
Acromegaly 63
Prolactinoma 6
Other pituitary tumors 5
Time between CRH test and con! rmation test (months) 25.5 (2days*–219 months)
Con! rmation test (n=97):
ITT 55
CRH 16
ACTH stimulation test 21
Metyrapone test 5
* Basal serum cortisol was low, however CRH test peak cortisol 0.61; 2 days after CRH test a 
metyrapone test was performed
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Patients with a decreased postoperative cortisol response to CRH (n=42)
! e peak levels of cortisol during the postoperative CRH test classi" ed 
42 of the 144 patients with pituitary-adrenal insu'  ciency (peak cortisol 
< 550 nmol/L) (Figure 1). In 22 of these 42 patients with a median peak 
cortisol response to CRH of 480 (30–547) nmol/L, a second stimulation 
test was performed during follow-up: ITT (n=8), ACTH stimulation test 
(n=8), CRH stimulation test (n=5) and metyrapone test (n=1). ! ese 
con" rmation tests were performed with a median interval of 27.5 (1–139) 
months a& er the initial postoperative CRH test. Based on this repeat test, 
9 of these 22 (41%) patients had persistent adrenal insu'  ciency [median 
initial cortisol response 356 (30–547) nmol/L; median cortisol response 
con" rmation test 219 (3–514) nmol/L}, who received hydrocortisone 
(HC) replacement and 13 (59%) with a normal response, in whom 
HC was discontinued. In these 13 patients, the median peak cortisol 
level to postoperative CRH stimulation was 480 (340–543) nmol/L, 
whereas the median peak cortisol level during the second test were 
672 (570–890) nmol/L (P < 0.001). ! e clinical characteristics of these 
patients are detailed in Table 2. Based on the results of the CRH test, four 
patients did not receive HC directly a& er surgery, or only if necessary. In 
two of these patients (Table 3; patient 2 and 8) the physician de" ned the 
HPA axis as normal based on the peak cortisol of the CRH test (540 and 
543 nmol/L respectively). No clinical events were reported. 
In 20 of these 42 patients with a median CRH-stimulated cortisol 
concentration of 194 (6–510) nmol/L, no additional stimulation test of 
adrenal function was performed during follow-up, but basal morning 
cortisol levels a& er the withdrawal of hydrocortisone for 18-24 h were 
used to assess the axis. Persistent adrenal insu'  ciency was considered to 
be present in these 20 patients because of pre-existent panhypopituitarism 
before or immediately a& er surgery (n=12), pre-existent isolated severe 
adrenal insu'  ciency before surgery (n=4) or very low basal serum cortisol 
concentrations (mean 10 nmol/L) during follow-up a& er surgery (n=4). 
Accordingly, all these patients received hydrocortisone supplementation 
directly a& er the post surgical CRH test until now.
Patients with a normal postoperative cortisol response to CRH (n=102) 
! e peak levels of cortisol during the postoperative CRH test classi" ed 
102 of the 144 patients with normal pituitary-adrenal function (peak 
cortisol > 550 nmol/L) (Figure 1). In 75 of these 102 patients, adrenal 
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function was assessed during follow-up using a second stimulation test 
and by basal postabsorptive cortisol levels only in the other 27 patients. 
! ese 27 patients were not subjected to a second stimulation test because 
of basal serum cortisol levels > 550 nmol/L (n=12), normal urine cortisol 
levels (n=3), short follow-up between repeated surgery or additional 
radiotherapy (n=2), and follow-up < 1 yr (n=2) or unspeci" ed reasons 
(n=7). One patient returned within three months a& er surgery with 
complaints and basal postabsorptive serum cortisol levels of 90 nmol/L 
and HC was started without additional stimulation test. ! e ITT was 
used in 49 of the 75 patients, the CRH test in 11 patients, the ACTH 
stimulation test in 11, and the metyrapone test in four patients. A normal 
response to these tests was found in 62 patients. However, 13 patients 
had an insu'  cient adrenal response to these tests. With the inclusion 
of the patient with very low basal serum cortisol levels (see above), 
14 patients were classi" ed as adrenal insu'  cient (Table 3). ! irteen of 
these 14 patients had been diagnosed with any other additional pituitary 
insu'  ciencies and 8 of these patients (57%) had panhypopituitarism. 
Six patients already received HC directly a& er surgery. None of these 
14 patients experienced any clinical event related to cortisol de" ciency. 
Prevalence of additional pituitary insu!  ciency
A total of 73 patients had additional pituitary insu'  ciency. ! e prevalence 
of additional pituitary insu'  ciency was signi" cantly higher in patients 
diagnosed with an insu'  cient CRH stimulation test a& er surgery 
compared to patients with a normal test result (any hypopituitarism 
P < 0.001; GHD P < 0.001; TSH de" ciency P < 0.001; LH/FSH de" ciency 
P = 0.001).
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Discussion 
! is study evaluated the postoperative response of cortisol to CRH 
stimulation in a large cohort of patients a& er TS for pituitary adenomas 
compared with the adrenal function assessed during postoperative 
follow-up. ! e second adrenal function test documented a normal 
cortisol response in 31% of the patients with a decreased cortisol response 
to CRH stimulation directly a& er surgery. Conversely, the second adrenal 
stimulation test documented an insu'  cient cortisol response in 14% of 
the patients with a normal cortisol response to direct postoperative CRH 
stimulation. ! erefore, the postoperative CRH test does not reliably 
predict adrenal function a& er TS for pituitary adenomas in all patients. 
Nonetheless, our substitution strategy of hydrocortisone guided by the 
postoperative cortisol responses to CRH did not result in any case of 
adrenal crises in our patients. 
Although CRH stimulation has been incorporated in the diagnostic 
procedures of ACTH dependent Cushing’s syndrome (21–23), reports 
on the use of CRH stimulation to assess cortisol dependency a& er 
transsphenoidal surgery for other pituitary adenomas are scarce. We 
found three publications that assessed pituitary function using CRH, but 
these were not speci" cally in patients a& er transsphenoidal surgery (8;9). 
Dullaart et  al. (9) and Schmidt et  al. (8) compared the CRH test with 
basal serum cortisol levels and found no higher diagnostic applicability 
of the CRH test to basal morning cortisol levels. In contrast, Maghnie 
et al. concluded that the CRH test provided better results than the short 
Synacthen test (SST) and low-dose short Synacthen test (LDSST), and 
that CRH may be useful in patients who have a contraindication for 
ITT (6). 
In the current study, the postoperative CRH stimulation test 
classi" ed 42 of the 144 patients with hypocortisolism. However, 13 of 
these patients had su'  cient adrenal function during follow-up. ! ere 
are several explanations for these discrepant results. ! ey may be related 
to di% erences in cut-o%  values of the di% erent tests. Regularly accepted 
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cut-o%  values (500-550 nmol/L) have been de" ned for the ITT, which 
still remains the gold standard test for the assessment of the HPA axis. 
For the CRH test, some authors have proposed di% erent cut-o%  values 
for peak cortisol responses. For example, Schmidt et al.(8) reported an 
optimal peak cortisol cut-o%  of < 377 nmol/L, yielding a 96% speci" city, 
but poor sensitivity of 76% for the diagnosis of adrenal insu'  ciency (8). 
A sensitivity of 100% was reached using a peak cortisol levels of 
514 nmol/L (with a speci" city of 32%), and 100% speci" city with peak 
cortisol levels of 349 nmol/L (sensitivity 66%). Dullaart et al. found that 
a peak cortisol value of 420 nmol/L re+ ected 100% speci" city, but 100% 
sensitivity for the CRH test was only reached using a peak cortisol of 
615 nmol/L. Because in our center the CRH test is used as a screening 
test for hypocortisolism a& er TS to identify those patients that require 
hydrocortisone supplementation, we applied a generally accepted 
stringent criterion of 550 nmol/L. ! e data indicate that this choice for a 
higher sensitivity of the CRH test is at the expense of a lower speci" city. 
In other words, using this strategy a higher proportion of patients will be 
incorrectly diagnosed with adrenal insu'  ciency. Based on the available 
literature the use of a cut-o%  levels of peak cortisol of 514 nmol/L would 
have resulted in 4/13 patients which would not have been diagnosed with 
adrenal insu'  ciency, but with the criteria suggested by Dullaart et al. 
even more patients would have had discrepant results (8;9). 
Recovery of preoperative adrenal insu'  ciency following TS has 
been described previously (24;25). In a recent study that compared the 
ITT response at 3 and 12 months a& er TS, recovery of adrenal function 
was demonstrated within the " rst year (26). In agreement, we found a 
normal function of the HPA axis in eight patients within the " rst year 
a& er surgery who were initially diagnosed as being adrenal insu'  cient, 
indicating the necessity of an extensive follow-up in patients a& er surgery 
within one year.
In the current study, the postoperative CRH test classi" ed 102 of the 
144 patients as having a normal functioning of the HPA axis based on the 
post-operative CRH test. Fourteen percent of these patients later proved to 
have hypocortisolism by a second test. ! ese discrepant test results can be 
potentially life-threatening because these patients are at risk for adrenal 
crises. It is possible that additional pituitary insu'  ciencies a% ected 
pituitary-adrenal function. Growth hormone and thyroid hormone 
de" ciency can in+ uence these test results. Growth hormone replacement 
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therapy in patients with GH de" ciency may also play an important role 
because of the in+ uence of GH on the cortisol metabolism. Growth 
hormone stimulates 11-β hydroxysteroid dehydrogenase (11βHSD-1), 
leading to increased cortisol-cortisone interconversion (27) . ! e use of 
GH replacement therapy in GH de" cient patients may therefore unmask 
cortisol de" ciency (28;29). ! is may also be the case in some of our 
patients, because their adrenal insu'  ciency became clear a& er start of 
rhGH therapy. Despite all the confounding factors none of our patients 
had a clinical event.  
In conclusion, the CRH test can be safely used to guide hydrocortisone 
substitution a& er TS. Nonetheless, the cortisol response to this test 
cannot reliably predict adrenal function in all patients during longer 
follow-up a& er TS. We therefore recommend to perform a second test 
of pituitary adrenal function during longer follow-up, e.g. 3–6 months 
a& er surgery (see Figure 2). ! is approach is not required in patients with 
an impaired postoperative cortisol response to CRH, who have multiple 










                              < 550 nmol/L                               
  Su!cient:
Peak cortisol






nmol/L   
> 100  nmol/L and no





Start HC No test
necessary 
< 100




nmol/L       
Figure 2. Proposed algorithm for the postoperative follow-up of adrenal function in 
non ACTH dependent pituitary disease (HC; hydrocortisone)
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Context: ! e long-term prevalence of adrenal insu'  ciency a& er 
transsphenoidal surgery for GH secreting pituitary adenomas is 
unknown. However, recently a single study reported a high prevalence 
of adrenal insu'  ciency in acromegalic patients a& er surgical and/or 
medical treatment without postoperative radiotherapy.
Objective: ! e objective of the study was to assess the prevalence and 
incidence rates of adrenal insu'  ciency in consecutive patients during 
long-term follow-up a& er successful transsphenoidal surgery for 
acromegaly.
Design: In 91 consecutive patients in remission a& er transsphenoidal 
surgery only, we retrospectively reviewed insulin tolerance tests, CRH 
stimulation tests, metyrapone tests, and ACTH stimulation tests used to 
assess corticotrope function.
Results: Early postoperatively, insu'  cient adrenal function was observed 
in 16 patients (18%), which was transient in eight and irreversible in eight 
other patients in the " rst year of postoperative follow-up. ! erefore, a& er 
the " rst year, the prevalence of adrenal insu'  ciency was 9%. Late, new-
onset adrenal insu'  ciency developed in only three patients 13, 18, and 
24 yr a& er surgery. ! e incidence rate of late adrenal insu'  ciency a& er 
successful surgery was 2/1000 person-years. A& er long-term follow-up, a 
median of 8.1 (1–31 yr), the prevalence of secondary adrenal insu'  ciency 
was 12% in patients in remission a& er surgery for acromegaly.
Conclusion: ! e prevalence of adrenal insu'  ciency 1 yr a& er surgery was 
9%, whereas during prolonged follow-up, the incidence rate of adrenal 
insu'  ciency was only 2/1000 person-years in patients in remission a& er 
surgery. ! erefore, development of late-onset adrenal insu'  ciency is a 
very infrequent complication in patients with acromegaly in remission 
a& er transsphenoidal surgery only. 
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Introduction
Acromegaly is a chronic disabling disease caused by a GH-producing 
pituitary adenoma. Transsphenoidal surgery is the curative treatment of 
choice and somatostatin analogs or radiotherapy is given as needed (1). 
Hypopituitarism, requiring replacement therapy, can be present 
postoperatively as a result of surgical or additional radiotherapy. Pituitary 
irradiation induces hypopituitarism in 50%–75% of the patients a& er 
10–20 yr of follow-up (2). ! e prevalence of late-onset hypopituitarism 
in surgically treated patients is not precisely known, but it is generally 
considered to occur infrequently. ! e 2009 guidelines on management of 
acromegaly state that pituitary function should be assessed three months 
a& er surgery and that if a dynamic evaluation reveals normal function, 
there is no need for repeated dynamic function tests unless a patient 
receives radiotherapy or has clinical symptoms of hypopituitarism (1). 
Recently, however, Ronchi et al. (3) evaluated adrenal function using the 
low-dose 1 μg ACTH stimulation test in 36 patients with acromegaly 
treated by surgery with or without somatostatin analog treatment or by 
primary medical treatment with somatostatin analogs. A cut-o%  value 
for cortisol of 500 nmol/L was used to demonstrate normal adrenal 
function. ! ey reported a high prevalence of adrenal insu'  ciency in 
32% of patients a& er a median duration of follow-up of 6 yr a& er surgery 
and eventually somatostatin analog treatment. ! e authors concluded 
that hypothalamic-pituitary-adrenal (HPA) axis function may worsen 
over time and should be carefully monitored by dynamic testing in 
all acromegalic patients, independently from the type of treatment. 
! is recommendation has obvious implications for the long-term 
management of nonirradiated patients with acromegaly (3). However, 
the high prevalence of HPA axis insu'  ciency in surgically treated 
acromegalic patients is not yet con" rmed by others. ! erefore, the aim of 
the present study was to evaluate the prevalence of adrenal insu'  ciency 
during long-term follow-up in an unselected cohort of consecutive 
patients in remission of GH excess by transsphenoidal surgery in our 





For this study, all 164 consecutive patients, diagnosed with acromegaly 
and treated at the Leiden University Medical Center, a tertiary referral 
center, by transsphenoidal surgery between 1979 and 2003 were 
reviewed. For the purpose of this study, we excluded patients, who were 
additionally treated by radiotherapy (n=59) as well as patients who had 
persistent active disease a& er surgery (n=14). Consequently, 91 patients 
were included. ! e diagnosis of acromegaly was based on clinical 
characteristics and con" rmed by insu'  cient suppression of GH levels 
a& er an oral glucose tolerance test. All patients had careful preoperative 
and postoperative biochemical evaluation. Criteria for cure were serum 
GH less than 2.5 μg/L, normal glucose-suppressed GH levels (<1.25 μg/L 
for the RIA and <0.38 μg/L for the immuno+ uorometric assay), and 
normal IGF-I values for age. During postoperative follow-up, serum 
GH, glucose-suppressed GH levels, and IGF-I values were measured 
at yearly intervals. ! e surgical results of the complete cohort have 
been reported previously (4). Data regarding clinical and biochemical 
characteristics, treatment, and pituitary function were available from all 
patients. HPA axis function was routinely studied early postoperatively 
(7–10 days postoperatively), using the CRH test or the insulin tolerance 
test (ITT). ! erea& er nonstimulated morning cortisol measurements 
were performed at yearly follow-up visits, and dynamic tests to assess 
corticotrope function were performed at increasing nonstandardized 
follow-up intervals. ! e Medical Ethical Committee approved the 
analysis of treatment results in patients with acromegaly, and no 
informed consent was required for this retrospective analysis.
Methods
We retrospectively evaluated HPA axis function in the total, unselected 
cohort of patients in remission a& er surgery to exclude a potential 
selection bias. None of the patients received pharmacological treatment 
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for acromegaly. We reviewed all available dynamic tests in our database 
performed to evaluate corticotrope function. We considered the ITT as 
the gold standard test. If ITT results were not available, other stimulation 
tests like the CRH, ACTH, and metyrapone tests were evaluated. In 
addition, basal morning cortisol values were collected. Patients were 
considered to have adrenal insu'  ciency if they had biochemically 
con" rmed insu'  ciency (see below). All patients had an endocrine 
assessment every year. ! e use of hormone stimulation tests changed 
during the follow-up period. Initially, ITT was used early postoperatively 
and during follow-up. A& er the clinical introduction of the CRH 
and GHRH test, the ITT lost its leading position in the screening for 
somatotrope and corticotrope de" ciencies for obvious reasons. From 
1990 onward, according to protocol, the CRH test was performed 
early postoperatively to assess whether corticotrope function was 
su'  cient to discharge patients without hydrocortisone replacement, and 
con" rmation tests were performed at the outpatient department.
! e metyrapone test was used for follow-up assessment in patients 
with contraindication for ITT. In recent years, 1 μg ACTH tests were 
performed to screen for corticotrope de" ciency in late follow-up. 
However, the ITT remained the gold standard for con" rmation of 
adrenal insu'  ciency, especially if other test revealed borderline results 
(in patients without a contraindication for ITT). 
Evaluation of HPA axis 
An insulin tolerance test (insulin 0.1 IE/kg, Actrapid; Novo Nordisk, 
Bagsvaerd, Denmark) was administered i.v. in the postabsorptive state 
between 0800 and 0900 h to induce hypoglycemia (< 2.2 mmol/L). 
Cortisol was measured at -15, 0, 15, 30, 45, 60, 90, and 120 min. A cut-
o%  value of cortisol greater than 550 nmol/L was used to de" ne normal 
function of the HPA axis (5–9). An ACTH stimulation test (ACTH 
1μg Synacthen®; Novartis Pharma B.V., Arnhem, ! e Netherlands) was 
administered i.v. between 0800 and 0900 h a& er blood samples had been 
taken at -15 and 0 min for measurement of cortisol values. ! e response 
of cortisol to ACTH was assessed in a single blood sample obtained 
30 min a& er ACTH injection. A cut-o%  value of cortisol greater than 550 
nmol/L was used to de" ne normal adrenal function (10–12). 
CRH test (CRH 100 μg; Ferring B.V., Hoofddorp, ! e Netherlands) 
was administered in the postabsorptive state between 0800 and 0900 h. 
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Cortisol and ACTH were measured at -15, -5, 15, 30, 45, and 60 min. 
A cut-o%  value for cortisol of greater than 550 nmol/Liter was used to 
de" ne normal function (13, 14). A Metyrapone test (metyrapone 30 mg/
kg, Metopiron; Novartis Pharma B.V., Arnhem, ! e Netherlands) was 
administered at midnight. ! e next morning postabsorptive blood 
samples were obtained for measurement of 11-deoxycortisol, cortisol, 
and ACTH levels. A cut-o%  value for 11-deoxycortisol of 200 nmol/L was 
used to de" ne normal adrenal function (15–17).
For morning cortisol, blood was sampled between 0800 and 0900 h 
for assessment of cortisol values. A cut-o%  value of cortisol greater than 
500 nmol/L was used to de" ne normal function only in case dynamic 
tests were not available. Premenopausal women were tested a& er stopping 
estrogen replacement for 3 months.
Assays
Cortisol was measured between 1978 and 1986 by in-house RIA with an 
interassay coe'  cient of variation (CV) of 10% and with a detection limit of 
5 nmol/L. Between 1986 and 1994, cortisol was measured by + uorescence 
energy-transfer immunoassay (Syva-Advance; Syva Co., Palo Alto, CA) 
with an interassay variation coe'  cient of 3.6–6.1% and a detection 
limit of 0.05 μmol/L. From 1994, cortisol was measured by + uorescence 
polarization assay on a TDx (Abbott Laboratories, Abbott Park, IL). ! e 
interassay variation coe'  cient is 5–6% above 0.50 μmol/L and amounts 
to 12% under 20 nmol/L. ! e detection limit was 2 nmol/L. Before 
1993 GH was measured by RIA (Biolab; Serona, Coissins, Switzerland), 
calibrated against World Health Organization international reference 
preparation 66/21 (detection limit: 0.5 mU/L, with an interassay CV 
less than 5%; for the conversion of micrograms per liter to milliunits 
per liter, multiply by 2). A& er 1993 serum GH concentration was 
measured with a sensitive time-resolved + uoroimmunoassay (Wallac, 
Turku, Finland). ! e assay is speci" c for 22 kDa GH. ! e standard was 
recombinant human GH (Genotropin; Pharmacia & Upjohn, Uppsala, 
Sweden), which was calibrated against the World Health Organization 
First International Reference Preparation 80/505 (to convert milliunits 
per liter to micrograms per liter, divide by 2.6) (18). ! e limit of detection 
(de" ned as the value 2 SD above the mean value of the zero standard) 
was 0.03 mU/L (0.0115 μg/L). ! e intraassay CV varied from 1.6 to 8.4% 
in the assay range 0.26–47 mU/L, with corresponding interassay CV of 
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2.0–9.9%. Until 2005 serum IGF-I concentrations were determined by 
RIA (Incstar, Stillwater, MN) with a detection limit of 1.5 nmol/L and 
an interassay CV below 11%. IGF-I is expressed as SD scores for age- 
and gender-related normal levels determined in the same laboratory 
(18). From 2005 onward, serum IGF-I concentration (nanograms per 
milliliter) was measured with an immunometric technique on the 
Immulite 2500 system (Diagnostic Products Corp., Los Angeles, CA). 
! e intraassay CV was 5.0 and 7.5% at mean serum concentrations of 
8 and 75  nmol/L, respectively. ! e IGF-I concentration was expressed 
as SD score, using the λ-μ-σ smoothed reference curves based on 
measurements in 906 healthy individuals (19).
Statistical analysis
All results are shown as mean±SD. Descriptive statistics were calculated. 
Student’s t-tests were used when appropriate. P < 0.05 was considered 
to be statistically signi" cant. Duration of follow-up in person-years was 
calculated for all patients as time between surgery until July 1, 2010, if 
patients were followed-up in our center, until date of secondary treatment 
in case of a recurrence, until last visit if patients were lost to follow-up, 
or until date of death in case patients had died. Incidence rates were 
calculated using number of cases divided over person-years of follow-up. 






We included 91 consecutive patients, 49 male and 42 female patients 
cured by transsphenoidal adenomectomy for a GH producing pituitary 
adenoma (Table 1). ! e mean age at the time of surgery was 46.8 ± 
12.3 yr (range 18–76 yr). ! e mean disease duration before surgery 
was 9.0 ± 8.0  yr. Twenty-eight patients had a microadenoma (31%), 55 
had a noninvasive macroadenoma (60%), and eight had an invasive 
macroadenoma (9%). Mean GH preoperative concentrations and IGF-I 
SD scores decreased signi" cantly a& er surgery (P < 0.001, Table 1). Mean 
GH concentrations were 0.8 ± 1.0 μg/L, and IGF-I SD scores were 0.8 ± 
2.1 at the end of follow-up. 
Immediate postoperative assessment of adrenal function 
Seven to 10 days a& er surgery, assessment of adrenal function was 
performed by CRH test (49%), ITT (43%), or by basal cortisol level 
in a minority of patients (2%). ! ree patients (3%) were not retested 
postoperatively because they had been cortisol dependent preoperatively. 
Data were missing in 2%. Su'  cient adrenal function was observed 
in 36 of 44 patients according to the results of the CRH test, 35 of 
39 patients according to ITT, and one of two patients according to basal 
cortisol. ! us, early postoperative adrenal insu'  ciency was observed 
in 16  patients (18%) including the three patients with preoperative 
secondary insu'  ciency. Hydrocortisone replacement was prescribed to 
11 patients.
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Table 1.  Baseline characteristics and follow-up characteristics of patients with 
acromegaly cured by transsphenoidal surgery
Patients (n=91)
M/F 49/42
Age at TNS (yrs) 46.8 ± 12.3 (range: 18–76)
Disease duration (yrs) 9.0 ± 8.0
Tumorclass (n(%))
Class 1 – Microadenoma
Class 2 – Non-invasive macroadenoma
























F, female; M, male; TNS, transnasosphenoidal surgery
Data are shown as mean ± SD unless mentioned otherwise. Signi! cant decrease following 
surgery (P <0.001) for both GH and IGF-I SD. No di" erence between postoperative and follow-up 














response  at 1 year (n=8)
Recurrence (n=12)
Late onset insu!cient











Figure 1. Flowchart of corticotrope function during long-term follow-up
Adrenal function 1 yr after surgery
At 1 yr postoperatively, the prevalence of adrenal insu'  ciency was 9% 
(eight of 91), three patients being diagnosed preoperatively and " ve 
patients diagnosed early postoperatively. ! ese eight patients received 
hydrocortisone replacement therapy. Adrenal insu'  ciency was 
diagnosed by insu'  cient response to ITT (n=3), CRH (n=3), metyrapone 
test (n=1), or low basal cortisol of 20 nmol/L (n=1).
In the eight other patients with an early postoperative insu'  cient 
cortisol response to dynamic testing (CRH or ITT), retesting within the 
" rst year revealed normal adrenal function. ! e results of postoperative 
tests and follow-up tests in these patients are detailed in Table 2. 
Adrenal function during prolonged follow-up 
During prolonged follow-up, 262 ITT, 110 CRH tests, and 67 ACTH 
tests were performed in the patients cured by transsphenoidal surgery. 
Twelve patients with initial cure developed a recurrence of acromegaly 
(13%) a median of 8.7 yr (range 1.2–24.6 yr) a& er surgery. Consequently, 
79 patients were in long-term cure a& er surgery only. Patients with 
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a recurrence of acromegaly were followed up until the date of the 
secondary treatment for the present analysis. At late evaluation (n=91), 
a median of 8.1 yr (1–31 yr) postoperatively, corticotrope function was 
assessed by ITT (67%), CRH (7%), ACTH (10%), or basal cortisol levels 
greater than 0.50 μmol/Liter (6%), whereas there were no data available 
in 10% of patients due to death (n=3) or loss to follow-up (n=6). During 
long-term follow-up of 1489 person-years, lateonset adrenal insu'  ciency 
developed in three patients (3%) 13, 18, and 24 yr postoperatively. ! e 
incidence rate for new-onset adrenal insu'  ciency was 2/1000 person-
years. ! e clinical characteristics of these patients with late-onset 
adrenal insu'  ciency and their presenting symptoms of late adrenal 
de" ciency are detailed in Table 3. All three patients had been treated for 
a noninvasive macroadenoma. Two patients had complaints of tiredness, 
dizziness, and/or general malaise. ! e third patient presented with 
unexplained hypoglycemias. Due to high age, no ITT was performed, 
but the ACTH test revealed insu'  cient response of cortisol. All patients 
improved clinically a& er replacement therapy. ! us, at the end of follow-
up, adrenal insu'  ciency was present in 12% (11 of 91) of the patients 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































! e present study documents that new-onset adrenal insu'  ciency 
a& er successful surgical treatment for acromegaly in follow-up is not 
frequently observed. ! e prevalence of adrenal insu'  ciency was 9% 1 yr 
a& er surgery. In our well-characterized cohort of consecutive patients in 
remission a& er transsphenoidal surgery, the incidence rate of new-onset 
late adrenal insu'  ciency was only 2/1000 person-years during a long-
term clinical follow-up. In accordance with the study by Ronchi et al. (3), 
our study demonstrates that HPA axis function may worsen over time, 
but adrenal insu'  ciency is an infrequent complication in patients in 
remission of acromegaly a& er surgery. 
! e discrepancies in the prevalence of adrenal insu'  ciency between 
the current study and the study by Ronchi et al. (3) may be explained 
by di% erences in study design and study population. In the study by 
Ronchi et al., 16 of 36 patients had neuroradiological evidence of residual 
postoperative tumor remnants, and 16 were treated by somatostatin 
analogs. In addition, the authors used the low-dose ACTH stimulation 
test, which may lead to a false-negative response in 10% of healthy 
subjects (20).
Furthermore, Ronchi et  al. used a cut-o%  value for cortisol of 
500  nmol/L for the evaluation of the HPA axis, whereas we used 
mainly the ITT and CRH test with a cut-o%  value of 550 nmol/L. ! e 
ITT is generally regarded as the gold standard (7;21). Alternatively, 
the di% erences between the two studies may also be caused by patient 
selection and di% erences in surgical techniques. Ronchi et al. (3) observed 
a remarkably high prevalence of adrenal insu'  ciency in 32% of the 
patients treated by surgery and/or somatostatin analogs for acromegaly. 
However, only 16% of their patients required substitution therapy with 
hydrocortisone, in agreement with our data.
Potential caveats in our study include changed cortisol binding 
globulin (CBG) levels in acromegaly and the presence of postoperative 
GH de" ciency. However, studies on the e% ect of GH on serum CBG 
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concentration are controversial. Some authors reported that GH 
administration in hypopituitary patients decrease CBG levels by 
approximately 20% (22–24), but other studies in larger cohorts did not 
observe a di% erence in CBG levels during GH treatment (25;26). Data on 
CBG concentrations in patients with active acromegaly are also scarce. 
One study investigated the e% ect of pegvisomant treatment on cortisol 
metabolism (27). ! ese authors did not observe any change in serum 
CBG concentrations, although the majority of the patients reached 
normal IGF-I levels. Collectively these data indicate that the e% ect of 
GH on serum CBG levels is not unequivocal, especially in GH-de" cient 
patients, and an increase in CBG concentrations a& er GH normalization 
in acromegaly has not been demonstrated.
GH has a strong impact on cortisol metabolism by its action on 
11β-hydroxysteroid dehydrogenase, leading to increased cortisol-
cortisone interconversion (28). For instance, GH replacement therapy 
in GH-de" cient patients may unmask cortisol de" ciency (23;26). In our 
study, untreated GH de" ciency in the presence of a normal corticotrope 
function was present in only three of 58 patients (5%) with available GH 
measurements during ITT (data not shown), suggesting that it is unlikely 
that this signi" cantly a% ected our results. Patients underwent surgery on 
a low-dose dexamethasone scheme, which may have in+ uenced the test 
results, leading to overestimation of adrenal insu'  ciency shortly a& er 
surgery. Indeed, in eight patients with suboptimal cortisol response to 
ITT or CRH postoperatively, adrenal function normalized within 1 yr. 
! is observation is in accordance with a recent study that compared 
the ITT response at 3 and 12 months postoperatively (29). In that 
study, cortisol peak responses increased by 17% and adrenal function 
had recovered in four of 20 patients with an insu'  cient cortisol peak 
response directly a& er surgery. 
Recovery of preoperative adrenal insu'  ciency a& er transsphenoidal 
surgery has been described previously (30;31). ! erefore, early 
postoperative testing may not re+ ect the de" nitive outcome of adrenal 
function. ! e outcome of these tests can be in+ uenced by incipient GH 
or thyroid hormone de" ciency, as discussed above (32). ! is observation 
emphasizes the importance of repeated dynamic tests also in patients 
with early postoperative insu'  cient response to adrenal function tests. 
A& er 1 yr, less frequent control of dynamic pituitary function may su'  ce 
in those patients with a con" rmed normal adrenal function.
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A recent meta analysis of 12 studies on the diagnostic value of basal 
cortisol values using summary receiver-operating characteristic curves 
showed an area under the curve of 0.79 (95% con" dence interval 0.75–
0.82). A lower cut-o%  value for basal cortisol less than 140 nmol/L 
(likelihood ratio > 9) was used to diagnose hypoadrenalism and an upper 
cut-o%  value of greater than 370 nmol/L (likelihood ratio < 0.15) was 
used to exclude hypoadrenalism. To be eligible for inclusion in this study, 
adult and pediatric subjects had to be suspected of adrenal insu'  ciency 
from pituitary disease longer than four wk from prolonged exogenous 
glucocorticoid administration. Only studies with ITT or metyrapone 
test as a reference test were included (33). It seems reasonable to use 
the guidelines as proposed by these authors. ! us, in patients with a 
basal serum cortisol greater than 370 nmol/L without complaints, the 
likelihood to have adrenal insu'  ciency is very low, and screening using 
basal cortisol may su'  ce in asymptomatic patients.
We had the opportunity to review long-term follow-up data in a 
carefully followed cohort and to have the availability of multiple tests 
in the vast majority of patients in the presence of few missing data. 
Nonetheless, limitations of our study are the retrospective nature of the 
study and the fact that patients had been tested using di% erent cortisol 
stimulation tests and assays. However, this does not a% ect our conclusions 
because the ITT, CRH, and metyrapone tests are all accepted tests for the 
evaluation of HPA function, and we have used unchanged cut-o%  values 
of cortisol throughout the years. Nevertheless, several reports suggest 
that the sensitivity of the CRH test is less than that of the ITT (34–38). 
! is conclusion is partly related to the cut-o%  value of CRH-stimulated 
cortisol responses. Unfortunately, there are no large studies of the CRH 
test in healthy subjects across ages, body mass index, and gender.
! erefore, we used a restrictive approach and retested subjects 
with an insu'  cient response to CRH by ITT. ! e CRH test may not 
detect hypothalamic insu'  ciency, whereas the ITT is a test for the 
hypothalamus-corticotrope- adrenal cortex ensemble. However, we 
have no a priori reason to assume hypothalamic damage in our patients 
because they had no previous pituitary irradiation or very large tumors 
impinging on the hypothalamus. Furthermore, our " ndings are 
strengthened by the consecutive nature of the patient series and the 
yearly assessment of the pituitary function. For the evaluation we used 
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preferably results of ITT. However, ongoing follow-up a& er the last ITT 
did not raise the suspicion of new adrenal de" ciencies. 
! e recurrence of GH overproduction a& er initial cure by surgery 
may be due to either regrowth of residual tumor tissue or true recurrence 
(38–42). In our series we retested all patients cured by surgery at regular 
intervals. In our experience, recurrence of GH excess may occur, even 
a& er many years of postoperative cure documented by repeatedly 
normal IGF-I levels and normal GH nadir responses during the glucose 
tolerance test. ! is was also true a& er 1993, when a more sensitive GH 
assay was introduced. Even though this sequence of events may not 
exclude recurrence from persistent, but apparently longtime subclinical, 
postoperative adenomatous tissue, this observation indicates that the 
recurrence rate in our series is not merely the consequence of persistent 
postoperative disease. Moreover, in patients retested a& er surgical cure 
with regular intervals, we have previously documented that biochemical 
recurrence of GH excess a& er initial surgical cure clearly precedes 
radiological recurrence (42). ! erefore, even in cases with biochemical 
recurrence of GH excess, it is highly unlikely that mass e% ects of 
adenomatous tissue were present. Finally, in the present study, we 
included the patients until the start of additional treatment of GH excess 
in the case of recurrent disease. ! erefore, it is unlikely that recurrences 
of GH excess a& er years of biochemical remission a% ect our conclusions.
In conclusion, the incidence rate of late-onset adrenocortical 
insu'  ciency a& er successful surgery for acromegaly is very low (2/1000 
person-years). We propose to repeat the dynamic test of HPA function 1 yr 
a& er surgery in patients with postoperative HPA insu'  ciency. Further 
research is required to assess whether yearly basal cortisol values may 
su'  ce to monitor adrenal function in asymptomatic patients. However, 
in case of low basal cortisol levels or symptoms suggestive of corticotrope 
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Context: Cranial radiotherapy is an important cause of hypopituitarism. 
! e prevalence of hypopituitarism varies considerably between studies.
Objective: We conducted a systematic review and meta-analysis 
of reported prevalences of hypopituitarism in adults radiated for 
nonpituitary tumors.
Data sources: We searched PubMed, EMBASE, Web of Science and the 
Cochrane Library to identify potentially relevant studies.
Study selection: Studies were eligible for inclusion with following 
criteria: 1) cranial radiotherapy for nonpituitary tumors and/or total 
body irradiation for haematological malignancies 2) adult population 
(>18 yr old) 3) report on endocrine evaluation. 
Data extraction: Data review was done by two independent reviewers. 
Besides extraction of baseline and treatment characteristics, also 
endocrine tests; de" nitions and cut-o%  values used to de" ne pituitary 
insu'  ciency, were extracted.
Results: Eighteen studies with a total of 813 patients were included. 
! ese included 608 patients treated for nasopharyngeal cancer (75%) 
and 205 for intracerebral tumors. ! e total radiation dose ranged from 
14 to 83 and 40 to 97 Gy for nasopharyngeal and intracerebral tumors, 
respectively. ! e point prevalence of any degree of hypopituitarism 
was 0.66 [98% con" dence interval (CI), 0.55–0.76]. ! e prevalence of 
GH de" ciency was 0.45 (95% CI, 0.33–0.57), of LH and FSH 0.3 (95% 
CI, 0.23–0.37), of TSH 0.25 (95% CI, 0.16–0.37), and of ACTH 0.22 
(95% CI, 0.15–0.3), respectively. ! e prevalence of hyperprolactinemia 
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was 0.34 (CI 0.15–0.6) ! ere were no di% erences between the e% ects of 
radiotherapy for nasopharyngeal vs. intracerebral tumors.
Conclusion: Hypopituitarism is prevalent in adult patients a& er cranial 
radiotherapy for nonpituitary tumors. ! erefore, all patients treated by 





Pituitary insu'  ciency is a late onset sequel of cranial irradiation for 
intracerebral and nasopharyngeal tumors or total body radiotherapy for 
hematological malignancies in children (1–9). In the Childhood Cancer 
Survivor Study (CCSS) 43% of children treated for cerebral tumors 
had one or more endocrinopathies (10). Consequently, structured 
follow-up programs for childhood cancer survivors include endocrine 
assessments. In the last decades, survival rates of patients treated with 
cranial radiotherapy for various malignancies as well as for benign 
tumors have improved substantially by introduction of new surgical, 
radiotherapeutical, and chemotherapeutical options. In contrast to the 
long-term survivors of cranial radiotherapy in childhood, endocrine 
surveillance programs have not been routinely incorporated in adults 
treated with cranial radiotherapy. ! e prevalence of hypopituitarism 
a& er cranial radiotherapy is a% ected by several factors. First, the time 
interval between radiotherapy and the assessment of pituitary function 
is important because the development of pituitary failure is likely to 
increase in time a& er radiotherapy (11–13). Second, hypothalamic and 
pituitary insu'  ciencies are more likely to develop with increasing 
radiation exposure (10;14). Finally, methodological di% erences between 
the studies with respect to endocrine evaluation, like the use of di% erent 
endocrine tests with di% erent criteria for pituitary insu'  ciency, will also 
a% ect the prevalence of hypopituitarism. 
! e aim of this study was to systematically assess the reported 
prevalence of pituitary insu'  ciency a& er cranial or total body 
radiotherapy for intracerebral tumors, nasopharyngeal tumors or 
haematological malignancies at the adult age. 
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Design
Search strategy and eligibility criteria
We searched the following databases for studies on cranial radiotherapy 
and pituitary failure: PubMed, Cochrane Library, Web of Science, 
EMBASE, CINAHL database, Academic Search Premier, and Science 
Direct. ! e search was performed on August 14, 2010.
In collaboration with a trained clinical librarian, we composed a search 
strategy for the above mentioned databases, focusing on radiotherapy, 
pituitary function, cerebral tumors and nasopharyngeal tumors. We used 
all relevant keyword variations, including free text words. ! e complete 
strategy is provided in the Appendix 1. Furthermore, the references of 
relevant articles were checked for additional articles. 
Only original articles in English were included. Studies were eligible 
for inclusion in this review if they ful" lled the following criteria: 1) cranial 
radiotherapy for nonpituitary tumors and/or total body irradiation for 
hematological malignancies 2) >18 yr old at the time of radiotherapy 
3) report on endocrine evaluation. 
In case of mixed cohorts (i.e. including both paediatric and adult 
patients), patients younger than 18 yr were " ltered from the results. 
In case of duplication of reports involving the same patient cohort the 
results on the di% erent axes were combined in the analyses and tables, 
and only the paper with the longest duration of follow-up was included. 
Data review and analysis
Initial selection of studies by title and abstract was performed by two 
reviewers (N.M.A-D en N.E.K.). ! ese studies were retrieved for full 
assessment. All studies were evaluated by the two reviewers independently. 
Disagreements were resolved by consensus. Data extraction was based on 
data from each study provided at the population level. ! e de" nition of 
hypopituitarism had to be stated in the paper, including the endocrine 
tests used for the evaluation, de" nitions and cut-o%  values used to de" ne 
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pituitary insu'  ciency for each axis, hormone assays and reference values 
provided by the authors.
Statistical analysis
! e main outcome of the present meta-analysis was the pooled proportion 
of patients with pituitary insu'  ciency a& er cranial radiotherapy. For all 
studies, the proportion of patients with hypopituitarism was calculated 
as the number of patients with the pituitary insu'  ciency divided by the 
total number of tested patients. 
Meta-analysis was performed using an exact likelihood approach. 
! e method used was a logistic regression with a random e% ect at the 
study level (15). Given the expected clinical heterogeneity, a random 
e% ects model was performed by default, and no " xed e% ects analyses 
were performed. For meta-analysis of proportions, the exact likelihood 
approach based on a binomial distribution has advantages compared to 
a standard (DerSimonian and Laird) random e% ects model that is based 
on a normal distribution. First, estimates from a binomial model are less 
biased than estimates from models based on a normal approximation 
(15;16). ! is is especially the case for proportions that are close to 0 or 1. 
Secondly, no assumptions are needed for the exact approximation when 
dealing with zero-cells, whereas the standard approach needs to add an 
arbitrary value (o& en 0.5) when dealing with zero-cells. Adding values 
to zero-cells is known to contribute to the biased estimate of the model 
(17;18). 
Meta-regression analyses were also performed with an exact 
likelihood approach. A random e% ects meta-regression was performed 
to address the question whether the tumor site (nasopharyngeal vs 
intracerebral) in+ uences the prevalence of pituitary insu'  ciency. All 
analyses were performed with STATA 10.0 (Stata Corp, College Station, 
TX, USA).
Risk of bias assessment
An additional evaluation of the risk of bias was performed to identify 
components that could potentially bias an association between cranial 
radiotherapy and hypopituitarism. ! e following study characteristics 
were evaluated: 1) adequacy of exposure determination, 2) adequacy of 
inclusion and follow-up, and 3) adequacy of outcome determination. For 
exposure determination, one point was given if it was stated clearly that 
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the pituitary was involved in the radiation " eld, and one point was given 
if the estimated dose at the pituitary was reported. For the evaluation of 
inclusion of patients, one point was given for each study that included 
(consecutive) non-selected patients. For outcome determination, one 
point was given when the hormonal evaluation also included dynamic 
tests, and one point was given if all patients in the study were tested. 
Consequently, each study could attain a maximum score of 5 points. 
Studies that scored 0–2 points were considered to have a high risk of bias, 
studies with 2–3 points as intermediate risk, and studies with 4–5 points 





! e initial search resulted in a total of 849 articles (301 in PubMed, 
four in Cochrane Library, 131 in Web of Science, 353 in EMBASE, 
16 in CINAHL database, 27 in Academic Search Premier, and 17 in 
Science Direct). Of these articles, 616 were unique without duplications 
(Figure  1). We excluded 378 papers based on title and abstract or 
language, 157  studies that evaluated patients younger than 16 yr, and 
seven papers which were not available for evaluation. Consequently, a 
total of 74 potentially relevant papers were retrieved for full assessment. 
Of these 74 publications, 51 papers were excluded from further analysis 
because the studies did not ful" ll one or more of the eligibility criteria.
616 potentially relevant papers
identied and screened 
378 excluded based on title and abstract
157 excluded because of pediatric literature
7 papers not possible to obtain 
49 papers did not meet inclusion criteria 
25 papers included 
1 paper excluded due to overlap in 
patient groups
74 potentially relevant papers
retrieved for more detailed
assessment
24 papers included for analysis
Figure 1. Flowchart of study assessment and exclusion stages
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! erefore, ultimately, our search strategy resulted in 23 manuscripts 
meeting the inclusion criteria. However, some reports described data 
from the same patient cohort (19–26). In these cases, the results were 
combined as one study in the analysis, or the study with the longest 
follow-up was included. Consequently, a total of 18 studies were included 
in the present review, comprising 813 patients. ! e number of included 
patients per study ranged from only six (27) to 312 (20). Five studies 
included patients younger than 18 yr (26–30). However, in only three 
of these " ve studies (27;28;30) it was possible to obtain the numbers of 
patients treated a& er the age of 18 yr. ! e remaining two were included 
because of the low number of patients younger than 18 yr, or sub-analysis 
on the patient group younger than 18 yr was performed with no di% erent 
outcome then the older group (Table 1). 
Study characteristics 
Details of the 18 included studies are summarized in Table 1 and 2. ! e 
studies were published between 1975 and 2009. Seventy-" ve percent 
of the patients (608 of 813) were treated for nasopharyngeal cancer 
(Table  1). ! e remaining 25% were treated for intracerebral tumors 
(Table 2). ! e majority of studies were cross-sectional studies with time 
a& er irradiation ranging from 4 months to 30 yr. However, the time 
a& er radiation varied considerably between individuals, even within 
one single study. Two studies did not report the time interval between 
irradiation and endocrine evaluation (28;31). None of the included 
papers evaluated patients treated with prophylactic body irradiation in 
the course of stem cell transplantation for haematological malignancies.
In three reports, patient selection criteria were not stated (20;28;31), 
whereas four studies selected symptomatic patients by recruiting from 
a radiotherapy complication outpatient clinic or by inclusion of only 
patients suspected for any degree of hypopituitarism (21;30;32;33). For 
example, two studies used questionnaires on fatigue or diminished libido 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Risk of bias assessment
One study was classi" ed as high risk (received 1 point) (28), eight studies 
as intermediate risk (20;22;29–31;33–35), and nine studies as low risk for 
selection bias (21;23;26;27;32;36–39).
Radiotherapy
! e radiation dose was reported in all, but one study (31) and ranged 
from 14 to 83 and 40 to 97 Gy in patients treated for nasopharyngeal 
carcinomas and intracerebral tumors, respectively. A total of nine studies 
(six involving patients treated for nasopharyngeal tumors and three 
for intracerebral tumors) also calculated the estimated dose delivered 
to the pituitary, ranging from 46 to 83 Gy (in patients treated for 
nasopharyngeal tumors) and 25 to 97 Gy (in patients with intracerebral 
tumors) (21;23;26;29;30;36–39). 
Endocrine assessment 
! e overall prevalence of any degree of hypopituitarism di% ered 
considerably between the studies, ranging from 25% (22) to 100% (21;37) 
in studies involving patients treated for nasopharyngeal tumors, and 
from 37% (31) to 77% (39) in patients treated for intracerebral tumors 
(Figure 2, Table 1 and 2).
GH-IGF-I axis (n=724)
Fourteen studies evaluated the GH-IGF-I axis. However, in only 61% 
(440  of 724) of the patients the axis was evaluated using basal serum 
IGF-I and/or GH levels and/or a stimulation test [glucagon stimulation 
test, insulin tolerance test (ITT), arginine test, and combined GHRH plus 
arginine tes] (20–23;26;27;30–32;35–40). ! e prevalence of GH de" ciency 
varied between 24 and 100%. ! e prevalence of 100% was assessed in one 
study of six patients that evaluated only two patients using ITT (35). 
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Hypothalamic-pituitary-adrenal (HPA) axis (n=751)
! e HPA axis was evaluated in 14 studies. In only 61% (460/751) of 
the patients the axis was tested by basal serum cortisol levels and/or 
a stimulation test (CRH test, ITT, glucagon or ACTH test). Adrenal 
insu'  ciency was diagnosed in 0–50% of patients with nasopharyngeal 
tumors and in 3–62% of the patients with intracerebral tumors.
Hypothalamic-pituitary-thyroidal-axis (n=488)
Sixteen studies evaluated thyroid function using either basal serum 
hormone levels or a TRH-stimulation test. TSH de" ciency was diagnosed 
in 26% of the patients (126/488). ! e prevalence rates ranged from 
0 to 67% and 13 to 25% in patients with nasopharyngeal cancers and 
intracerebral tumors, respectively.
Hypothalamic-pituitary-gonadal axis (n=469)
! e pituitary-gonadal axis was assessed in 14 studies. Hypogonadotropic 
hypogonadism was present in 30% (143/469): in 30–82% of cases 
treated for nasopharyngeal cancer and in 38–61% of cases treated for 
intracerebral tumors. 
Hyperprolactenemia (n=502)
Prolactin levels were measured in 15 studies, documenting hyper-
prolactinemia in 144 of 502 patients (29%, 2–100% in patients treated for 
nasopharyngeal cancers, and 7–100% in patients treated for intracerebral 
tumors). One study did not use basal prolactin levels for de" nition of a 
prolactin secretion disturbance but de" ned abnormal prolactin secretion 
as a failure to rise more than three-fold in response to a TRH test (39). 















































































Figure 2B. Random e" ects meta-analysis of prevalence of pituitary insu%  ciency 
according to tumor site
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Meta-analysis (Figure 2A and B)
! e pooled prevalence of any degree of hypopituitarism was 0.66 
[95% con" dence interval (CI), 0.55–0.76). GH de" ciency was the most 
prevalent pituitary de" ciency, with a prevalence of 0.45 (95% CI, 0.33–
0.57), followed by LH/FSH de" ciency 0.3 (95% CI, 0.23–0.37) and TSH 
de" ciency 0.25 (95% CI, 0.16–0.37), respectively. ! e prevalence of 
hyperprolactinemia was 0.34 (95% CI, 0.15–0.6) and ACTH de" ciency 
had the lowest prevalence 0.22 (95% CI, 0.15–0.3). 
In a random e% ects meta-regression, the e% ect of tumor localization 
(nasopharyngeal vs cerebral) on the prevalence of de" ciencies was 
assessed. ! ere was no statistically signi" cant association between the 
probability of any pituitary de" ciency (P = 0.14), GH de" ciency (P = 0.36), 
ACTH de" ciency (P = 0.75), TSH de" ciency (P = 0.11) LH/FSH de" ciency 
(P = 0.21) as well as hyperprolactinemia (P = 0.44) and the indication for 
radiotherapy (nasopharyngeal cancer vs. intracerebral tumors).
A sensitivity analysis with four studies explicitly mentioning the 
inclusion of consecutive unselected patients was performed (23;29;36). 
! e pooled prevalence of any pituitary de" ciency was 0.62 (95% CI 
0.45–0.77), which is similar to the pooled prevalence of 0.66 when 
combining all the studies.
Pituitary insu!  ciency related to duration of follow-up after radiotherapy
Two studies reported on the occurrence in time of hypopituitarism (23;26).
! e prevalence of pituitary failure in patients treated for nasopharyngeal 
tumors was 6% a& er 1 yr, 35% a& er 2 yr, 56% a& er 3 yr and 62% a& er 4 and 
5 yr (23). Samaan et al. (26) reported on the classical sequential order of 
failure of individual pituitary functions in time. GH de" ciency occurred 
a& er a mean of 2.6 yr, followed by failure of the pituitary-gonadal axis 
and hyperprolactinemia a& er approximately 3.8 yr, ACTH insu'  ciency 




! is systematic review and meta-analysis demonstrated that pituitary 
insu'  ciency is a highly prevalent condition in adult patients a& er 
cranial radiotherapy for nasopharyngeal and intracerebral tumors. ! e 
prevalence of any form of hypopituitarism was 0.66 (95% CI, 0.55–0.76). 
! ere were considerable variations in the reported prevalence rates of 
hypopituitarism a& er cranial radiotherapy, ranging from hardly any 
e% ect on pituitary function to almost 100% of the patients being a% ected. 
! ese variations were associated with di% erences in the number of 
patients included in the study and the manner of endocrine evaluation. 
! e risk of development of hypopituitarism a& er cranial radiotherapy 
is a well recognized phenomenon in children. ! e likelihood to develop 
hypothalamic-pituitary insu'  ciency increases with increasing radiation 
exposure and with prolonged duration of follow-up up a& er radiotherapy 
(11;12). In the CCSS 43% of pediatric patients treated for cerebral tumors 
had one or more endocrinopathies (10). Our meta-analysis showed 
that hypopituitarism is present in approximately two thirds of all adult 
patients previously treated with cranial irradiation. ! e prevalence 
of hypopituitarism a& er cranial radiotherapy is a% ected by several 
factors including radiation dose and techniques. Furthermore, the time 
interval between radiotherapy and the assessment of pituitary functions 
is important because the development of pituitary failure is likely to 
increase during prolongation of follow-up a& er radiotherapy (11;12). 
A random e% ects meta-regression revealed no signi" cantly di% erent 
e% ects of underlying disease on pituitary function between the two 
groups of adult patients reported in literature; i.e. those treated for 
nasopharyngeal cancer vs. intracerebral tumors. In addition, the 
overall di% erence in radiation dosage did not di% er between groups: 
40–83 Gy for the patients treated for nasopharyngeal carcinoma and 
40–97 Gy for the patients with intracerebral tumors. ! e use of di% erent 
radiotherapeutical techniques, however, will most likely a% ect the rate of 
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subsequent hypopituitarism because higher cumulative radiation doses 
are associated with increasing incidence rates of pituitary failure (11;12). 
Patients treated for nasopharyngeal tumors are usually treated with 
a higher average dosage and additive high dose single tumor boost. 
! erefore, a separate analysis of the studies concerning nasopharyngeal 
tumors vs. the other studies was performed (Figure  2A). However, 
there were no signi" cant di% erences in the prevalence of any pituitary 
insu'  ciency between both groups. ! ere are various possible 
explanations for this lack of signi" cant di% erences between the two 
patient groups despite di% erences in irradiation dose. In nine studies 
from which the estimated doses delivered to the pituitary could be 
extracted (six involving patients treated for nasopharyngeal tumors 
and three for intracerebral tumors), the dose ranges were wide in both 
patient groups and showed a considerable overlap. In patients treated for 
nasopharyngeal tumors, the dose ranged from 46–83 Gy, and in patients 
with intracerebral tumors the dose ranged from 25–97 Gy. Duration of 
follow-up since radiotherapy varied from 11–253 months in the patient 
group treated for nasopharyngeal tumors and from 12 – 156 months in 
the group treated for intracerebral tumors. Finally, the overall prevalence 
of pituitary insu'  ciency is already high in both groups with 0.54 (95% 
CI, 0.42–0.66) for intracerebral tumors vs. 0.74 (95% CI, 0.57–0.86) for 
nasopharyngeal tumors. ! is 0.2 di% erence in prevalence, however, did 
not result in signi" cant di% erences between groups (P = 0.14). 
According to our risk of bias strati" cation, nine studies were 
considered as being at low risk of bias. ! e majority of studies used cross-
sectional study designs with large di% erences in the time of evaluation 
in relation to previous radiotherapy. ! e selection of patient groups 
di% ered largely between the studies. Patient selection criteria were not 
stated in some of the reports (20;28;31), whereas the description of the 
selection procedures in other studies suggests preselection of patients, 
like recruitment from a radiotherapy complication outpatient clinic 
or by including only symptomatic patients suspected for any degree of 
hypopituitarism (21;30;32;33). Two studies, (n=186), used a prospective 
design; the reasons for loss to follow-up were not mentioned in any of 
the studies, precluding de" nite answers a& er 5 yr of follow-up (23;26). 
We additionally performed a sensitivity analysis of studies that quali" ed 
as a potential low – intermediate risk of bias (23;29;36;39). ! is analysis 
revealed a pooled proportion of any pituitary de" ciency of 0.62 (95% CI, 
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0.45–0.77), which is remarkably close to the overall found prevalence of 
0.66 (95% CI, 0.55–0.76) calculated for all studies. ! is outcome illustrates 
that signs and symptoms of hypopituitarism a& er cranial irradiation 
apparently are not predictive of hypopituitarism in individual patients 
with their condition.  
Di% erences in endocrine evaluation may also a% ect the reported 
prevalence. ! e majority of patients were not evaluated by proper 
stimulation tests. ! erefore, it is likely that the estimates of hypo-
pituitarism a& er cranial radiotherapy represent a rather conservative 
estimation of the true prevalence of hypopituitarism. In addition, studies 
that did perform stimulation tests used di% erent tests and cut-o%  values, 
and only 10 of 18 studies assessed all pituitary axes (but even then, not 
all patients were tested for each axis). Moreover, the hypothalamic-
pituitary-thyroidal axis and the hypothalamic-pituitary-gonadal axis 
can also be in+ uenced by the use of alkylating chemotherapeutics 
and exposure of the thyroid gland and gonads to irradiation (19; 
41–43). Primary hypothyroidism in patients treated for nasopharyngeal 
carcinoma occurs up to 20–30% within the " rst year a& er treatment (44). 
In the random e% ects regression model the prevalence of TSH de" ciency 
was 0.33 (95% CI, 0.19–0.5), and 0.16 (95% CI, 0.08–0.32) for the patients 
treated for intracerebral tumors. ! ese di% erences were not signi" cant, 
with P=0.11. Hypogonadism a& er cranial radiotherapy was di'  cult to 
quantify because some studies reported testosterone or estrogen levels, 
whereas others used delayed or insu'  cient LH/FSH responses to GnRH 
as a criterion for hypogonadism. In addition, primary gonadal failure is 
highly prevalent in patients treated with chemotherapy, especially when 
treated with alkalyting agents which could overestimate the results (41). 
Patients treated for nasopharyngeal tumors were more likely to receive 
chemotherapy but, again, no signi" cant di% erences between groups were 
found.
Prolactin might be another possible tool to estimate the likelihood 
of radiation induced damage of the hypothalamic area. Because 
hyperprolactinemia might be a consequence of decreased hypothalamic 
dopamine secretion, hyperprolactinemia is variable in severity and o& en 
subclinical; it diminishes and might even normalize in time due to slowly 
evolving radiationinduced damage of lactotrophs. If hyperprolactinemia 
is to be considered as an indicator of disturbed hypothalamic dopamine 
secretion, one could expect the prolactin level to be high in the " rst years 
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a& er radiation and normal a& er several years when lactrotroph function 
has declined. Unfortunately, none of the studies provided information on 
prolactin levels in relation to the time interval since radiotherapy.
Considering the high prevalence of hypopituitarism found, 0.66 
(95% CI, 0.55–0.76), and that there was no signi" cant di% erence between 
groups, assessment of pituitary function should be included in the long-
term follow-up of all cranially irradiated patients. Current literature does 
not provide a timeline or a sequence of axis failure. Hypopituitarism can 
occur as soon as the " rst year a& er treatment, but can also occur 11 yr 
a& er treatment (23;26). Taken into consideration the improved survival of 
patients, duration of follow-up for at least 15 yr should be advisable. ! is 
follow-up period should include a basal morning hormone sample and 
dynamic testing of the HPA axis in every patient not on corticosteroids. 
Dynamic testing of the somatotrope axis should be de" ned per patient, 
since GH failure will not have therapeutical consequences, although it 
might be an indicator for radiation induced pituitary damage.  
! is systematic review underscores the need for structured, 
periodical, endocrine assessments of all patients who survive a& er cranial 
radiotherapy for all kinds of diagnosis. ! erefore, an increasing number 
of patients will require a structured tailored periodical evaluation of 
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Context: Recombinant human GH (rhGH) is prescribed for the treatment 
of adultsz with GH de" ciency (GHD). However, con+ icting data are 
available on the e'  cacy of rhGH treatment in elderly GHD patients.
Objective: To assess the e'  cacy of rhGH treatment in elderly GHD 
subjects.
Methods: We searched PubMed, Cochrane Library, Web of Science and 
EMBASE.
Study selection: Eligible studies included GHD patients, aged > 60 years, 
treated with rhGH. Data extraction was performed by two reviewers 
independently.
Results: We found 11 eligible studies with a total of 534 patients. Only two 
studies had prospective, randomized, placebo-controlled study designs 
of rhGH treatment with a duration of 6 (n=15) and 12 months (n=62), 
respectively. Treatment with rhGH decreased total and low density 
lipoprotein (LDL) cholesterol levels by 4–8 and 11–16%, respectively, but 
did not alter high density lipoprotein or triglyceride levels. RhGH did not 
a% ect body mass index, but decreased waist circumference (by ~3 cm) 
and waist/hip ratio. RhGh did not consistently a% ect blood pressure or 
bone mineral density. RhGH increased lean body mass by 2–5% and 
decreased total fat mass by 7–10% in four studies, but did not a% ect body 
composition in two other studies. RhGH consistently improved quality 
of life (QoL) parameters re+ ected in AGHDA-scores. ! ere are no explicit 
data on elderly GHD patients aged > 80 years. 
Conclusion: RhGH replacement in elderly subjects with GHD decreases 
LDL cholesterol levels and improves QoL, but the e% ects on other 
parameters are not unequivocal. ! ere are no data on the e'  cacy and 
safety of rhGH treatment in octogenarians with GHD.
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Introduction
In healthy adults, GH secretion declines with increasing age (1;2). Some 
of the clinical features of normal aging resemble the manifestations of 
pathological GH de" ciency (GHD). ! ese features include changes in 
body composition (BC), such as increased total fat mass, decreased lean 
body mass (LBM) and decreased bone mass, as well as a higher prevalence 
of cardiovascular risk factors and diminished cardiac function (3).
Consequently, a number of studies have examined the e% ect of 
recombinant human GH (rhGH) on various clinical parameters in 
otherwise healthy elderly subjects (4) as well as in elderly patients with 
GHD. Rudman et  al. (1990) (5) were the " rst to report that 6 months 
of rhGH treatment in healthy elderly men reduced adiposity and 
increased muscle mass and bone mineral density (BMD). Other studies 
observed similar bene" cial e% ects, suggesting a potential role for rhGH 
as anti-aging therapy (6–8). A recent systematic review and meta-
analysis of randomized controlled trials observed that rhGH treatment 
decreased overall fat mass decreased by ~2.1 kg and increased overall 
LBM increased by ~2.1 kg (CI, 1.3–2.9) (P<0.001), without any e% ect on 
weight. However, rhGH was associated with increased rates of adverse 
e% ects (4). Moreover, in healthy elderly subjects, higher physiological 
insulin like growth factor-I (IGF-I) concentrations are associated with 
increased mortality (9). Several studies assessed the clinical bene" ts of 
rhGH therapy in elderly GHD patients. Some studies in elderly patients 
with GHD documented that, rhGH improved QoL (10;11), BC (12–14) 
and lipoprotein pro" les (11, 15, 16), although another study showed 
no e% ects (17). A consensus statement on the treatment of GHD adults 
states that ‘the age-related decline in the GH-IGF-I status does not 
warrant rhGH supplementation, but patients with proved GHD should 
be treated’. ! ese guidelines indicate that the dose of rhGH should be 
adjusted with advancing age, because of the normal age-related decline in 
GH secretion (18). Apparently, there is no clear age limitation in treating 
elderly GHD adults with rhGH.
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! e aim of the present study was to critically assess the available 
literature in order to evaluate the available evidence for treatments of 
elderly patients with GHD. ! erefore, we performed a structured review 
of the available literature on this subject.
175
GROWTH HORMONE REPLACEMENT THERAPY IN ELDERLY PATIENTS
Subjects and methods
Search strategy
We performed a systematic search in the following database: PubMed, 
EMBASE, Web of Science, Cochrane Library, CINAHL database and 
Academic Search Premier. ! e search strategy included three main 
issues: growth hormone de" ciency, age > 60 years and growth hormone 
replacement therapy. We used all relevant keyword variations, including 
free text words. ! is resulted in the following search string: (((“Growth 
hormone de# ciency”[ti] OR “Growth Hormone/de# ciency”[Majr] 
OR “GH de# ciency”[ti] OR “Growth hormone de# cient”[ti] OR “GH 
de# cient”[ti] OR GHD[ti]) AND (“aged”[mesh] OR elderly[tw] OR oldest 
old OR Nonagenarians OR Nonagenarian OR septuagenarian OR 
septuagenarians OR Octogenarians OR Octogenarian OR Centenarians 
OR Centenarian)) OR ((“Growth hormone de# ciency”[ti] OR “Growth 
Hormone/de# ciency”[Majr] OR “GH de# ciency”[ti] OR “Growth hormone 
de# cient”[ti] OR “GH de# cient”[ti] OR GHD[ti] OR “growth hormone 
de# ciency” OR “growth hormone de# cient” OR “gh de# ciency” OR “gh 
de# cient”) AND (“Growth Hormone/administration and dosage”[Mesh] 
OR “Growth Hormone/therapeutic use”[Mesh] OR “Growth Hormone/
therapy”[Mesh] OR ((growth hormone OR growth hormones OR 
Somatotropin OR Somatotropins) AND (therapy OR therapeutic OR 
replacement))) AND (“aged”[mesh] OR elderly[tw] OR oldest old OR 
Nonagenarians OR Nonagenarian OR septuagenarian OR septuagenarians 
OR Octogenarians OR Octogenarian OR Centenarians OR Centenarian))) 
AND (English [lang]). Furthermore, the references of relevant articles 
were checked for additional articles. ! e following exclusion criteria 
were used: age < 60 year, non-GHD subjects, no rhGH therapy. 
Data review
! e following data were extracted from each study: 1) age, gender and 
number of patients, 2) the endocrine tests used to diagnose GHD, 
3) criteria used to de" ne GHD, 4) duration of treatment and treatment 




! e initial search resulted in a total of 577 articles (527 in PubMed, 3 in 
Cochrane Library, 15 in Web of Science, and 26 in EMBASE, 0 CINAHL 
database and 6 Academic Search Premier). Of these 577 articles, 534 were 
unique without duplications. We excluded 403 papers based on title and 
abstract (studies on GHD without speci" c focus on rhGH replacement 
therapy and/or age < 60 yr (n=326), reviews (n=77)). In 89 additional 
papers, which included patients with an age> 60 yrs, the individual data 
of the patients could not be extracted. Two additional papers were not 
available for evaluation. 
! erefore, a total of 40 potentially relevant manuscripts were retrieved 
for full assessment, of which 26 studies were excluded from further 
analysis because those studies did not meet one or more of the eligibility 
criteria (age < 60 yrs, no rhGH therapy, healthy elderly). 
Ultimately, the search strategy resulted in a total of 14 manuscripts 
meeting our inclusion criteria. However, only eight di% erent cohorts 
of patients were described in these 14 studies, because several studies 
described data from the same patient cohort. ! e studies by Götherström 
et  al. 2010 (12) and Götherström et  al. 2005 (19) described the same 
patient cohort (n=24) a& er 5 and 10 years of rhGH treatment. ! e studies 
by Elzgyri et al. (16) and Fernholm et al.(13) (n=31) as well as Gill et al. 
(14) and Toogood et  al.(20) (n=12) also described the same patient 
cohort. ! erefore, the data of these studies are described in combination
(12–14;16;19;20). ! e studies reported from the KIMS database included 
di% erent numbers of patients in each publication (n=64, n=125, n=135, 
n=64). Although it is likely that similar patients have been included, the 
di% erent numbers of subjects preclude combination of the data of these 
separate studies (10;11;15;21).
Consequently, a total of 11 studies were included in the present 
review, comprising 534 patients (Figure 1).
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534 relevant studies
identied and screened 
403 excluded based on title and abstract
No rhGH replacement therapy and/or age < 60 yr (n=324)
Reviews (n=77)
2 papers not possible to obtain 
129 potentially relevant studies
retrieved for more detailed
assessment  
89 excluded because of age; included patients > 60 yr
however data could not be extracted
26 studies did not fulll inclusion criteria
14 studies remained
6 papers used identical patient cohort;
results were combined
11 studies included  
Figure 1.  Summary of study assessment and exclusion stages
Study designs
Two studies (n=65) had a prospective placebo-controlled, randomized 
design assessing the e% ects of rhGH treatment during 6 (n=15) and 
12  n=62) months, respectively, in elderly GHD patients (16;17). ! e study 
by Elzgyri et  al. (2004) (16), that evaluated the e% ects of rhGH versus 
placebo for six months, was continued for another 12 months using a 
nonrandomized prospective study design. ! e other nine studies had a 
non-randomized prospective study design, in which the basal data prior 
to rhGH treatment were used to assess the e% ects of rhGH (n=469). Four 
of these studies (n=388) used patients derived from the KIMS database 
(10;11;15;21).
In this review, we only included studies with patients above the 
age of 60 years. Two studies did not specify the age of the patient, but 
only indicate that all patients are >60 years (10;11). One study assessed 
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patients between the age 60 and 70 years (22), and in three studies, the 
age ranged between 60 and 75 years (12;21;23). Five studies included 
patients >75 years and only two of these studies included patients with 
age >80 years (14–17;24).
Endocrine evaluation 
All 11 studies used stimulation tests for the evaluation of GH reserve 
(Table 1). Di% erent tests, however, were used, including insulin tolerance 
test (ITT), combined GHRH plus arginine (GHRH-arginine) test, 
glucagon stimulation test or stimulation with arginine alone (Table 1). 
! e ITT was used in the total population or in the majority of patients in 
seven studies (11;12;15;17;21–23). ! e study by Koltowska et al. (2009) (10) 
did not mention which tests were used to diagnose GHD. However, that 
study also described patients from the KIMS database, and, therefore, 
it can be assumed that the ITT was also used in the majority of these 
patients. ! e remaining three studies either used GHRH tests (16), 
arginine tests (14) or combined GHRH-arginine tests (24). All but one 
studies applied the generally used cut-o%  value for severe GHD of a peak 
GH < 3 μg/L.
In the study by De Marinis et al. (24), which used the GHRH-arginine 
test, severe GHD was de" ned as a GH peak < 15 μg/L, without corrections 
for the e% ects of body mass index (BMI).
Duration and dose of rhGH treatment
! e duration of treatment with rhGH ranged from 6 months (n=15) to 
10 years (n=24). 
Six studies (n=390) calculated the GH dose based on bodyweight 
(11;12;15;16;21;24). One of these studies used a prede" ned dose per 
kg bodyweight per day (0.0119 mg/kg/day) (12). ! e other " ve studies 
titrated the rhGH dose per kg per week (0.017 – 0.042 mg/kg/wk) (11;15; 
16;21;24).
Of the remaining " ve studies, one study gave three " xed doses of 
rhGH (0.17, 0.33, and 0.5 mg/day) for 12 weeks. ! ese patients received 
the highest dose of rhGH, i.e. 0.5 mg/day (14). In the remaining four 
studies, rhGH was titrated on an individual basis with the aim to reach 
IGF-I levels within the normal age- and sex-related range or clinical 
improvements, taking QoL and BC into account. ! e mean dose of rhGH 
ranged from 0.11 to 0.37 mg/day (11;15;21;24).
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IGF-I levels and SD scores
Seven of the 11 studies used age-adjusted IGF-I levels measured in a 
control population to titrate rhGH dose (11;12;14;16;21–23). Götherström 
et  al. and Franco et  al. 2005 both used the same references values 
measured in a group of 392 patients aged between 25 and 64 years, as 
described by Landin-Wilhelmsen et al. 1994 (25). Feldt-Rasmussen and 
Monson and colleagues both refer to a study by Drake et al. 1998 (26). 
However, that study does not mention the IGF-I reference values, but 
refers to a dose " nding study by Janssen and colleagues 1997 (27), in 
which normative data were based on 54 healthy control subjects aged 
20–70 years. ! e study by Elzgyri et al. 2004 use reference values derived 
from the study by Hilding et  al. 1999 (28), in which IGF-I values are 
measured in a population of 448 healthy controls aged 20–96 years. ! e 
remaining two studies measure reference values in an own reference 
population of 450 (18–80 years) (22) and 124 (60–84 years) (14) healthy 
controls, respectively.
All studies titrated the rhGH dose with the aim of normalizing IGF-I 
S.D. scores, i.e. aiming at IGF-I SDS in physiological levels for age and sex 
(between -2 and +2). However, four studies also took the clinical response 
and BC into account for titration of the rhGH dose. Feldt-Rasmussen 
et al. 2004 and Monson et al. 2000 both took the clinical response into 
account when titrating rhGH dose, referring to a study by Drake et al. 
1998 (26), in which waist/hip (W/H) measurements and improvement of 
QoL measured by AGHDA were taken into account for the titration of the 
dose. ! e remaining two studies (12;23) both state that, when adjusting 
the rhGH dose, the aim is to ‘normalizing IGF-I and BC.’, both referring 
to a study by Johannssen et al. 1997 (7), in which individualized doses of 
rhGH are Q2 compared with doses based on body weight. In their study, 
normalization of BC was of great importance and normal values derived 
from a study by Bruce et al. 1980 (29), comprising 376 patients in the age 
20–70 years, were used to evaluate patients and adjust rhGH levels. 
E" ects of rhGH on cardiovascular and metabolic parameters
Five studies (n=424) assessed the e% ects on plasma lipid pro" les 
(11;15;16;21;23). In general, rhGH treatment decreased total and low 
density lipoprotein (LDL) cholesterol levels by 4–8% (15;16;23) and by 
11–16%, respectively, whereas rhGH increased high density lipoprotein 
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(HDL) only by 17% in one other study (16). Treatment with rhGH did not 
a% ect triglyceride (TG) levels at all.
Six studies assessed the e% ects of rhGH on body weight, height, BMI 
and/or W/H ratios (11;12;15;21;23;24). In two studies, rhGH did not a% ect 
BMI (12;24). In three of " ve studies which reported W/H ratios, there was 
a signi" cant decrease in waist circumference (3 cm in de study by Franco 
et  al. 2006 (23)) and W/H ratios (11;15;21;23). However, the two other 
studies did not " nd any e% ect of rhGH on W/H ratios (15;24).
Five studies assessed the e% ects of rhGH on blood pressure (BP) 
(n=379) (11;15;16;21;23). ! ere were no clear consistent e% ects of rhGH 
treatment on BP. Treatment with rhGH did not a% ect (16), only transiently 
decreased BP (23), or decreased diastolic BP only (11;15;21). 
One study used an exercise test to evaluate cardiac function (n=31). 
Treatment with rhGH induced a transient increase in heart rate at rest 
and exercise. However, rhGH treatment did not a% ect cardiac structural 
and functional parameters (16).
E" ects of rhGH on bone parameters
! e e% ects of rhGH therapy on bone metabolism were evaluated in three 
studies (n=65). Treatment with rhGH did not a% ect BMD. One study 
found that treatment with rhGH increased osteocalcin and calcium 
levels without any change in PTH levels (23). Another study found that 
rhGH treatment lowered PTH and urinary cAMP levels, associated 
with higher adjusted calcium and bone turnover markers, indicating a 
higher PTH target organ sensitivity (22). ! e third study observed that 
treatment with rhGH induced higher markers for bone formation (bone-
speci" c alkaline phosphatase activity, osteocalcin and procollagen I 
carboxyl-terminal peptide in serum) (13). ! e e% ects of rhGH treatment 
on fracture incidence were not described.
E" ects of rhGH on body composition
Six studies assessed the e% ects of rhGH on body composition using DEXA 
scan (n=138) (11;12;14;16;23;24). Two studies (n=35) found no e% ect 
of rhGH on body composition (23;24). In contrast, the other 4 studies 
(n=103) found that 6 months of rhGH treatment induced a signi" cant 
increase in lean body mass (LBM) by 2–5% and a signi" cant decrease 
in total body fat by 7–10% (12;14;16). Moreover, these e% ects of rhGH on 
body composition were reversed, when rhGH therapy was subsequently 
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stopped (n=12) (14). One study used a four compartment model to assess 
body fat, body cell mass and extra cellular weight, but these parameters 
were not a% ected by rhGH therapy (12;19).
E" ects of rhGH on QoL and cognitive functioning
! e e% ects of rhGH treatment on quality of life (QoL) parameters 
was assessed using only the AGHDA questionnaire in " ve studies 
(n=400) (10;11;14;15;21). ! e majority of these patients were from the 
KIMS database (n=388). Treatment with rhGH induced signi" cant 
improvements of AGHDA scores in all studies. 
Only one study assessed cognitive functioning (n=34) using 
computerized psychometric test package (Neurobehavorial Examination-
System 2). However, compared with placebo rhGH therapy was not 
associated with improvement in cognition a& er 12 months. 
E" ects of rhGH on muscle strength
One study assessed the e% ects of 5 and 10 years of rhGH treatment on 
muscle strength (n=24) (12). Treatment with rhGH induced a transient 
improvement only in knee + exor strength. However, rhGH treatment 
protected from most of the normal age-related decline in muscle 
performance and neuromuscular function. 
Adverse e" ects
Six of the 11 studies mention possible adverse e% ects of rhGH treatment. 
In two studies the number of adverse events (AEs) was similar for 
younger and older patients with GHD (11;15). However, younger patients 
appeared to have more AEs related to + uid retention (i.e. headaches, 
oedema and arthralgias), whereas patients > 65 yrs had more AEs related 
to glucose metabolism, cerebrovascular events and neoplasms (11). One 
of the two placebo-controlled studies mentioned AEs and found no 
di% erences between the placebo and rhGH groups (17).
In the study by Fernholm et al. 25% of the patients (8/31) developed 
side e% ects probably due to + uid retention (peripheral edema, joint 
sti% ness and muscle pain).
However, these side e% ects subsided spontaneously or a& er minor 
dose reduction (13). ! e study using the highest dose, found AEs in 3 of 
the 12 patients. ! e AEs subsided when the dose was down titrated (20). 
One study needed to reduce the dose of rhGH because of symptoms of 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































! is systematic literature review assessed the e% ects of rhGH treatment 
in elderly GHD patients. ! e data indicate that rhGH treatment 
positively a% ects total and LDL cholesterol levels, and quality of life 
parameters. ! ere is controversy about the in+ uence of rhGH therapy 
on other cardiovascular risk factors, including insulin, HDL-cholesterol 
and triglyceride levels blood pressure or body composition. Some studies 
show improvement a& er treatment with rhGH, whereas others " nd no 
changes. Moreover, treatment with rhGH did not improve BMD in elderly 
subjects with GHD. Finally, studies on the e% ects of rhGH treatment in 
elderly GHD patients on clinically relevant endpoints, e.g. cardiovascular 
morbidity, fractures and mortality, have not been reported. 
! ere is hardly any information on the treatment of very old GHD 
patients with rhGH. Although 2 studies included patients > 80 years, 
but data of these patients could not be extracted. ! erefore, at present, 
there is no information with respect to the e'  cacy and safety of rhGH 
treatment in GHD octogenarians. 
All patients described in the studies included in this systematic 
review were diagnosed with severe GHD based on di% erent endocrine 
stimulation tests. However, because of the decline in GH secretion during 
ageing, aging may have a% ected the cut-o%  values of the GH stimulation 
tests. Studies using the insulin tolerance test (ITT) have been performed 
in these patients with various results. A study by Finucane et al. show that 
the ITT is a safe test even in elderly patients (30). However, other studies 
do show a lower GH response to ITT in the elderly (31). Nonetheless, 
the ITT is contra-indicated in patients with cardiac ischemia or 
arrhythmias. ! ere are discrepancies between the studies on the cut-o%  
values of the combined GHRH-arginine test and of the arginine test. In 
previous studies age seemed to be of no in+ uence when using these tests
(32;33). However, there is a signi" cantly lower peak GH response in 
elderly compared to younger patients in the GHRH-arginine test (34). 
! erefore, the omission to reduce the cut-o%  values of GH stimulation 
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tests in aging subjects may result in an erroneous diagnosis of GHD in 
some of these subjects. It is at present uncertain to which extent this may 
have a% ected the conclusions of the studies. 
During ageing GH secretion decreases, associated with a decline of 
IGF-I levels. ! erefore, age-adjusted IGF-I SD scores are necessary to be 
able to assess the treatment response to rhGH. All studies titrated the 
rhGH dose with the aim of normalizing IGF-I SD scores, i.e. aiming at 
IGF-I SDS in physiological levels for age and sex (between -2 and +2). 
However, from the analysis described in the results section, it becomes 
evident that in some studies SD scores were higher. In addition, some 
studies included the response of body composition to titrate the rhGh 
dose. Finally, some studies used IGF-I scores from reference populations 
with a di% erent age distribution. ! erefore, there are methological 
di% erences between the included studies that may have a% ected the 
relation between physiological rhGH replacement and responses in 
elderly subjects. 
In GHD elderly subjects, treatment with rhGH had undisputed positive 
e% ects on total and LDL cholesterol levels, and on QoL (10;11;14;15;21). 
Treatment with rhGH decreased total and LDL-cholesterol levels by 
4–8 % and 11–18 %, respectively. RhGH decreased W/H ratio in 3 of the 
5 studies that report this parameter, but this was not con" rmed in 2 other 
studies. RhGH increased lean body mass (LBM) by 2–5% and decreased 
fat mass by 7–10% (12;14;16) in 4 studies (n=192) (11;12;14;16), but this was 
not con" rmed in 2 other studies (n=35) (23;24). One study documented 
that these positive e% ects of rhGH on body composition were reversed 
when rhGH therapy was subsequently stopped, even a& er only 3 months 
(n=12) (14). ! erefore, there are undeniable e% ects of rhGH substitution 
in elderly subjects with GHD for some, but not all, parameters. 
Several animal models of GH de" ciency show prolonged, rather 
than decreased, longevity. Mice with mutations that cause GHD 
or GH resistance, live longer than their genetically normal siblings 
(9;35–38). In addition, adult body size, which can be considered a 
biological outcome marker of GH actions, was negatively correlated 
with longevity in other species, including rats (39), horses (40) and 
domestic dogs (41;42). ! erefore, from an evolutionary perspective the 
natural decrease of GH and IGF-I levels during normal aging may even 
be bene" cial. Epidemiological studies in humans, however, documented 
an association between both decreased and increased IGF-I levels and 
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increased mortality, indicating that the optimal relation between IGF-I 
and rhGH dose may not be simple (9;43). Accordingly, it is presently not 
straightforward that all elderly subjects with GHD should be treated 
unconditionally. 
In conclusion, only a small number of randomized placebo controlled 
trials have assessed the bene" cial e% ects of rhGH therapy in the elderly. 
! ese studies show relatively limited e% ects. ! erefore, the question 
remains whether the treatment with rhGH is clinically relevant in elderly, 
and especially very old, patients with GHD. 
193
GROWTH HORMONE REPLACEMENT THERAPY IN ELDERLY PATIENTS
References
1.  Corpas E, Harman SM & Blackman MR. Human growth hormone and human aging. Endocr Rev 
1993 14 20–39
2. Arvat E, Giordano R, Gianotti L, Broglio F, Camanni F & Ghigo E. Neuroendocrinology of the 
human growth hormone-insulin-like growth factor I axis during ageing. Growth Horm IGF Res 
1999 9 Suppl A 111–115
3.  de Boer H, Blok GJ & Van dVAE. Clinical aspects of growth hormone de! ciency in adults. 
Endocr Rev 1995 16 63–86
4.  Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM et al. Systematic review: the safety 
and e%  cacy of growth hormone in the healthy elderly. Ann Intern Med 2007 146 104–115
5.  Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF et al. E" ects of human 
growth hormone in men over 60 years old. N Engl J Med 1990 323 1–6
6.  Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M et  al. Growth 
hormone replacement in healthy older men improves body composition but not functional 
ability. Ann Intern Med 1996 124 708–716
7.  Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P et  al. Growth hormone 
treatment of abdominally obese men reduces abdominal fat mass, improves glucose and 
lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997 
82 727–734
8.  Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA & Johannsson G. Growth hormone 
treatment reduces abdominal visceral fat in postmenopausal women with abdominal 
obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005 90 1466–1474
9.  van Bunderen CC, van N, I, van Schoor NM, Deeg DJ, Lips P & Drent ML. The association of 
serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the 
elderly: a population-based study. J Clin Endocrinol Metab 2010 95 4616–4624
10.  Koltowska-Haggstrom M, Mattsson AF & Shalet SM. Assessment of quality of life in adult 
patients with GH de! ciency: KIMS contribution to clinical practice and pharmacoeconomic 
evaluations. Eur J Endocrinol 2009 161 Suppl 1 S51–S64
11.  Feldt-Rasmussen U, Wilton P & Jonsson P. Aspects of growth hormone de! ciency and 
replacement in elderly hypopituitary adults. Growth Horm IGF Res 2004 14 Suppl A S51–S58
194
CHAPTER 7
12.  Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G 
& Svensson J. Muscle strength in elderly adults with GH de! ciency after 10 years of GH 
replacement. Eur J Endocrinol 2010 163 207–215
13.  Fernholm R, Bramnert M, Hagg E, Hilding A, Baylink DJ, Mohan S et  al. Growth hormone 
replacement therapy improves body composition and increases bone metabolism in elderly 
patients with pituitary disease. J Clin Endocrinol Metab 2000 85 4104–4112
14.  Gill MS, Toogood AA, Jones J, Clayton PE & Shalet SM. Serum leptin response to the acute and 
chronic administration of growth hormone (GH) to elderly subjects with GH de! ciency. J Clin 
Endocrinol Metab 1999 84 1288–1295
15.  Monson JP, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E et al. 
Growth hormone de! ciency and replacement in elderly hypopituitary adults. KIMS Study 
Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic 
Database. Clin Endocrinol (Oxf) 2000 53 281–289
16.  Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M & Bramnert M. The e" ects of GH 
replacement therapy on cardiac morphology and function, exercise capacity and serum lipids 
in elderly patients with GH de! ciency. Clin Endocrinol (Oxf) 2004 61 113–122
17.  Sathiavageeswaran M, Burman P, Lawrence D, Harris AG, Falleti MG, Maru"  P et  al. E" ects 
of GH on cognitive function in elderly patients with adult-onset GH de! ciency: a placebo-
controlled 12-month study. Eur J Endocrinol 2007 156 439–447
18.  Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH de! ciency II: 
a statement of the GH Research Society in association with the European Society for Pediatric 
Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine 
Society, and Endocrine Society of Australia. Eur J Endocrinol 2007 157 695–700
19.  Gotherstrom G, Bengtsson BA, Sunnerhagen KS, Johannsson G & Svensson J. The e" ects of 
! ve-year growth hormone replacement therapy on muscle strength in elderly hypopituitary 
patients. Clin Endocrinol (Oxf) 2005 62 105–113
20.  Toogood AA & Shalet SM. Growth hormone replacement therapy in the elderly with 
hypothalamic-pituitary disease: a dose-! nding study. J Clin Endocrinol Metab 1999 84 131-136
21.  Monson JP & Jonsson P. Aspects of growth hormone (GH) replacement in elderly patients with 
GH de! ciency: data from KIMS. Horm Res 2003 60 112–120
22.  White HD, Ahmad AM, Durham BH, Patwala A, Whittingham P, Fraser WD et  al. Growth 
hormone replacement is important for the restoration of parathyroid hormone sensitivity 
and improvement in bone metabolism in older adult growth hormone-de! cient patients. 
J Clin Endocrinol Metab 2005 90 3371–3380
23.  Franco C, Johannsson G, Bengtsson BA & Svensson J. Baseline characteristics and e" ects of 
growth hormone therapy over two years in younger and elderly adults with adult onset GH 
de! ciency. J Clin Endocrinol Metab 2006 91 4408–4414
195
GROWTH HORMONE REPLACEMENT THERAPY IN ELDERLY PATIENTS
24. De Marinis L, Mancini A, Giampietro A, Gentilella R, Bianchi A, Perrelli M et al. GH de! ciency 
syndrome in elderly patients. J Endocrinol Invest 2002 25 40–41
25.  Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA et al. Serum 
insulin-like growth factor I in a random population sample of men and women: relation 
to age, sex, smoking habits, co" ee consumption and physical activity, blood pressure and 
concentrations of plasma lipids, ! brinogen, parathyroid hormone and osteocalcin. Clin 
Endocrinol (Oxf) 1994 41 351–357
26.  Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF et  al. Optimizing 
growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin 
Endocrinol Metab 1998 83 3913–3919
27.  Janssen YJ, Frolich M & Roelfsema F. A low starting dose of genotropin in growth hormone-
de! cient adults. J Clin Endocrinol Metab 1997 82 129–135
28.  Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL & Thoren M. Serum levels of insulin-like 
growth factor I in 152 patients with growth hormone de! ciency, aged 19–82 years, in relation 
to those in healthy subjects. J Clin Endocrinol Metab 1999 84 2013–2019
29.  Bruce A, Andersson M, Arvidsson B & Isaksson B. Body composition. Prediction of normal 
body potassium, body water and body fat in adults on the basis of body height, body weight 
and age. Scand J Clin Lab Invest 1980 40 461–473
30.  Finucane FM, Liew A, Thornton E, Rogers B, Tormey W & Agha A. Clinical insights into the 
safety and utility of the insulin tolerance test (ITT) in the assessment of the hypothalamo-
pituitary-adrenal axis. Clin Endocrinol (Oxf) 2008 69 603–607
31.  Eskes SA, Tomasoa NB, Endert E, Geskus RB, Fliers E & Wiersinga WM. Establishment of 
reference values for endocrine tests. Part VII: growth hormone de! ciency. Neth J Med 2009 67 
127–133
32.  Toogood AA, Jones J, O’Neill PA, Thorner MO & Shalet SM. The diagnosis of severe growth 
hormone de! ciency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol 
(Oxf) 1998 48 569–576
33.  Ghigo E, Go%   S, Nicolosi M, Arvat E, Valente F, Mazza E et  al. Growth hormone (GH) 
responsiveness to combined administration of arginine and GH-releasing hormone does not 
vary with age in man. J Clin Endocrinol Metab 1990 71 1481–1485
34.  Colao A, Di SC, Savastano S, Rota F, Savanelli MC, Aimaretti G et al. A reappraisal of diagnosing 
GH de! ciency in adults: role of gender, age, waist circumference, and body mass index. J Clin 
Endocrinol Metab 2009 94 4414–4422
35.  Bartke A & Brown-Borg H. Life extension in the dwarf mouse. Curr Top Dev Biol 2004 63 
189–225




37.  Bonkowski MS, Pamenter RW, Rocha JS, Masternak MM, Panici JA & Bartke A. Long-lived 
growth hormone receptor knockout mice show a delay in age-related changes of body 
composition and bone characteristics. J Gerontol A Biol Sci Med Sci 2006 61 562–567
38.  Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A & Kopchick JJ. Deletion, but not 
antagonism, of the mouse growth hormone receptor results in severely decreased body 
weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 
2003 144 3799–3810
39.  Rollo CD. Growth negatively impacts the life span of mammals. Evol Dev 2002 4 55–61
40.  Brosnahan MM & Paradis MR. Assessment of clinical characteristics, management practices, 
and activities of geriatric horses. J Am Vet Med Assoc 2003 223 99–103
41.  Greer KA, Canterberry SC & Murphy KE. Statistical analysis regarding the e" ects of height and 
weight on life span of the domestic dog. Res Vet Sci 2007 82 208–214
42.  Patronek GJ, Waters DJ & Glickman LT. Comparative longevity of pet dogs and humans: 
implications for gerontology research. J Gerontol A Biol Sci Med Sci 1997 52 B171–B178
43.  Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: 
a metaanalysis. J Clin Endocrinol Metab 2008 93 61–67
CHAPTER 8
Chapter 8





II. Evaluation of pituitary function in patients a  er Traumatic 
Brain Injury (TBI) 200
III. Dynamic tests of pituitary function in other pituitary 
diseases  203
IV. Treatment of GHD 208
V. Concluding remarks 210
199
GENERAL DISCUSSION AND SUMMARY
I. Introduction
Many tests are available for the assessment of pituitary function. ! e 
thyroid, gonadotropic and prolactine axes can be appropriately assessed 
by the combination of clinical symptoms and unstimulated serum 
hormone levels. However, stimulation tests are mandatory for appropriate 
evaluation for the assessment of the HPA and GH-IGF-I axes (1). 
Di% erent stimulation tests are available, for which di% erent cut-o% 
values have been reported. When using a stimulation test, it is of great 
importance to take other confounding factors into account such as 
age, gender, BMI and medication. GH secretion decreases resulting in 
lower serum levels with increasing age and BMI (2–4). Medication can 
alter hormone levels and therefore in+ uence test outcome. ! e pituitary 
gland does not necessarily be stable, but can change over time, e.g. a& er 
traumatic brain injury (TBI) or pituitary surgery (5;6). Consequently, 
pituitary stimulation tests performed immediately a& er surgery may 
give altered results. In this thesis several studies are reported aiming to 
provide better insight into the complexity of di% erent endocrine tests 
used for the evaluation of possible pituitary insu'  ciency and in the 
treatment of patients with pituitary insu'  ciency. 
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II. Evaluation of pituitary function 
in patients after Traumatic 
Brain Injury (TBI)
A& er TBI patients experience persistent, invalidating complaints that 
resemble those observed in patients with hypopituitarism, such as 
impaired cognition, depression, fatigue and impaired quality of life 
(QoL) (7–9). Consequently, pituitary insu'  ciency following TBI may 
contribute to the problems reported by these patients. ! is condition is 
important to identify since it can be treated by hormone replacement 
therapy resulting in improved QoL (10). 
In the past decade a high prevalence of pituitary insu'  ciency 
following TBI has been reported (11–24). However, there is great 
variation in the reported prevalence rates. Several factors in+ uence the 
prevalence of hypopituitarism a& er TBI: the time interval between TBI 
and endocrine assessment, the type and severity of the trauma  and 
also the methods (i.e. endocrine tests, assays and criteria) used for the 
diagnosis of hypopituitarism. Some reviews have addressed TBI-related 
hypopituitarism and concluded that hypopituitarism is a common 
complication of TBI and might contribute to morbidity and poor 
recovery a& er brain injury (25). However, these reviews did not take 
into account the variability in diagnostic strategies and de" nitions of 
pituitary insu'  ciency. We hypothesized that methodological di% erences 
may have contributed, at least in part, to the discrepancies in prevalence 
rates of hypopituitarism a& er TBI. ! erefore, the aim of our systematic 
review in chapter 2 was to critically compare the pituitary function tests, 
and de" nitions of hypopituitarism between studies that assessed the 
long-term outcome of TBI on pituitary function for each pituitary axis.
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We found that the reported prevalence rates of pituitary insu'  ciency 
indeed vary considerably and that this is associated with major di% erences 
in endocrine and analytic methods of assessment en de" nitions used for 
the diagnosis hypopituitarism. ! e studies in the review used di% erent 
endocrine tests, cut-o%  values and analytic methods. Moreover, several 
confounding factors (such as BMI) were not taken into account when 
assessing the pituitary axes. ! is is especially of importance for the 
assessment of the GH axis given the decrease of GH concentration 
with increasing BMI. ! is all may result in an overestimation of 
hypopituitarism following TBI in obese subjects. ! ese discrepancies 
limit the possibility to compare the results of studies on TBI. Future 
studies should be designed to ensure a high diagnostic robustness for 
proper identi" cation of reliable predictors, as the results may be highly 
dependent on diagnostic pitfalls (26).
Because of the large variations published on prevalence rates reported 
and the variations in endocrine and analytical methods to assess 
pituitary functions, we performed a cross-sectional study in the 
Netherlands in a large cohort of TBI patients evaluated a& er long-term 
follow-up (described in chapter 3). We included 112 patients with TBI, 
hospitalized for at least 3 days and duration of follow-up > 1 yr a& er TBI 
from 5 (neurosurgical) referral centers. Evaluation of pituitary function 
included fasting morning hormone measurements and insulin tolerance 
test (ITT n=90) or, when contraindicated, ACTH-stimulation and/or 
CRH-stimulation test and a GHRH-arginine test (n=22). 
Our study demonstrates that prevalence of hypopituitarism a& er 
TBI a& er long-term follow-up is low. Using a standardized evaluation 
that included the golden standard tests for the evaluation of GH and 
cortisol secretory reserves in the majority of the patients, we found a 
prevalence of any pituitary insu'  ciency of only 5.4% (severe growth 
hormone de" ciency (2.8%), hypogonadism (0.9%), adrenal insu'  ciency 
(1.8%)). ! is prevalence is much lower compared to the prevalence rates 
reported in the majority of the previous studies (15–90%)(5–17). ! is 
discrepancy might be explained by the use of di% erent endocrine tests 
and di% erent cut-o%  values in the previous studies. If possible we used 
the golden standard test: the insulin tolerance test. In accordance with 
the data by Klose et  al. (21), this resulted in lower prevalence rates of 
GHD and adrenal insu'  ciency. If ITT was contraindicated, we used 
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the combined stimulation with GHRH and arginine to assess the GH 
axis which has been shown to be a good alternative test, provided higher 
cut-o%  GH levels are used. As mentioned above, GH secretion decreases 
with increasing BMI (2–4). We, therefore, used BMI-adjusted cut-
o%  values for the combined stimulation with GHRH and arginine. In 
addition to di% erences in endocrine test, the time interval between TBI 
and endocrine evaluation as well as trauma severity may also a% ect the 
reported prevalence rates. Studies have reported that in the acute phase 
a& er TBI hormone alterations mimicking pituitary insu'  ciency can be 
present (21;27). To avoid this transient e% ect of TBI, we evaluated patients 
at least 1 year post TBI. Increased trauma severity increases the risk of 
pituitary insu'  ciency. ! erefore, we included only patients with more 
severe trauma. Patients had to be hospitalized for at least 3 days and GCS 
was evaluated. In contrast to many previous studies, the prevalence of 
pituitary insu'  ciency appeared to be low in patients with more severe 
trauma at least one year a& er trauma, using these inclusion criteria and 
golden standard test for pituitary assessment whenever possible and 
BMI-adjusted cut-o%  values if necessary. 
Our results indicate that consensus for a more uniform endocrine 
evaluation of pituitary function in general and a& er TBI in particular is 
needed. Nonetheless, pituitary failure, even if present a& er TBI in a very 
small proportion of patients, is potentially treatable, may be life-saving, 
and is likely to ameliorate quality of life (7;10). 
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III. Dynamic tests of pituitary 
function in other pituitary 
diseases 
Pituitary adenomas can be treated by transsphenoidal surgery (TS), 
additional radiotherapy and/or medication. Pituitary insu'  ciency is a 
complication that can be attributed to the tumor itself (compression), 
surgery and/or radiotherapy. ! erefore, accurate assessment of pituitary 
function is critical for appropriate management of patients with pituitary 
adenoma a& er surgery with or without irradiation. 
Endocrine assessment after pituitary surgery
A& er TS the assessment of the hypothalamic-pituitary adrenal (HPA) axis 
is of clinical relevance to judge the need for hydrocortisone replacement 
therapy at discharge. ! e ITT is the golden standard to evaluate the HPA 
axis in patients suspected of secondary adrenal insu'  ciency. Because 
of contraindications for the induction of hypoglycemia di% erent other 
dynamic tests of the HPA axis are available such as the metyrapone test, 
the ACTH stimulation test and the corticotrophin releasing hormone 
(CRH)-test. In our clinic (from 1990 onwards) adrenal function of 
patients directly a& er surgery has been evaluated by stimulation with 
CRH. Based on the test result it is decided whether the patients were 
discharged with our without hydrocortisone replacement therapy. 
Speci" c data on the clinical applicability of the CRH test directly a& er TS 
are hardly available. ! erefore, in chapter 4 we retrospectively evaluated 
the clinical relevanceof the CRH stimulation test in assessing pituitary 
adrenal function a& er TS. 
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We performed a retrospective chart review of all patients who had been 
treated by TS in our center. We included a total of 144 non-Cushing 
patients of whom data were available on postsurgical CRH tests, of whom 
second (con" rmation) tests were also available and who had not been 
subjected to confounding factors like use of exogenous glucocorticoids, 
re-operation or postsurgical radiotherapy. Forty-two patients were 
diagnosed with hypocortisolism of whom 13 (31%) had su'  cient adrenal 
function during follow-up.
A possible explanation for these discrepant results is the use of 
di% erent cut-o%  values. For the ITT (golden standard) regularly accepted 
cut-o%  values have been de" ned. However, for the CRH test di% erent  cut-
o%  values for peak cortisol responses have been proposed. Because in our 
center the CRH test is used as a screening test to identify those patients 
that require hydrocortisone supplementation a& er TS, we applied a 
generally accepted stringent criterion of 550 nmol/L (28;29). Aiming 
for a higher sensitivity will be at the expense of a lower speci" city, i.e a 
greater proportion of patients will be incorrectly diagnosed with adrenal 
insu'  ciency.
Another possible explanation is the recovery of preoperative adrenal 
insu'  ciency a& er TS within one year (5;6). ! is has been described in a 
study that compared the ITT response at 3 and 12 months a& er TS. In 
agreement, we found a normal adrenal function in 8 patients within the 
" rst year a& er surgery who were inititally diagnosed as being adrenal 
insu'  cient. ! is indicates the necessity of an extensive follow-up in 
patiens a& er surgery within one year.
A normal function of the HPA axis was assessed in 102 of the 
144 patients. However, fourteen of these patients (14%) appeared to have 
hypocortisolism based on a second test. ! ese discrepant results can be 
potentially life-threatening because these patients are at risk for adrenal 
crises. It is possible that additional pituitary insu'  ciency in+ uenced the 
test results of these patients. Growth hormone and thyroid hormone 
de" ciency can in+ uence the test results(5;30–32). Moreover, growth 
hormone replacement therapy in patients with GHD may also play an 
important role because of the in+ uence of GH on the cortisol metabolism. 
Growth hormone stimulates 11–β hydroxysteroid dehydrogenase 
(11βHSD-1), leading to increased cortisol-cortisone conversion (31). ! e 
use of GH replacement therapy in GH-de" cient patients may therefore 
unmask cortisol de" ciency (30;32). 
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Based on our results we conclude that the CRH test can be safely used 
to guide hydrocortisone substitution a& er TS. Nonetheless, the cortisol 
response to this test can not reliably predict adrenal function in all 
patients during longer follow-up a& er TS. We therefore recommend 
to perform a second test of pituitary adrenal function during longer 
follow-up, e.g. 3–6 months a& er surgery. ! is approach is not required in 
patients with an impaired postoperative cortisol response to CRH, who 
have multiple pituitary insu'  ciencies. 
In chapter 4 we retrospectively assessed the HPA function in all 
patients who had been treated by TS in our center, whereas in chapter 5 
we focused on postoperative assessment of HPA function in a speci" c 
postoperative group; patients a& er TS for GH secreting adenomas i.e. 
patients with acromegaly. A recent study by Ronchi and colleagues 
evaluated the HPA axis in acromegalic patients a& er TS. ! ey found 
a remarkably high prevalence of adrenal insu'  ciency (32%) a& er TS 
in these patients. ! ey concluded that the function of the HPA axis 
may worsen over time and should be carefully monitored by dynamic 
testing in all acromegalic patients, independently from the type of 
treatment. ! is recommendation has obvious implications for the long-
term management of non-irradiated patients with acromegaly (33). 
! erefore, the aim of chapter 5 was to evaluate the prevalence of adrenal 
insu'  ciency during long-term follow-up in our own unselected cohort 
of consecutive patients in remission of GH excess a& er transsphenoidal 
surgery. 
We retrospectively reviewed the assessment of corticotrope function 
in 91 consecutive patients in remission a& er transsphenoidal surgery 
using ITT, CRH stimulation, metyrapone test and ACTH stimulation 
tests. We found insu'  cient adrenal function in 16 patients (18%) in the 
early postoperative period, which was transient in 8 but irreversible in 
8 other patients within the " rst year of postoperative follow-up. ! erefore, 
a& er the " rst year of follow-up a& er curative surgery for acromegaly, 
the prevalence of adrenal insu'  ciency was only 9%. Late, new-onset 
adrenal insu'  ciency developed in only 3 patients, 13, 18 and 24 years 
a& er surgery, resp. ! e incidence rate of late adrenal insu'  ciency a& er 
successful surgery was only 2/1000 person years. A& er long-term follow-
up, with a median duration of 8.1 yr (range 1–31 yr), the prevalence of 
secondary adrenal insu'  ciency was 12% in patients in remission a& er 
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surgery for acromegaly. ! erefore, new-onset adrenal insu'  ciency 
a& er TS for acromegaly is not frequently present. ! e discrepancies 
in prevalence with the study by Ronchi et  al. and our study may be 
explained by di% erences in study design and study population but also 
by patient selection and di% erences in surgical techniques. We used the 
golden standard test (ITT) and CRH test in a large whereas Ronchi and 
colleagues used a low-dose ACTH test in patients (33). Other potential 
mechanisms of in+ uence may be changed cortisol binding globulin 
levels (CBG) in acromegaly (31;32;34;35), the presence of postoperative 
GH de" ciency (30;35;36) and the possibility of recovery of preoperative 
adrenal insu'  ciency following transsphenoidal surgery (5;6;37), 
although this is most likely a rare event. 
Limitations of our study are the retrospective nature of the study and 
the fact that patients had been tested by di% erent cortisol stimulation 
tests and assays. However, this does not a% ect our conclusions, since the 
ITT, CRH and metyrapone tests are all accepted tests for the evaluation 
of HPA function and we have used unchanged cut-o%  values of cortisol 
throughout the years. 
We propose to repeat dynamic test of HPA function 1 yr post surgery 
in patients with postoperative HPA insu'  ciency. Further research 
is required to assess whether yearly basal cortisol values may su'  ce 
to monitor adrenal function in asymptomatic patients. However, in 
case of low basal cortisol levels, symptoms suggestive of corticotrope 
insu'  ciency or progressive impairment of other pituitary functions, 
additional dynamic testing of the HPA axis should be performed.
 Endocrine assessment following cranial radiotherapy
Patients with nonpituitary intracranial and/or nasopharyngeal tumors 
are frequently treated by radiotherapy, in which the pituitary gland is 
involved in the radiation " eld. ! ese patients are at risk for pituitary 
insu'  ciency. ! is is well described in children treated with cranial 
radiotherapy (38–46), but the assessment of pituitary function during long 
term follow-up has not been implemented in the guidelines of patients 
treated by cranial radiotherapy for nonpituitary tumors. To assess the 
prevalence of pituitary insu'  ciencies a& er cranial radiotherapy in these 
patients, we performed a systemic literature search and meta-analysis 
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focusing on the prevalence of pituitary dysfunction in adult patients 
treated with radiotherapy for nonpituitary tumors, which is described 
in chapter 6. 
Our review ultimately included 18 studies (n=813) evaluating 
patients treated for nasopharyngeal cancer or intracerebral tumors
(47–64). ! ere were considerable variations in the reported prevalence 
rates of hypopituitarism a& er cranial radiotherapy, ranging from 
hardly any e% ect on pituitary function to almost 100% of the patients 
being a% ected. ! ese variations may be associated with di% erences in 
radiotherapeutic techniques, study design, time of evaluation, patient 
selection and di% erences in endocrine evaluation. ! e majority of 
patients was not evaluated by pituirary stimulation tests. If stimulation 
tests had been used, di% erent cut-o%  values and diagnostic criteria were 
used. Our meta-analysis showed that any hypopituitarism is present in 
approximately two thirds of all adult patients previously treated by cranial 
radiotherapy (0.66, CI 0.55–0.76). ! e prevalence of growth hormone 
de" ciency was 0.45 (CI 0.33–0.57), of LH and FSH 0.3 (CI 0.23–0.37), of 
TSH 0.25 (CI 0.16–0.37), and of ACTH 0.22 (CI 0.15–0.3), respectively. 
! e prevalence of hyperprolactinemia was 0.34 (CI 0.15–0.6) ! ere were 
no di% erences between the e% ects of radiotherapy for nasopharyngeal 
versus for intracerebral tumors. 
Based on these data we conclude that hypopituitarism is rather 
prevalent in adult patients a& er cranial radiotherapy for nonpituitary 
tumors. Considering this high prevalence of hypopituitarism, the 
evaluation of pituitary function should be included in the guidelines of 
long-term follow-up of all patients treated by cranial radiotherapy. 
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IV. Treatment of GHD
When growth hormone de" ciency is considered, the therapeutical 
implications should be carefully evaluated, especially in elderly subjects 
in whom normal growth hormone secretion and IGF-I levels are low 
compared to young adults and GH and IGF-I levels overlap between 
normal and growth hormone de" cient subjects. 
In chapter 7, we performed a systematic review, to critically assess the 
available literature on the evidence of clinical e'  cacy of rhGH in elderly 
patients with GHD. We ultimately included only 11 eligible studies with 
a total of 534 patients (65–78). ! e studies show that there are undeniable 
e% ects of rhGH substitution in elderly subjects with GHD for some, but 
not all, parameters. RhGH treatment unequivocally positively a% ects 
total and LDL cholesterol levels and QoL parameters. However, there is 
controversy on the e% ects on other cardiovascular risk factors, including 
insulin, HDL cholesterol, BP and BC, whereas rhGH therapy does not 
improve plasma triglyceride levels. Moreover, treatment with rhGH did 
not improve BMD in elderly subjects with GHD. Studies in octogenarians 
have not been performed. Finally, there are no data on the e% ects of rhGH 
on clinically relevant end points, like cardiovascular disease or fractures.
Several factors should be taken into account in the assessment of 
the e% ects of rhGH therapy in elderly subjects. With increasing age GH 
secretion decreases. ! is decrease in GH levels may a% ect the response 
to stimulation tests and, therefore, a% ect the cut-o%  values of the GH 
stimulation tests. Studies using the ITT and GHRH-arginine stimulation 
test have been performed in these patients with various results. Some 
studies show a lower peak of GH response in elderly compared to 
younger patients (79;80), whereas other studies show no di% erences (81). 
Nonetheless, the omission to reduce the cut-o%  values of GH stimulation 
tests in aging subjects might result in an erroneous diagnosis of GHD in 
at least some of these subjects. ! e extent to which this may have a% ected 
the conclusions is uncertain at present. 
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! e decline of GH levels during aging is associated with a decline in 
IGF-I levels. ! erefore, age-adjusted IGF-I SD scores are necessary to 
enable to assess the treatment response to rhGH. In this respect, there 
were methodological di% erences between the included studies, which 
may have a% ected the relation between physiological rhGH replacement 
and responses in elderly subjects. Moreover, from an evolutionary 
perspective, the natural decrease of GH and IGF-I levels during normal 
aging may even be bene" cial. In animal models of decreased GH-IGF-I 
function longevity was increased (82–89). Accordingly, it is presently 
not straightforward that all elderly subjects with GHD should be treated 
unconditionally.
In conclusion, only a small number of randomized placebo-controlled 
trials have assessed the bene" cial e% ects of rhGH therapy in elderly 
with GHD. ! ese studies show relatively limited e% ects. ! erefore, the 
question remains whether the treatment with rhGH is clinically relevant 
in elderly patients with GHD. ! ere are no data whatsoever on the e% ects 




! e conclusions of the studies described in this thesis can be summarized 
as follows:
Pituitary function after TBI
! ere is a wide variation in the reported prevalence rates of 
hypopituitarism a& er TBI. ! is is at least in part caused by di% erences in 
de" nitions, endocrine assessments of hypopituitarism, and confounding 
factors. ! ese methodological issues prohibit simple generalizations 
of results of original studies on TBI-associated hypopituitarism in the 
perspective of meta-analyses or reviews.
! e prevalence of hypopituitarism during long-term follow-up a& er TBI 
is most likely very low, if stringent criteria and appropriate pituitary tests 
are used. ! e reported prevalence rates of pituitary insu'  ciency a& er 
TBI are most likely overestimated. 
Pituitary function after transsphenoidal surgery
! e CRH test is a valuable tool to de" ne clinically relevant cortisol 
de" ciency immediately a& er pituitary surgery. ! is test can be safely 
used to de" ne hydrocortisone dependency at discharge until a second 
test is performed. 
In patients with acromegaly cured by transsphenoidal surgery, the 
prevalence of adrenal insu'  ciency very low: 9% one year a& er surgery 
and only 2/1000 person-years in patients in long term remission a& er 
surgery. ! erefore, development of late-onset adrenal insu'  ciency is a 
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very infrequent complication in patients with acromegaly in remission 
a& er transsphenoidal surgery only. 
Pituitary function after cranial radiotherapy
Hypopituitarism is very prevalent in adult patients a& er cranial 
radiotherapy for nonpituitary tumors. ! erefore, all patients treated by 
cranial radiotherapy should have structured periodical assessment of 
pituitary function during follow-up. ! is should be implemented in the 
guidelines of follow-up of these patients.
Pituitary function in elderly subjects
Recombinant  GH replacement in elderly subjects with GHD decreases 
LDL cholesterol levels and improves QoL, but the e% ects on other 
parameters are not unequivocal. ! ere are no data on the e'  cacy and 
safety of rhGH treatment in octogenarians with GHD. ! ere are no data 
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Voor de beoordeling van de functie van de hypofyse zijn diverse 
diagnostische testen beschikbaar. Er kan gebruik gemaakt worden van 
basale hormoonspiegels, maar ook van hormoon stimulatietesten. Voor 
de beoordeling van de schildklier-as, de gonadotrope-as en het prolactine 
is het voldoende om basale (niet-gestimuleerde) hormoonspiegels te 
bepalen vroeg in de ochtend (8–9 uur) en daarbij rekening te houden 
met de klinische symptomen van de patiënt. Echter, de afgi& e van 
cortisol kenmerkt zich door een sterk dag-nacht ritme terwijl de 
groeihormoon (GH) secretie  wordt gekenmerkt door afgi& e in pulsen. 
Voor de beoordeling van de hypofyse bijnier- en GH-IGF-I as is het dus 
niet mogelijk alleen basale serum hormoonspiegels te bepalen. Voor 
de juiste evaluatie van deze assen is het gebruik van een stimulatie test 
noodzakelijk. 
Er zijn verschillende stimulatietesten beschikbaar, waarvoor 
verschillende a apwaarden worden gebruikt. Wanneer er gebruik wordt 
gemaakt van een stimulatietest is het van belang rekening te houden 
met verschillende factoren die van invloed kunnen zijn, zoals lee& ijd, 
geslacht, body mass index (BMI) en medicatiegebruik. Uit onderzoek is 
gebleken dat met vorderende lee& ijd en hogere BMI de secretie van GH 
afneemt, resulterend in lagere GH spiegels.  
Na traumatisch hersenletsel, een operatie aan de hypofyse, 
of bestraling van de hypofyse kunnen zowel de hypofyse als de 
hypothalamus beschadigd raken, met uitval van de hypofysefuncties 
(hypopituïtarisme) als gevolg. Uit onderzoek is echter gebleken dat 
hypofyseweefsel in staat is te herstellen. Dit gebeurt voornamelijk binnen 
het eerste jaar na trauma en/of operatie. Wanneer in deze periode een 
stimulatie test wordt gebruikt om de functie van de hypofyse te bepalen, 
kan dit dus tot een verkeerde interpretatie van de uiteindelijke restfunctie 
van de hypofyse leiden. 
Het doel van dit proefschri&  is om beter inzicht te krijgen in de 
complexiteit van de verschillende testen die beschikbaar zijn voor 
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de evaluatie van de hypofysefuncties bij verschillende aandoeningen 
die gepaard kunnen gaan met passagière of persisterende schade aan 
de hypofyse en/of de hypothalamus. Het e% ect van het gebruik van 
verschillende endocriene testen op de gevonden mate van uitval wordt 
hierbij kritisch tegen het licht gehouden. Ook is dit proefschri&  bedoeld 




II. Evaluatie van de functie van 
de hypofyse na traumatisch 
hersenletsel 
Patiënten die een traumatisch hersenletsel hebben ondergaan kunnen 
persisterende, invaliderende klachten hebben die lijken op de klachten 
van patiënten met hypopituïtarisme (zoals verminderde cognitie, 
depressie, vermoeidheid en een verminderde kwaliteit van leven (QoL)). 
Het kan dan ook zo zijn dat aanwezige, maar niet gediagnostiseerde uitval 
van de hypofysefuncties na trauma bijdraagt aan de klachten van deze 
patiënten. De behandeling van hypopituïtarisme is relatief makkelijk 
(toedienen van de ontbrekende hormonen) en uit onderzoek is gebleken 
dat de behandeling de kwaliteit van leven signi" cant kan verbeteren. Het 
is dus van belang hypopituïtarisme bij patiënten na een hersentrauma 
vast te stellen, dan wel uit te sluiten. 
In de afgelopen jaren is er veelvuldig onderzoek gedaan naar de 
relatie tussen traumatisch hersenletsel en hormoonuitval. Hierbij hebben 
verschillende onderzoeken een hoog percentage hypofyse-uitval na 
TBI beschreven. Er is echter wel een grote variatie in deze beschreven 
prevalentie. Tijdens de beoordeling van de functie van de hypofyse na 
hersentrauma is het van belang rekening te houden met de volgende 
factoren die van invloed kunnen zijn: het tijdsinterval tussen trauma en 
de endocriene beoordeling, het type en de ernst van het trauma, maar 
ook de methoden (d.w.z. endocriene testen en criteria) die gebruikt 
worden om de diagnose hypopituïtarisme te stellen. Sommige studies 
hebben geconcludeerd dat hypopituïtarisme een veel voorkomende 
complicatie is na TBI, maar zij hebben geen rekening gehouden met 
de grote variabiliteit in diagnostische testen en de" nities van hypofyse 
uitval. Het doel van onze systematische review in hoofdstuk 2 was 
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dan ook om kritisch te kijken naar de gebruikte stimulatie testen en de 
de" nities van hypopituïtarisme van studies die hebben gekeken naar de 
lange termijn uitkomsten na hersentrauma. 
Uit onze review blijkt dat er inderdaad een grote variatie bestaat 
tussen de gerapporteerde prevalentie cijfers, waarschijnlijk gebaseerd op 
de grote verschillen in endocriene en analytische methoden. De studies 
in de review gebruiken verschillende stimulatie testen, a apwaarden en 
analytische methoden. Bovendien is geen rekening gehouden met factoren 
die mogelijk van invloed kunnen zijn, zoals BMI. Dit is vooral van belang 
voor de beoordeling van de GH-IGF-I-as, aangezien de concentratie GH 
daalt met een hogere BMI. Dit kan resulteren in een overschatting van 
het percentage GH uitval na TBI bij patiënten met overgewicht. Al deze 
verschillen maken het moeilijk de resultaten van studies over TBI te 
vergelijken. Er is meer onderzoek nodig naar voorspellende factoren voor 
het optreden van hypopituïtarisme na TBI. 
Naar aanleiding van de grote variatie in prevalentie cijfers en de variatie 
in de endocriene en analytische methoden om de hypofyse functies te 
beoordelen, hebben we in hoofdstuk 3 onderzoek gedaan naar de lange 
termijn consequenties bij een grote groep patiënten na hersentrauma. 
In dit onderzoek hebben we 112 patiënten geïncludeerd die in het 
verleden traumatisch hersenletsel hadden opgelopen. De patiënten 
moesten minstens  drie dagen in het ziekenhuis hebben gelegen en het 
trauma moest meer dan een jaar geleden plaats hebben gevonden. Vijf 
verschillende ziekenhuizen in Nederland hebben geparticipeerd in 
dit onderzoek. De functie van de hypofyse werd geëvalueerd middels 
nuchtere basale hormoonspiegels in combinatie met een insuline 
tolerantie test (ITT n = 90) of, wanneer een ITT gecontraïndiceerd was, 
een ACTH stimulatie en/of CRH stimulatie test en een gecombineerde 
GHRH-arginine test (n = 22). 
Uit dit onderzoek bleek dat de prevalentie van hypopituïtarisme 
na traumatisch hersenletsel na lange follow-up laag was. Wanneer 
gebruik wordt gemaakt van de gouden standaard test (de ITT) voor 
de evaluatie van GH- en cortisol secretie in de meerderheid van de 
patiënten, vonden wij een percentage hypofyse uitval van slechts 
5.4% (een ernstige groeihormoonde" ciëntie (2.8%), hypogonadisme 
(0.9%), bijnierinsu'  ciëntie (1.8%)). Dit percentage uitval is veel lager 
in vergelijking met de prevalentie cijfers gerapporteerd in eerdere 
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soortgelijke studies (15–90%). Dit kan worden verklaard door het gebruik 
van verschillende endocriene testen en verschillende a apwaarden 
om de diagnose hypopituïtarisme te stellen. Waar mogelijk hebben wij 
in onze studie gebruik gemaakt van de gouden standaard test: de ITT. 
In overeenstemming met onderzoek verricht door Klose en collegae, 
resulteerde dit in een lage prevalentie van GHD en bijnierinsu'  ciëntie. 
Als de ITT was gecontraïndiceerd, gebruikten we de gecombineerde 
stimulatie met GHRH en arginine voor de beoordeling van de GH-as. 
Het is aangetoond dat dit een goede alternatieve test is, mits de gebruikte 
a apwaarden worden aangepast aan de BMI. In ons onderzoek hebben 
we wel gebruik gemaakt van aangepaste a apwaarden. 
Naast verschillen in endocriene testen, kan ook het tijdsinterval 
tussen trauma en de endocriene evaluatie, alsook de ernst van het 
trauma van invloed zijn op de gerapporteerde prevalentie cijfers. 
In de acute fase na een traumatisch hersenletsel zijn voorbijgaande 
hormoonveranderingen die lijken op hypopituïtarisme veelvuldig 
beschreven. Om te voorkomen dat dit van invloed zou kunnen zijn op de 
endocriene evaluatie in onze studie hebben wij alle patiënten minimaal 
een jaar na trauma geëvalueerd. Een ernstig trauma verhoogt het risico 
van het optreden van hypofyse uitval, zodat we tevens besloten hebben 
om in onze studie alleen patiënten met een ernstig trauma te evalueren. 
We hebben derhalve alleen patiënten geïncludeerd met een opname duur 
(ten gevolge van het trauma) van minstens drie dagen. Daarnaast is de 
Glasgow Coma Scale (GCS) ten tijde van opname beoordeeld om een 
indruk te krijgen van de ernst van het trauma. Ondanks het feit dat wij 
met al deze factoren rekening hebben gehouden, bleek het percentage 
hormoonuitval uiteindelijk toch laag. 
Als er sprake is van hypofyse-uitval, kan behandeling hiervan van 
levensbelang zijn en een aanzienlijke verbetering van de kwaliteit van 
leven geven. Daarom is het van belang om vooralsnog bij elke patiënt 
rekening te houden met mogelijke uitval van hypofysefuncties na 
hersentrauma, ondanks het feit dat op basis van onze resultaten dit 
mogelijk niet-frequent voorkomt. Bovendien is het van belang dat er 
consensus komt voor een meer uniforme endocriene evaluatie van 




III. Dynamisch testen van de 
hypofysefunctie bij andere 
 hypofysaire aandoeningen
Hypofyse adenomen kunnen behandeld worden middels transsfenoidale 
chirurgie (TS), aanvullende radiotherapie en/of medicatie. Een 
complicatie die kan optreden ten gevolge van de tumor zelf (compressie), 
of als gevolg van de behandeling (chirurgie en/of radiotherapie) is uitval 
van de hypofysefuncties. Voor een passende behandeling van patiënten 
met hypofyse adenomen is het daarom van essentieel belang de functie 
van de hypofyse te beoordelen ook na operatie en na bestraling. 
Endocriene evaluatie na hypofyse operatie 
Na TS is het van groot klinisch belang om de hypothalamus-hypofyse-
bijnieras (HPA as) te beoordelen, aangezien het belangrijk is te weten 
of de patiënt bijnierschorshormoon (hydrocortison) a ankelijk is. De 
gouden standaard test voor de evaluatie van de HPA as is de ITT. Als 
de ITT vanwege contra-indicaties (epilepsie en/of coronair lijden) niet 
kan worden uitgevoerd, zijn er verschillende andere dynamische testen 
beschikbaar, zoals de metyrapon test, de ACTH stimulatie test en de 
corticotro" ne releasing hormoon (CRH) test. Sinds 1990 wordt in ons 
ziekenhuis de bijnierfunctie van  patiënten direct na hypofyse operatie 
beoordeeld door stimulatie met CRH. Op basis van de testuitslag 
wordt vervolgens besloten of de patiënten met of zonder hydrocortison 
substitutietherapie naar huis wordt ontslagen. Gebaseerd op onze 
klinische ervaring is dit een goede test om de patiënten te screenen 
op uitval van HPA as.  Er is echter weinig literatuur beschikbaar met 
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betrekking tot de klinische toepasbaarheid van de CRH test direct na 
TS. Daarom hebben we in hoofdstuk 4 gekeken naar de klinische 
toepasbaarheid van deze test bij patiënten behandeld voor niet-ACTH 
producerende hypofyse-adenomen in ons ziekenhuis. 
We hebben retrospectief gekeken naar data van alle patiënten 
behandeld met TS in ons centrum. In totaal hebben we 144 niet-
Cushing patiënten geïncludeerd van wie gegevens beschikbaar waren 
met betrekking tot de CRH test direct na operatie, van wie tijdens de 
follow-up periode een bevestigingstest beschikbaar was en waarbij geen 
sprake was van het gebruik van exogene glucocorticoïden, of een tweede 
behandeling (zoals heroperatie of aanvullende radiotherapie) die een 
vergelijk met de eerste test onmogelijk zou maken. 
Op basis van de CRH test bleek er bij 42 patiënten sprake te zijn 
van hypocortisolisme. Echter, 13 van deze patiënten (31%) bleek 
uiteindelijk, op basis van de bevestigingstest, geen uitval van de HPA as 
te hebben. Hierbij kon de hydrocortsion suppletie worden gestopt.  Een 
mogelijke verklaring voor deze discrepante resultaten is het gebruik van 
verschillende a apwaarden. Voor de ITT zijn er alom geaccepteerde 
a apwaarden beschikbaar. Daarentegen, voor de CRH stimulatie test 
zijn er verschillende a apwaarden gede" nieerd die allemaal resulteren 
in een andere sensitiviteit en speci" citeit van de test. In ons ziekenhuis 
wordt de CRH test als screeningstest gebruik om hypocortisolisme direct 
na TS op te sporen. Wij  gebruiken daarom een stringente en hoge a ap 
waarde van 550 nmol/L. Echter, het streven naar een sensitieve test gaat 
ten koste van de speci" citeit van een test. Hierdoor zal dus een grotere 
aantal patiënten onjuist als bijnierinsu'  ciënt worden gediagnosticeerd. 
Een andere verklaring zou het herstel van de HPA as kunnen zijn. 
Een recente studie hee&  drie en twaalf maanden na TS de HPA as 
beoordeeld middels ITT. Hieruit bleek dat er binnen het jaar herstel was 
opgetreden van de HPA as. In overeenstemming met deze studie hebben 
wij ook 8 patiënten die in eerste instantie gediagnosticeerd waren met 
bijnieruitval, maar waarbij binnen een jaar na chirurgie herstel van de 
HPA as optrad. Dit toont aan dat een langdurige, uitgebreide follow-up 
van patiënten na TS van belang is.  
Bij 102 patiënten bleek er direct na TS sprake te zijn van een normale 
functie van de HPA as. Echter, bij 14 van deze patiënten bleek dat er 
alsnog sprake was van hypocortisolisme op basis van een tweede test. 
Deze discrepante resultaten kunnen potentieel levensbedreigend zijn, 
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aangezien deze patiënten at risk zijn voor het optreden van een adrenale 
crisis. Waarschijnlijk speelt uitval van overige hypofyse assen hierbij een 
rol, daar 13 van deze 14 patiënten namelijk ook uitval bleken te hebben 
van andere hypofyse hormonen. Uit onderzoek is gebleken dat GH en 
TSH de" ciëntie van invloed kunnen zijn op deze testuitslagen. Bovendien 
kan rhGH therapie bij patiënten met GHD ook een belangrijke rol spelen, 
vanwege de invloed van GH op het cortisol metabolisme. Groeihormoon 
stimuleert een enzym dat cruciaal is voor de werking van cortisol op 
weefselniveau, het 11-β hydroxysteroid dehydrogenase (11βHSD-1), dat 
de omzetting van cortisol-cortison reguleert. Het gebruik van rhGH bij 
GHD patiënten kan daarom een cortisol de" ciëntie ontmaskeren. 
Op basis van onze resultaten concluderen wij dat de CRH test veilig 
kan worden gebruikt om te evalueren of een patiënt na TS met of zonder 
HC naar huis kan worden ontslagen. Desalniettemin is de CRH test niet 
bij alle patiënten een betrouwbare voorspeller. Wij adviseren daarom 
om de HPA as tijdens follow-up middels een tweede test te evalueren, 
bijvoorbeeld 3–6 maanden na operatie. Bij patiënten met een verminderde 
reactie van cortisol op CRH direct postoperatief, die uitval van meerdere 
hypofyse hormonen blijken te hebben, is hertesten  niet noodzakelijk. 
In hoofdstuk 4 hebben we retrospectief gekeken naar alle patiënten die 
behandeld zijn met TS in ons centrum. In hoofdstuk 5 hebben we ons 
gericht op een speci" eke groep patiënten; patiënten behandeld met TS 
voor een GH producerende tumor d.w.z. patiënten met acromegalie. 
De aanleiding voor ons onderzoek was een recente studie van Ronchi 
en collegae die de functie van de HPA as bij acromegalie patienten 
behandeld middels TS hebben onderzocht. Zij vonden een opmerkelijk 
hoge prevalentie bijnierinsu'  ciëntie (32%) bij deze patiënten. Zij 
concludeerden dat de functie van de HPA as kan afnemen na verloop 
van tijd en dat deze as dus zorgvuldig tijdens follow-up na behandeling 
gecontroleerd moet blijven worden in alle acromegalie patiënten, 
ongeacht de aard van de behandeling. Deze aanbeveling hee&  duidelijk 
gevolgen voor de lange termijn behandeling van patiënten met 
acromegalie. Het doel van hoofdstuk 5 was dan ook om de prevalentie 
van bijnierinsu'  ciëntie na lange termijn follow-up te bepalen in ons eigen 
cohort van patiënten met acromegalie in remissie na behandeling met 
TS. We hebben retrospectief gekeken naar de gegevens van 91 patiënten 
in remissie na TS waarbij de HPA as was beoordeeld met behulp van de 
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ITT, CRH stimulatie, metyrapon- of ACTH stimulatie test. In ons cohort 
bleek er bij 16 patiënten (18%) in de direct postoperatieve periode sprake 
te zijn van bijnierinsu'  ciëntie. Dit bleek van voorbijgaande aard te zijn 
bij 8 patiënten en blijvend bij de overige 8 gedurende het eerste jaar na 
operatie. Dus een jaar na operatie was de prevalentie bijnierinsu'  ciëntie 
uiteindelijk slechts 9%. Slechts bij drie patiënten ontstond alsnog een 
bijnierinsu'  ciëntie 13, 18 en 24 jaar na de operatie. De incidentie van late 
bijnierinsu'  ciëntie na een succesvolle operatie was dus slechts 2 / 1000 
persoonsjaren. De prevalentie van bijnierinsu'  ciëntie bij patiënten in 
remissie na chirurgie voor acromegalie na langdurige follow-up (mediane 
follow-up 8.1 jaar (range 1–31 jaar)), was 12%. Op basis van onze gegevens 
kunnen wij zeggen dat het ontstaan van bijnierinsu'  ciëntie na TS niet 
vaak voorkomt. 
Het verschil in prevalentie tussen onze studie en de studie van Ronchi 
en collegae kan worden verklaard door verschillen in onderzoeksopzet 
en patiëntenpopulatie, maar ook door verschillen in patiëntenselectie en 
chirurgische technieken. In ons cohort hebben we in de meerderheid van 
de patiënten gebruik gemaakt van de gouden standaard test (ITT) en een 
CRH test terwijl in de studie van Ronchi gebruik is gemaakt van een lage 
dosis ACTH test. Daarnaast zouden de volgende factoren ook mogelijk 
van invloed kunnen zijn: een veranderd niveau van cortisol bindend 
globuline (CBG) in acromegalie, de aanwezigheid van postoperatieve 
GH de" ciëntie en de mogelijkheid van herstel van preoperatieve 
bijnierinsu'  ciëntie na TS. 
Beperkingen van onze studie zijn de retrospectieve aard van de studie 
en het feit dat de HPA as is beoordeeld middels verschillende cortisol 
stimulatie testen. Dit doet echter geen a reuk aan onze conclusies, 
omdat de ITT, CRH en metyrapon tests allen worden geaccepteerd als 
test voor de evaluatie van de HPA-as. 
Op basis van onze gegevens stellen wij voor om de HPA as een jaar na 
operatie opnieuw dynamisch te testen bij alle patiënten met postoperatie 
HPA insu'  ciëntie. Verder onderzoek is nodig om te beoordelen of 
jaarlijks basale cortisol waarden kunnen volstaan  om de bijnierfunctie 
te monitoren bij asymptomatische patiënten. Wanneer er echter sprake 
is van lage basale cortisol spiegels, symptomen van corticotrope 
insu'  ciëntie of overige hypofyse uitval, moeten aanvullende dynamisch 
testen van de HPA as worden uitgevoerd. 
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Endocriene evaluatie na craniële radiotherapie 
Patiënten met niet-hypofysaire hersentumoren en/of tumoren in het 
neus- en keel gebied worden vaak behandeld met radiotherapie. Tijdens 
deze behandeling ligt de hypofyse ook in het bestralingsgebied wat 
kan resulteren in hypofyse insu'  ciëntie. Voor kinderen is dit een goed 
beschreven complicatie na radiotherapie. Echter voor volwassenen is  de 
beoordeling van de hypofysefunctie  nog niet opgenomen in de richtlijnen 
voor de follow-up van deze patiënten. In hoofdstuk 6 rapporteren we een 
systematisch review waarbij we hebben gekeken naar de prevalentie van 
hypofyse insu'  ciëntie na craniële radiotherapie voor niet-hypofysaire 
tumoren bij volwassen patiënten. 
We hebben uiteindelijk slechts 18 studies (n=813) kunnen includeren. 
Er zijn grote verschillen in de gerapporteerde prevalentie van 
hypopituïtarisme na craniale radiotherapie, variërend van nauwelijks 
e% ect op de hypofyse functie tot bijna 100% van de patiënten met uitval. 
Het verschil in prevalentie kan worden toegekend aan verschillen in 
radiotherapeutische technieken, verschil in studie design, tijdstip van de 
evaluatie, selectie van patiënten en de verschillen in endocriene evaluatie. 
Bij de meerderheid van de patiënten werd geen gebruik gemaakt van 
hormoon stimulatietesten om de hypofysefunctie te beoordelen. 
Wanneer er wel gebruik werd gemaakt van stimulatietesten, werden 
er verschillende a apwaarden en diagnostische criteria gebruikt. De 
uitgevoerde meta-analyse toonde aan dat er bij ongeveer tweederde van 
alle volwassenen sprake is van enige vorm van hypofyse-uitval (0.66, 
95% CI 0.55–0.76). De prevalentie van groeihormoonde" ciëntie was 0.45 
(95% CI 0.33–0.57), van LH en FSH 0.3 (95% CI 0.23–0.37), van TSH 0.25 
(95% CI 0.16–0.37), en van ACTH 0.22 (95% CI 0.15–0.3). De prevalentie 
van hyperprolactinemie was 0.34 (95% CI 0.15–0.6). Er waren geen 
verschillen tussen de e% ecten van radiotherapie voor nasofaryngeale 
versus intracerebrale tumoren. Op basis van deze gegevens kunnen we 
concluderen dat hypopituïtarisme een veelvoorkomende complicatie is 
ook bij volwassen patiënten die behandeld zijn met craniële radiotherapie. 
Gezien deze hoge prevalentie zou de evaluatie van hypofysefuncties 
moeten worden opgenomen in de richtlijnen voor de follow-up van alle 
patiënten behandeld met craniële radiotherapie.
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IV. Behandeling van GHD 
Groeihormoon de" ciëntie (GHD) kan behandeld worden door toediening 
van recombinant GH (rhGH). Echter bij de behandeling van patiënten 
met GHD moet onder andere rekening worden gehouden met de lee& ijd 
aangezien de normale afgi& e van GH afneemt met de lee& ijd. 
In hoofdstuk 7 hebben we kritisch gekeken naar de beschikbare 
literatuur met betrekking tot de behandeling van de oudere GHD 
patiënt. We hebben gezocht naar artikelen die de e% ecten van rhGH 
bij patiënten boven de 60 jaar hebben geëvalueerd. Uiteindelijk konden 
we 11 bruikbare studies met een totaal van 543 patiënten meenemen in 
onze review. De studies laten zien dat er inderdaad een positief e% ect op 
totaal- en LDL-cholesterol is en dat ook de kwaliteit van leven bij deze 
patiënten verbeterd. Voor de overige uitkomstmaten wordt er echter geen 
positief e% ect beschreven. Ook zijn er geen gegevens over het e% ect van 
rhGH op klinisch relevante eindpunten zoals hart- en vaatziekten of het 
voorkomen van botbreuken. 
Bij de beoordeling van het e% ect van rhGH therapie bij oudere 
patiënten moet rekening worden gehouden met verschillende factoren. 
Allereerst is het van belang rekening te houden met het feit dat met 
toenemende lee& ijd, de GH productie en dus secretie afneemt. Deze 
afname kan invloed hebben op de uitkomsten van de stimulatietesten 
en indirect zal het dus ook van invloed zijn op de a apwaarden die 
worden gebruikt. Studies die hebben gekeken naar het gebruik van de 
ITT en de gecombineerde GHRH met arginine test bij oudere patiënten 
laten verschillende uitkomsten zien. Sommige studies geven aan dat 
er een lagere GH piek is bij ouderen vergeleken met jongere patiënten, 
terwijl andere studies geen verschil laten zien. Wanneer er helemaal geen 
rekening wordt gehouden met lee& ijd bij het bepalen van de a apwaarden 
kan het zijn dat patiënten onterecht gediagnosticeerd worden met 
GHD. Ondanks deze controversiële uitkomsten moet er toch rekening 
gehouden worden met lee& ijd. In hoeverre dit van invloed is voor het 
e% ect van rhGH therapie bij deze patiëntengroep is nog onduidelijk. 
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De afname van de GH concentratie gaat gepaard met een daling van de 
IGF-I concentraties. IGF-I SD scores worden gebruikt voor de diagnose 
van GHD, maar ook voor het goed instellen van de rhGH behandeling. 
Het is dus ook noodzakelijk voor lee& ijd gecorrigeerde IGF-I SD scores te 
bepalen. Vanuit een evolutionair perspectief blijkt de natuurlijke daling 
van GH en IGF-I tijdens veroudering zelfs gunstig. In onderzoek met 
dieren blijkt dat een verminderde GH-IGF-I functie de levensduur van 
de dieren verlengd. In hoeverre dit van toepassing is bij de mens is nog 
niet duidelijk. Maar een klein aantal studies laat een gunstig e% ect zien 
van rhGH bij oudere patiënten. De vraag blij&  dus of de behandeling van 
ouderen met rhGH klinisch relevant is. Er is meer onderzoek nodig in 




Hypofyse functie na TBI 
Er is een grote variatie in gerapporteerde prevalentie cijfers van 
hypopituïtarisme na traumatisch hersenletsel. Dit wordt voor een 
deel veroorzaakt door het gebruik van verschillende endocriene 
testen, verschillende a apwaarden en het niet rekening houden met 
overige factoren die van invloed (kunnen) zijn (zoals BMI). Door deze 
methodologische verschillen is het niet mogelijk de uitkomsten van deze 
verschillende studies met elkaar te vergelijken. 
Wanneer juiste endocriene testen en strenge criteria worden gebruikt 
is de prevalentie van hypopituïtarisme na een traumatisch hersenletsel 
waarschijnlijk zeer laag. De gerapporteerde prevalentie van hypofyse 
insu'  ciëntie na een traumatisch hersenletsel is zeer waarschijnlijk 
overschat. 
Hypofyse functie na transsfenoïdale chirurgie 
De CRH test lijkt een waardevolle aanvulling in het diagnostisch arsenaal 
van endocrinologische testen om klinisch relevant cortisol tekort te 
de" niëren onmiddellijk na hypofyse chirurgie. Deze test is weinig 
belastend en kan veilig worden gebruikt om te beslissen of patiënten met 
of zonder hydrocortison uit het ziekenhuis worden ontslagen. Gedurende 
follow-up is het echter wel noodzakelijk de HPA as nogmaals te testen. 
De prevalentie van bijnierinsu'  ciëntie bij patiënten in remissie van 
acromegalie na TS is zeer laag ( 9%) een jaar na operatie. Het optreden 
van ‘late-onset’ bijnierinsu'  ciëntie is een zeer zeldzame complicatie bij 
patiënten met acromegalie in remissie na transsfenoidale chirurgie. 
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Hypofyse functie na craniële radiotherapie 
Hypopituïtarisme is een veelvoorkomende complicatie bij volwassenen 
na craniële radiotherapie voor niet-hypofysaire tumoren. Daarom 
moeten alle patiënten die worden behandeld met craniële radiotherapie 
tijdens follow-up een gestructureerde periodieke beoordeling van de 
hypofyse functies ondergaan. Dit moet worden opgenomen in richtlijnen 
voor de behandeling en follow-up van deze patiënten. 
Hypofyse functie bij ouderen 
RhGH therapie bij oudere patiënten met GHD verlaagt het LDL-
cholesterol gehalte en verbetert de kwaliteit van leven, maar de overige 
e% ecten zijn niet eenduidig. Er zijn geen gegevens over de werkzaamheid 
en veiligheid van rhGH behandeling in tachtigjarige patiënten met GHD. 
Er zijn tot slot ook geen gegevens bij oudere patiënten met GHD over 
klinisch relevante eindpunten zoals cardiovasculaire aandoeningen of 
breuken. Gezien de hoge kosten van de behandeling en de potentiële 
schadelijke e% ecten van suprafysiologische rhGH substitutie op het 
ontstaan van maligniteiten adviseren we gerandomiseerd onderzoek bij 
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